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Mass spectrometry (MS)-based bottom-up proteomics and quantitative proteomic 
labeling strategies have led to unprecedented insights into systems biology and provided 
invaluable resources as a multifaceted analytical tool. We have utilized such techniques to 
analyze small GTPases of the Ras superfamily, which represent a class of crucial signaling 
molecules in cells, and the aberrant regulation of their expressions is implicated with 
various types of human diseases. In this dissertation, I report the development and 
applications of novel targeted quantitative proteomic methods for high-throughput and 
reproducible profiling of small GTPases in cultured human cells and patient-derived brain 
tissues that carry disease-related changes. 
In Chapter 2, I describe the development of a novel scheduled multiple-reaction 
monitoring (MRM)-based targeted quantitative proteomic method, in conjunction with 
stable isotope labeling by amino acids in cell culture (SILAC) for the quantification of 
more than 90 small GTPases in the paired primary/metastatic melanoma cell lines. The 
data reveal previously unrecognized roles of RAB38 in promoting melanoma metastasis in 
vitro. 
In Chapter 3, the established scheduled MRM-based method was further applied to 
assess the differential expression of small GTPases in wild-type MCF-7 and the paired 
tamoxifen-resistant breast cancer cells. The method facilitated robust quantification of 96 
small GTPases, among which down-regulation of RAB31 was analyzed further and 
demonstrated to play a role in the development of acquired tamoxifen resistance. 
In Chapter 4, we extended the use of the scheduled MRM method to comprehensively 
investigate the differential expression of small GTPases in paired primary/metastatic 
 xi 
colorectal cancer cell (CRC) lines SW480 and SW620. With this approach, 83 small 
GTPases were robustly quantified, leading to the identification of SAR1B as a potential 
suppressor for CRC metastasis. We also showed that diminished SAR1B expression could 
stimulate epithelial–mesenchymal transition (EMT), thereby promoting motility and in 
vitro metastasis of SW480 cells. 
In Chapter 5, I describe the development of a novel targeted quantitative proteomic 
assay based on MRM and the use of crude synthetic stable isotope-labeled (SIL) peptides 
as internal standards (IS) and surrogate standards (SS). By using this approach, we 
quantified ~80 small GTPases from lysates of frontal cortex from post-mortem 
Alzheimer’s disease (AD) patient brain tissue samples. The method displayed excellent 
throughput, sensitivity and reproducibility. Furthermore, we observed that the protein 
expression levels of Rab3A/C, Rab4A/B and Rab27B proteins, which are involved with 
synaptic and secretory vesicles, increased with degree of disease severity. The MRM 
quantification results were further verified by Western blotting. 
 xii 
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Chapter 1 Introduction 
1.1 General Overview 
The past two decades have witnessed increasingly widespread applications of mass 
spectrometry (MS)-based proteomics in systems biology by facilitating accurate, high-
throughput and specific interrogation of either, the entire or a subset, of the proteome from 
biological samples.1, 2 This boom in MS-based proteomics is largely due to the 
development of liquid chromatography-tandem mass spectrometry (LC-MS/MS), which is 
the method of choice for large-scale identification and quantification of proteins. Among 
the various proteomic techniques, bottom-up or shotgun proteomics is the most commonly 
used, where large proteins are proteolytically digested into mixture of peptides for 
downstream LC-MS/MS analysis.3 In this chapter, common ion detection methods 
including shotgun proteomics (also known as discovery proteomics) using data-dependent 
acquisition (DDA), data-independent acquisition (DIA) and targeted proteomics using 
multiple-reaction monitoring (MRM; also referred to as selected reaction monitoring, 
SRM) as well as parallel-reaction monitoring (PRM) will be discussed. 
I will move on to review common labeling strategies in quantitative proteomics, with 
specific emphasis on the following: label-free quantification (LFQ), chemical labeling 
approaches such as isotope-coded affinity tag (ICAT), isobaric tag for relative and absolute 
quantitation (iTRAQ), tandem mass tags (TMT); metabolic labeling approach such as 
stable isotope labeling by amino acids in cell culture (SILAC); and lastly, absolute 
quantification of proteins (AQUA) using stable isotope-labeled (SIL) internal standards. 
 2 
Next, I will elaborate on the classification, biological functions and public health 
relevance of GTP-binding proteins and small GTPases. At last I will detail the major focus 
of this dissertation, i.e. the development and applications of novel targeted quantitative 
proteomic methods in studying small GTPases of the Ras superfamily in cultured human 
cancer cells and patient-derived tissues, together with investigation of the roles of small 
GTPases in several human diseases including melanoma, breast cancer, colorectal cancer, 
and Alzheimer’s disease by using cell lines or tissue samples as study models. 
1.2 Detection Strategies in Bottom-up Proteomics 
1.2.1 Data-dependent Acquisition (DDA) 
A traditional MS-based bottom-up proteomic method is often performed in a “shotgun” 
format, where LC-MS/MS is operated in the DDA mode and the N most abundant 
precursor ions of peptides (N = 5–20) are selected from full or MS1 scans for the 
subsequent tandem mass spectrometry (MS/MS) analysis (Figure 1.1).4 The depth of 
proteome coverage in DDA analysis is largely dependent on sample complexity resulting 
from the background proteome, and the highest coverage is achieved from the least 
complex sample. Consequently, protein or peptide fractionation techniques prior to peptide 
separation on reverse-phase (RP) columns and downstream MS analysis are essential to 
obtaining a high-degree of protein coverage. 
Among the many prefractionation schemes such as strong cation exchange (SCX) or 
two-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (2D-SDS-
PAGE), multi-dimensional protein identification technology (MudPIT) is advantageous 
over gel-based methods with respects to the ease of sample handling, sensitivity and 
 3 
dynamic range.5-7 The concept of MudPIT was built upon the earlier work reported by Link 
et al.,6, 8 where complex peptide mixtures were loaded onto a biphasic SCX-RP 
microcapillary column and separated in a multidimensional manner. In this vein, MudPIT 
allows for an automated and high-throughput online two-dimensional separation pipeline 
that ultimately leads to large-scale global proteomic studies with simplified sample 
handling.6 As a predominant shotgun proteomic approach, MudPIT has achieved 
remarkable progress in resolving complex biological samples to facilitate protein 
identification and quantification. While achieving great proteome coverage, shotgun 
proteomics cannot guarantee that every precursor will be fragmented in each run and 
therefore, the peptides identified by shotgun proteomic analysis only display 35–60% 
overlap between technical replicates.9 
1.2.2 Data-independent Acquisition (DIA) 
One of the biggest challenges in discovery or shotgun proteomics is the unbiased 
identification and precise quantification of protein abundances in highly complex samples, 
which can consist of thousands of proteins. To address the growing needs for delivering 
accurate, complete and reproducible large-scale proteomic datasets, an emerging strategy 
termed sequential window acquisition of all theoretical mass spectra (SWATH-MS) on 
TripleTOF platforms was proposed by Gillet et al. in 2012, and this technology is capable 
of providing deep proteome coverage with quantitative consistency and accuracy.10, 11 
SWATH-MS is a specific variant of DIA methods, from which DIA generally refers to MS 
acquisition methods that continuously acquire MS/MS spectra of all ions in the target m/z 
range in an unbiased fashion (Figure 1.1). In 2015, a similar DIA method implemented on 
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Orbitrap platforms was termed hyper reaction monitoring (HRM).12 In DIA mode, all 
peptide precursors of the entire mass range are sequentially isolated in broader m/z 
windows and fragmented together in a systematic and unbiased fashion.10 One advantage 
provided by such a data collection scheme is a comprehensive and reliable digital 
fingerprint or data archive of the peptide mixture. However, the tremendously complex 
fragment ion spectra derived from multiple precursor ions render the data analysis 
extremely complicated and challenging. To enable unbiased peptide identification and 
SWATH-MS data interpretation, a commonly used strategy is data interrogation after 
construction of assay libraries.13 For example, the SWATH-MS raw data can be re-
interrogated over and over using updated peptide spectral libraries. Recent improvements 
in software tools enable the identification of 10,000 human protein groups from a single 
DIA run.14 Compared to conventional DDA workflows, this is an improvement of more 
than 30% without compromising quantification accuracy. 
1.2.3 Multiple-Reaction Monitoring (MRM) 
In recent years, targeted proteomics techniques have emerged as a powerful toolset in 
systems biology to comprehensively study a predefined set of proteins involved in distinct 
signaling pathways or gene families. Unlike shotgun proteomic methods, the targeted 
proteomics approach aims to deliver highly reproducible and sensitive measurement of 
target peptides and thus requires information about the analytes a priori. The most widely 
used targeted technique is MRM, also referred to as selected-reaction monitoring (SRM) 
performed on a triple quadrupole (QqQ) mass spectrometer. As depicted in Figure 1.1, 
when LC-MS/MS is performed in the MRM mode, the instrument is programmed to 
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monitor a pre-selected series of transitions (precursor/product ion pairs).15 MRM-based 
protein quantification is superior in that it provides unparalleled ability to characterize and 
quantify a set of proteins reproducibly, completely, and with high sensitivity. Therefore, 
MRM contributes to the routine quantitative pipeline for sensitive, reproducible and high-
throughput large-scale biomarker discovery, measurement and validation.16 Although 
MRM is capable of eliminating interference signals from background and highly abundant 
contaminating species, one major drawback lies in the low-resolution nature of the Q1 and 
Q3 mass filters in a QqQ instrument for precursor ion and fragment ion selections, 
respectively; this results in concomitant elution of interfering ions which cannot be 
circumvented, especially for complicated biological samples.17 
With automated or dynamic adjustment of the scheduled retention time (RT) windows, 
the analytical robustness of MRM can be dramatically enhanced to facilitate large-scale 
study.18 Previously prediction of retention times largely relied on intrinsic properties of 
peptides such as hydrophobicity, which can be calculated from peptide sequences, 
representative of the sequence-specific retention calculator (SSRCalc) algorithms.19 In 
2012, normalized retention time (iRT), which is an empirically determined RT scale for 
peptides, was introduced by Escher et al.20 They showed that using empirical data (iRT) 
instead of a calculated parameter (SSRCalc) provided significantly more reliable results 
for target peptide RT prediction.20 The RT scheduling in MRM based on iRT is 
schematically illustrated in Figure 1.2. 
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1.2.4 Parallel Reaction Monitoring (PRM) 
PRM is a recently developed paradigm for targeted quantitative proteomics typically 
performed on high-resolution hybrid quadrupole-Orbitrap (Q-OT) or time-of-flight (TOF) 
instruments.21, 22 As illustrated in Figure 1.1, a peptide precursor is first isolated by the 
quadrupole mass filter and then fragmented in the higher-energy collisional dissociation 
(HCD) cell, and the resulting fragment ions are then analyzed in a high-resolution mass 
analyzer that permits parallel detection of all target product ions (typically 10–20 ppm).21 
These parallel monitoring features contrast with MRM, allowing all detectable product ions 
scanned by the Orbitrap mass analyzer in the PRM mode to be used for accurate peptide 
quantification.21 As a result, there is no need for a priori selection or optimization of target 
peptide transitions. Furthermore, PRM offers higher specificity or selectivity than MRM 
on QqQ instruments due to the reduced presence of interfering ions, which are readily 
discriminated by the high-resolution MS/MS acquisition. In addition to higher specificity, 
sensitivity is also increased by the trapping capabilities of the C-trap; this is advantageous 
for detecting low-abundance species in the complex background through the use of longer 
fill times in the process of fragmentation/accumulation of fragments to increase the signal-
to-noise ratio.23 Several studies showed that PRM and MRM display comparable linearity, 
dynamic range, precision, and repeatability for protein quantification.24-26 Some papers 
reported that PRM exhibited a wider dynamic range than MRM in the presence of complex 
background matrix owing to higher selectivity.21 
Despite the immense benefit obtained from high-resolution mass analyzers, PRM 
analysis performed in an unscheduled mode is only confined to a limited set of analytes 
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(typically 50 peptides per analysis) when performing measurements in the upper range of 
acquisition parameter settings (i.e. a maximum fill time exceeding 100 ms at a resolving 
power of at least 35,000).23 To overcome such shortcoming, Gallien et al. proposed internal 
standard triggered (IS)-PRM for low-scale PRM experiments.23, 27 Collectively, PRM 
represents a promising new addition to the quantitative proteomics toolbox and an 
attractive alternative to MRM. 
1.3 Labeling Strategies in Quantitative Proteomics 
1.3.1 Label-free Quantification 
Modern proteomics has necessitated accurate, reproducible and rapid quantification of 
peptides/proteins with elevated sampling throughput and reduced labor. Therefore, label-
free quantification (LFQ) emerged as a frequently adopted strategy that offers reasonable 
sensitivity, high dynamic range and obviates the needs of chemical or metabolic labeling.28 
There are three major LFQ strategies: spectral counting, where relative quantification is 
achieved based on the number of identified MS/MS spectra for each protein;29 DIA 
approaches, which utilize product ion intensity;30, 31 and MS1 peak intensity, utilizing 
chromatographic peak area extracted from the selected peptide precursor.32 In the past 
decade, LFQ has received broad implementations in a myriad of shotgun or targeted 
proteomic studies. However, the main disadvantages include reliance on technical 
reproducibility, since LFQ is more prone to batch-to-batch variation due to differences in 
sample preparation and instrumentation (Figure 1.3).33 Moreover, LFQ requires more 
intense computational processing to normalize such differences. Therefore, tremendous 
efforts have been made in the field to improve the algorithms of LFQ.34, 35 
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1.3.2 Chemical Labeling 
Covalently attaching a small functional group will chemically label peptides, which 
retain similar chemical and physical properties yet distinguishable m/z values, compared 
to their natural counterparts; because comparison to the labeled standard could increase 
precision and accuracy, diverse labeling strategies were incorporated into MS-based 
proteomic workflows. Among them, isotope-coded affinity tag (ICAT) was developed in 
1999 by Gygi et al. as the first chemical tagging strategy in quantitative proteomics.8 
Typically, the ICAT reagent consists of three elements: an affinity tag (biotin), a light or 
heavy isotope-labeled (diethylene glycol) linker containing either hydrogens or deuterons, 
and a thiol reactive moiety which will specifically derivatize cysteine residues. By targeting 
different amino acid residues for active-site labeling, ICAT represents a flexible labeling 
strategy for proteome-wide quantification, in conjunction with subsequent affinity-based 
enrichment (Figure 1.3). Other similar chemical modification-based approaches were later 
developed such as stable-isotope dimethyl labeling, which utilizes formaldehyde to 
globally label the N-terminus and the side chain ε-amino group of lysine residues through 
reductive amination.36 
In addition to ICAT-based quantitation, isobaric mass tagging is another popular 
implementation of chemical derivatization in quantitative proteomics. In 2004, the isobaric 
tag for relative and absolute quantitation (iTRAQ) strategy was developed by Applied 
Biosystems (Ross et al.), in a 4-plex fashion.37 The design of the reagent consists of a 
reporter group (N-methylpiperazine), a mass balance group (carbonyl) and an amine-
reactive moiety (NHS ester). The amine-reactive NHS ester tag can covalently modify the 
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N-terminus and the side chain of lysine residue (Figure 1.4). After loss of the balance group 
during CID fragmentation of the isobaric peptide precursors, the resulting cluster of 
reporter ions (ranging from m/z 114.1 to 117.1 for 4-plex) can be used for relative protein 
quantification (Figure 1.4). One major advantage for iTRAQ lies in the simultaneous 
detection of isobaric peptides with identical molecular mass and chromatographic elution 
behavior during separation, which may reduce background interference. In 2012, Pottiez 
et al. 38 developed an 8-plex version of the iTRAQ reagents (Figure 1.4). Despite structural 
difference between the two iTRAQ tagging strategies, the 8-plex iTRAQ provides more 
consistent ratios without compromising protein identification. 
Earlier in 2003, Thermo Fisher Scientific also released a product similar to iTRAQ, 
tandem mass tags (TMT) 6-plex isobaric mass tagging kit, which can provide simultaneous 
quantification of up to 6 different samples.39 The structures of TMT reagents are composed 
of a mass reporter group (1,5-dimethylpiperidine), a mass balance group and an amine-
reactive group (NHS-ester) (Figure 1.5). In 2012, McAlister et al. expanded the 
multiplexing capacity of the TMT reagents to at least 10-plex.40 Recently, the TMT11-
131C reagent was developed to further expand the multiplexity to 11-plex.41 
In addition to the commercialized iTRAQ (SCIEX) and TMT (Thermo Scientific) 
reagents, individual research groups have made great efforts to design new isobaric tags 
for chemical labeling of peptides. In 2015, Li et al. developed a novel 12-plex DiLeu 
isobaric tags for quantitative proteomic analysis.42 In 2018, Virreira Winter et al. 
synthesized and utilized a new version of amine-derivatizing and sulfoxide-containing 
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isobaric labeling reagents, termed easily abstractable sulfoxide-based isobaric-tag (EASI-
tag), for highly accurate and multiplexed quantitative proteomics analysis.43 
Although the iTRAQ- or TMT-based approaches allow for highly multiplexed and 
precise quantitative analyses of proteins, quantification of complex proteomic samples 
could be biased due to the “ratio compression” issue originated from co-fragmentation of 
peptides.44 This is usually linked with reporter ion pattern distortion caused by inevitable 
co-isolated precursor interference during the MS/MS (MS2)-based quantitation.44 To 
circumvent this issue, the SPS-MS3 technique, namely isolation waveforms with multiple 
frequency notches (i.e., synchronous precursor selection, SPS) coupled to MS/MS/MS, can 
effectively enhance quantitative accuracy and sensitivity.45, 46 That said, MS2-based TMT 
outperforms MS3-based TMT since its higher precision and larger identification numbers 
allow detection of a greater number of significantly altered proteins.47 Lastly, the 
introduction of heavy labels at a late stage of sample preparation is more susceptible to 
experimental errors, compared to metabolic labeling (Figure 1.3).48 
1.3.3 Metabolic Labeling 
In vivo metabolic labeling approaches include stable isotope labeling by amino acids 
in cell culture (SILAC),49 stable isotope labeling in mammals (SILAM),50 and neutron-
encoded (NeuCode) SILAC or SILAM.51 Classical SILAC was first introduced by Ong et 
al. in 2002, which enables comparative analysis of the global proteome from two cell 
populations fully labeled with “light” or “heavy” isotope-labeled amino acids, 
respectively.49 The typical choice of labeled amino acids is lysine and arginine, which cam 
combine with trypsin digestion to ensure labeling of every peptide except for the C-
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terminal peptide of the protein.52 After equi-mass mixing of the “light” and “heavy” cell 
lysates followed by tryptic digestion, the resulting peptide mixtures are purified or 
fractionated prior to LC-MS/MS analysis, and each isotope-labeled peptide usually appears 
as a “doublet” in the mass spectra with easily distinguishable m/z shifts. By comparing the 
differential signal intensities of the paired isotope-derived peptide peaks, the differences in 
protein abundance between sample groups can be directly calculated.49 Naturally, the 
multi-Da spacing of isotopes in SILAC confines the quantitative capacity to triplex, or 
triple-SILAC, namely SILAC with three isotope labeling states can also be employed.53 
Lately, multiple SILAC-derived technical modifications have been developed to 
enlarge its practicability in the field of quantitative proteomics. The use of SILAC as an 
internal or “spike-in” standard was proposed by Geiger et al., wherein SILAC is only used 
to produce heavy labeled reference proteomes and is not incorporated in the early steps of 
biological experiments.54 Another similar strategy named “super-SILAC” has been 
expanded to five SILAC-labeling cell lines which serve as the internal standards for tissue 
proteome quantification.55 In another variation of the classical SILAC methodology, the 
pulse-chase or pulsed SILAC (pSILAC) technique, after the pulse labeling with heavy 
amino acids in cells, all newly synthesized proteins will incorporate heavy isotopes; this 
has been successfully applied to study global cellular proteostasis by assessing protein 
degradation, synthesis/translation and turnover.56, 57 With this strategy, the transient 
changes in protein abundance reflective of either protein degradation or synthesis can be 
investigated by MS analysis. To enhance the multiplexing capabilities of metabolic 
labeling, NeuCode SILAC was described in 2013 as a novel strategy to improve duplex or 
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triplex SILAC method by reducing the mass window between isotopologs.51 NeuCode 
produces precursor partners spaced by as little as 6 mDa and as much as ∼40 mDa apart; 
this enables amino acid counting and peptide quantification without the need to increase 
MS1 spectral complexity. 
The analytical advantages of SILAC lie in its greater ease of implementation, 
quantitative accuracy, and reproducibility compared with chemical labeling or LFQ 
approaches. These advantages arise because SILAC allows earlier introduction of labeling 
during sample processing and thereby greatly reduces variation and errors (Figure 1.3).49, 
52 That said, traditional SILAC is only applicable to cultured cells or mouse models, 
whereas clinical samples such as tissue samples and biological fluids are not amenable to 
metabolic labeling. Furthermore, to achieve similar breadth of quantitative multiplexity 
enabled by chemical labeling and/or LFQ, traditional duplex-SILAC scheme requires not 
only time-consuming and labor-intensive metabolic labeling steps but also vastly tedious 
efforts in sample preparation. 
1.3.4 Absolute QUAntitation (AQUA) Using Isotope-labeled Internal Standards 
Increased sample multiplexing capacity enabled by chemical labeling strategies has 
broadened opportunities for conducting large-scale global proteomic studies. These 
techniques, nonetheless, only provide relative quantification for peptides of interest. In 
contrast, absolute quantitation (AQUA) is performed by spiking complex samples with 
stable isotope-labeled (SIL) synthetic peptides that act as internal standards for a specific 
subset of peptides (Figure 1.3). These peptides are synthesized with incorporated stable 
isotopes and serve as ideal internal standards by mimicking native peptides formed by 
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proteolysis (e.g. trypsin digestion). Hence, they are designed to be structurally identical to 
tryptic peptides generated by sample preparation and can therefore ensure co-elution in LC 
with target peptide and simultaneous MS analysis. 
Once the assay is optimized for a predetermined set of peptides, AQUA used in 
conjunction with MRM offers the highest level of reproducibility and sensitivity in targeted 
profiling from multiple samples. This approach has been reported to detect proteins with 
concentrations less than 50 copies per cell in unfractionated lysates, demonstrating that this 
quantitative approach largely unaffected by sample complexity. As a gold standard in 
delivering precise and reliable absolute quantity of target proteins and post-translational 
modifications (PTMs), AQUA has received wide applications in a plethora of clinical 
studies, such as quantifying disease biomarkers in patient-derived samples from plasma or 
serum by coupling the use of MRM with stable isotope dilution.58-61 Although using SIL 
peptides for absolute quantification is very precise, availability and costs for such reference 
peptides limit their applications in assays with a great number of proteins. 
1.4 GTP-binding Proteins and Small GTPases 
1.4.1 Overview 
In cells, guanosine mono-, di-, and triphosphate (GMP, GDP, GTP) constitute 
fundamental building blocks and messengers for a broad spectrum of cellular processes. 
Guanine nucleotide binding proteins, or GTP-binding proteins, include septins (SEPT 
family), tubulins (TUBB family), eukaryotic translation initiation/elongation factors 
(eIF/eEF family), heterotrimeric G protein alpha subunit (Gα), and so on. By shuffling 
between the active GTP-bound form and the inactive GDP-bound form these proteins act 
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as molecular switches, as such they play essential roles in various cellular processes and 
orchestrate a diversity of signaling networks. For large guanosine triphosphatases 
(GTPases), the hydrolysis of GTP fuels organelle re-organization, while for small 
GTPases, the GTP hydrolysis induces protein conformational changes and subsequently 
the interaction with downstream effectors to transmit extracellular signals. Guanine 
nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) are two 
distinct classes of molecular chaperones that mediate the activity of small GTPases (Figure 
1.6).62 In general, GEFs turn on signaling by catalyzing the exchange from GTPase-bound 
GDP to GTP, whereas GAPs terminate signaling by facilitating GTP hydrolysis.62, 63 For 
certain small GTPases that carry C-terminal farnesyl or geranylgeranyl modifications, 
GDP/GTP switch involves cytosol/membrane alternation and hence is modulated by 
guanine dissociation inhibitors (GDIs).63 
1.4.2 Small GTPases 
As the largest gene family of monomeric GTP-binding proteins, the Ras superfamily 
of small GTPases is comprised of over 150 human members (Figure 1.7), with highly 
evolutionarily conserved orthologs in Drosophila, C. elegans, S. cerevisiae, S. pombe, and 
plants.64-66 Based on structural similarities, they can be further classified into five families, 
Ras, Rho, Rab, Ran, and Arf, as well as the “orphan” or atypical GTPases RhoBTB1/2/2. 
The Ras family of GTPases responds to extracellular stimuli to regulate cellular gene 
transcription, proliferation and survival; while the Rho family of GTPases couples the same 
stimuli to mediate gene expression and cytoskeletal organization.67-69 The Rho family of 
GTPases are also known for their role in regulating cell shape and plasticity of cell 
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migration.70 The Rab and the Arf families of GTPases control receptor internalization, 
intracellular vesicular trafficking and actin remodeling.71, 72 The Ran protein, the single 
member of the Ran subfamily, is the most abundant small GTPase in cells and is 
responsible for microtubule stability and nucleocytoplasmic transport.73 
Growing lines of evidence suggest that small GTPases and their regulators (i.e. GAPs 
and GEFs) may be potential therapeutic targets for drug discovery in treating a wide variety 
of diseases, including cancer.74 Aberrant regulation of small GTPase expression has been 
reported in various types of cancer including hepatocellular carcinoma (RAB1B,  RAB4B,  
RAB10,  RAB22A, and RAB24), non-small lung carcinoma (RAB14, RHOA, RAC1, and 
CDC42), pancreatic carcinoma (RAB20, RAC1) colorectal cancer (RAB22A, RAC1B) 
and prostate cancer (RAB3B).75, 76 Given the important functions of these proteins in signal 
transduction and trafficking, a better mechanistic understanding of their roles in disease 
development and progression may provide new insights into strategies for therapeutic 
intervention. 
1.4.3 Heterotrimeric G Proteins 
Heterotrimeric G proteins consist of two functional units, an α subunit (Gα) and a 
tightly associated βγ complex (Gβγ), which play pivotal roles in signal transduction 
involved with G-protein-coupled receptor (GPCR) activation. The Gα subunit harbors the 
guanine nucleotide-binding site and is associated with the βγ complex in its GDP-bound 
inactive state. Agonist-receptor binding triggers GDP/GTP exchange, a conformational 
change of Gα, subunit dissociation from the βγ complex, and ultimately downstream 
signaling cascades.77 It has been estimated that ∼700 approved drugs target GPCRs, 
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suggesting that approximately 35% of approved drugs target GPCRs.78 GPCRs and GPCR-
related proteins, i.e. those proteins upstream or downstream in the GPCR-related pathways, 
represent ∼17% of all protein targets for approved drugs, with GPCRs themselves 
accounting for ∼12%. As such, GPCRs constitute the largest family of proteins targeted 
by approved drugs.78 
1.4.4 Proteomic Profiling of GTP-binding Proteins 
1.4.4.1 Acyl-phosphate GTP Affinity Probes 
Several structurally distinct chemical probes have been developed for targeting GTP-
binding proteins. One example is the commercialized lysine-reactive desthiobiotin-GTP 
probes that contains an acyl phosphate anhydride (ActivX Biosciences)79; these probes 
target the conserved lysine residue in the GTP-binding GXXXXGK motif (P-loop)80 and 
have been employed by several studies examining the GTPase proteome. Patricelli et al.81 
and Qiu et al.82 reported a lysine-reactive nucleotide acyl phosphate probe for the 
proteome-wide profiling of nucleotide-binding proteins, including kinases and GTPases. 
By exploiting a similar strategy, Xiao et al. identified 66 GTP-binding proteins in HL-60 
cell lysates83, and later a similar approach utilizing 6-thioguanosine triphosphate (SGTP) 
acyl-phosphate probe combined with SILAC was devised for proteome-wide 
quantification of SGTP-binding proteins in Jurkat-T cell lysates84, in which 91 GTP-
binding proteins were quantified. Hunter et al. used the desthiobiotin-GTP probe for 
characterizing an active site inhibitor of oncogenic KRAS-G12C in MIA PaCa cell 
lysates85, which led to the detection of over 100 GTP-binding proteins. Recently, Cai et. al 
further extended this approach by combining the use of isotope-coded desthiobiotin-GTP 
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acyl-phosphate probes with MRM and quantified 91 GTP-binding proteins in 
SW480/SW620 cell lysates.86 However, these chemical proteomic probes which 
incorporate adenine/guanine cofactor-based chemical scaffolds may suffer from off-target 
engagement of adenosine-binding proteins due to their widespread reactivity.87 
1.4.4.2 Photoreactive GTP Affinity Probes 
Another type of GTP affinity probe relies on the photoactive covalent modifications 
that occur at the GTP-binding sites. Kaneda et al.88 first synthesized a GTP probe that 
allows simple and efficient photoaffinity-based proteomic profiling of GTP-binding 
proteins. Another example is the GTP-BP-yne probe reported by Cisar et al.,89 which 
facilitated active-site labeling of more than 30 annotated GTP-binding proteins 
subsequently identified by MudPIT.  
1.4.4.3 Gel Electrophoresis (Ge) Coupled to LC-MRM (GeLC-MRM) 
In addition to small-molecule probes, other profiling techniques take advantage of the 
GTPase-binding domain of individual downstream effectors and their distinct molecular 
weights (15–37 kDa) to enrich specific active small GTPases. Zhang et al.90 first combined 
such pull-down strategies with gel electrophoresis (Ge) coupled to LC-MRM (GeLC-
MRM) for the development of quantitative multiplexed small GTPase activity assay, and 
they were able to detect 12 active isoforms of small GTPases simultaneously. Halvey et 
al.91 also demonstrated that GeLC-MRM is a robust and sensitive approach to quantify 
KRAS mutant variants in complex biological samples.  
 18 
1.5 Scope of the Dissertation 
Compared to conventional discovery-based proteomic approaches, i.e. shotgun 
proteomics, targeted proteomic techniques show clear advantages in achieving better 
reproducibility, higher sensitivity and superior quantitative accuracy. In this dissertation, 
we reported the development and application of novel targeted quantitative proteomic 
methods for high-throughput and reproducible profiling of small GTPases in cultured cells 
and patient-derived brain tissues that carry disease-related changes. We believe this is an 
important area of study because small GTPases of the Ras superfamily represent a class of 
crucial signaling molecules in cells, and the aberrant regulation of their expressions is 
implicated with various types of human diseases. 
In Chapter two, we describe the development of a novel targeted quantitative proteomic 
method that involves metabolic labeling by SILAC, total protein quantitation, prior 
enrichment of small GTPases by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) in the low molecular weight (15–37 kDa) protein fraction 
and the subsequent scheduled LC-MS/MS analysis in the multiple-reaction monitoring 
(MRM) mode. Owing to the largely reduced complexity of the proteome analyzed, this 
method allows reliable high-throughput quantification of small GTPases of the Ras 
superfamily with relatively low protein inputs (5–100 μg) and without the need for 
chemoaffinity or immunoaffinity enrichment. Taking advantage of both the effective 
enrichment of small GTPases by gel-based fractionation and the analytical robustness of 
the scheduled MRM analysis, over 90 small GTPases were robustly quantified in two 
scheduled LC-MRM runs. We also demonstrated that this MRM-based assay displayed 
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much better sensitivity, reproducibility and accuracy than the discovery-based shotgun 
proteomic method. We applied this method to probing the differential protein abundance 
of small GTPases in three pairs of primary/metastatic human melanoma cell lines: WM-
115/WM-266-4, IGR39/IGR37 and WM793/1205Lu. Bioinformatic analyses of The 
Cancer Genome Atlas (TCGA) data and other publicly available data as well as cell-based 
assays revealed previously unrecognized roles of RAB38 in promoting melanoma 
metastasis. Diminished promoter methylation and the subsequent augmented binding of 
transcription factor MITF contributed to elevated expression of the RAB38 gene in 
metastatic versus primary melanoma cells. Moreover, RAB38 promoted invasion of 
cultured melanoma cells by modulating the expression and activities of matrix 
metalloproteinases-2 and -9. Together, these data establish a novel targeted proteomic 
method for interrogating the small GTPase proteome in human cells and identify epigenetic 
reactivation of RAB38 as a contributing factor to metastatic transformation in melanoma. 
In Chapter three, we applied the established quantitative proteomic method in probing 
the differential expression of small GTPases associated with acquired tamoxifen resistance 
in the estrogen-receptor (ER)-positive MCF-7 breast cancer cells. Briefly, we employed 
the established quantitative proteomic method to assess the differential expression of small 
GTPases in wild-type MCF-7 and the paired tamoxifen-resistant breast cancer cells. The 
method displayed superior sensitivity and reproducibility over the shotgun-proteomic 
approach, and it facilitated the quantification of 96 small GTPases. Among them, 13 and 
10 proteins were significantly down- and up-regulated (with >1.5-fold change) in the 
tamoxifen-resistant line relative to the parental line, respectively. Notably, we observed a 
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significant down-regulation of RAB31 in tamoxifen-resistant cells, which, in combination 
with bioinformatic analysis and downstream validation experiments, supported a role for 
RAB31 in tamoxifen resistance in ER-positive breast-cancer cells. Together, our results 
demonstrate that the targeted proteomic method constituted a powerful approach for 
revealing the role of small GTPases in therapeutic resistance. 
In Chapter four, we sought to conduct a systematic study of the implications of small 
GTPases in the metastatic transformation of colorectal cancer (CRC). By utilizing the 
established MRM method, we investigated comprehensively the relative expression of the 
small GTPase proteome in a pair of matched primary/metastatic CRC cell lines 
(SW480/SW620). Among the 83 quantified small GTPases, 25 exhibited at least a 1.5-fold 
difference in protein expression in metastatic SW620 relative to primary SW480 cells. 
Bioinformatic analyses revealed that diminished SAR1B mRNA expression is significantly 
associated with higher CRC stages and unfavorable patient prognosis, which supports a 
potential role of SAR1B in suppressing CRC metastasis. In addition, diminished SAR1B 
expression could stimulate epithelial–mesenchymal transition (EMT), thereby promoting 
motility and in vitro metastasis of SW480 cells. In summary, we profiled systematically, 
by employing an MRM-based targeted proteomic method, the differentially expressed 
small GTPases in a matched pair of primary/metastatic CRC cell lines. Our results revealed 
the potential roles for SAR1B in suppressing CRC metastasis and in the prognosis of CRC 
patients. 
In Chapter five, we present the development of a novel targeted quantitative proteomic 
assay aimed at switching from metabolic labeling to the use of stable isotope-labeled (SIL) 
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peptides. We applied this MRM method, which was built upon in-house shotgun 
proteomics data and online MRM assay design tool, for simultaneous assessment of the 
relative expression of small GTPases from Alzheimer’s disease (AD) patient derived brain 
tissues. The scheduled GeLC-MRM analyses provided robust quantification of more than 
80 small GTPases in tissue samples by using a 90-min LC-MRM run, with excellent 
throughput and reproducibility. Interestingly, levels of RAB27B, RAB3A and RAB3D 
proteins, which were previously shown to be involved with synaptic and secretory vesicles, 
were found to increase in brain tissue samples with higher degree of disease severity. This 
facile and accurate assay provides invaluable knowledge to probe the potential roles for 
small GTPases in the development and progression of AD. 
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Figure 1.1 Representative scanning modes used in MS-based bottom-up proteomics. 
Shown is a schematic diagram representing common ion detection methods in MS. 
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Figure 1.2 A schematic workflow that outlines the empirical determination of iRT 
scale, conversion of RTs for targeted peptides into iRTs, and RT scheduling for 
MRM. 
To simplify, RT1 and RT2 represent 2 of the 10 reference peptides (iRT-peptides) used for 
iRT transformation based upon linear regression. The retention time of the target peptide 
(RTx) is can be empirically transformed into iRT (iRTx) using the established linear 
regression of the iRT-peptides. iRTx values can then be transferred to a different 
chromatographic setup by using an RT calibration of the iRT-peptides. 
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Figure 1.3 Comparison of commonly used labeling strategies in quantitative 
proteomics. 
The blue and orange asterisk indicates the introduction of light and heavy stable isotope 
labeling, respectively.
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Figure 1.4 Design and concept of iTRAQ. 
(A) The backbone structure and the detailed description of the 4-plex iTRAQ reagents. (B) 
The backbone structure and the detailed description of the 8-plex iTRAQ reagents. The 
dashed line indicates the fragmentation site of CID. 
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Figure 1.5 Design and concept of TMT. 
(A) The backbone structure of TMT reagent. (B) The detailed molecular structures of the 
11-plex version of the TMT reagent, where asterisk denotes the position of isotopic labelled 
13C or 14N, the zig-zag line indicates the fragmentation site of ETD, and the dashed line 
indicates the fragmentation site of HCD. 
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Figure 1.6 Regulation of small GTPases by GEFs, GAPs, and GDIs. 
A diagram depicting the regulation of the GDP/GTP switch of small GTPases modulated 
by GEFs, GAPs, and GDIs (adopted from Ref63). 
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Figure 1.7 Phylogenetic relationships and gene structure of the Homo Sapiens 
small GTPase genes. 
The unrooted tree was generated using the MEGA v7.0 software with the full-length amino 
acid sequences of the Homo Sapiens small GTPase proteins using a Neighbor-Joining (NJ) 
method, including 1,000 boot-strap replications. All the protein sequences were aligned 
using ClustalW. The phylogenetic tree was visualized using the FigTree v1.4.4 software. 
The five sub-families of small GTPase genes are highlighted with different colored tree 
branches. 
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Chapter 2 A Targeted Quantitative Proteomic Approach Assesses the 
Reprogramming of Small GTPases during Melanoma Metastasis 
2.1 Introduction 
Small GTPases of the Ras superfamily are highly conserved in eukaryotes, including 
more than 100 members that could be divided into six subfamilies, i.e. Ras, Rho, Rab, 
Sar1/Arf, Ran and others.1 They can exist in the GTP-bound active state or GDP-bound 
inactive state, which are modulated by guanine nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors 
(GDIs).2 Small GTPases serve as master regulators of cellular trafficking and are involved 
in numerous cell signaling cascades.1, 3 In addition, emerging evidence has linked aberrant 
expression of small GTPases with cancer progression, including RHOC and RAB27A in 
melanoma.4-5 
Despite the importance of small GTPases in cell signaling and human diseases, very 
few studies have been conducted to assess quantitatively the small GTPases at the 
proteome-wide scale. In recent years, multiple-reaction monitoring (MRM)-based targeted 
proteomic method has emerged as a powerful approach for analyzing proteins and peptides 
of interest with high specificity and sensitivity.6-7 We reason that a targeted proteomic 
method for the measurement of small GTPases may enable mechanistic studies of small 
GTPase signaling and facilitate the discovery of novel roles of small GTPases in the 
etiology of human diseases. 
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In the present study, we developed a facile and effective MRM-based method for high-
throughput profiling of small GTPases in cultured human cells and we also applied the 
method for assessing the roles of small GTPases in melanoma metastasis. We chose to 
examine the roles of small GTPases in melanoma metastasis because melanoma is one of 
the most aggressive and treatment-resistant types of human cancers. In this vein, an 
estimated 91,270 new cases of melanoma and 9320 deaths are expected in the United States 
in 2018,8 and the high mortality rate of melanoma is attributed to its high probability to 
metastasize.9 
2.2 Materials and Methods 
2.1.1 Cell Culture 
HCT-116 human colorectal cancer cells, HEK293T human embryonic kidney cells, 
HL-60 human promyelocytic leukemia cells, Jurkat-T human T lymphocytic leukemia 
cells, MCF-7 human breast cancer cells, WM-115 and WM-266-4 human melanoma cells 
were purchased from American Type Culture Collection (ATCC; Manassas, VA). 
GM00637 human skin fibroblasts were kindly provided by Prof. Gerd P. Pfeifer (the City 
of Hope). IGR39 and IGR37 human melanoma cells were generous gifts from Prof. Peter 
H. Duesberg (University of California, Berkeley). WM793 and 1205Lu human melanoma 
cells were purchased from Wistar Institute. HCT-116, HEK293T, GM00637, MCF-7, 
WM-115 and WM-266-4 cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM; Invitrogen-Gibco, Carlsbad, CA). HL-60, Jurkat-T, IGR39, IGR37, WM793 and 
1205Lu cells were cultured in RPMI 1640 Medium (Invitrogen-Gibco). All culture media 
were supplemented with 10% fetal bovine serum (FBS; Invitrogen-Gibco) and 
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penicillin/streptomycin (100 IU/mL). Cells were maintained at 37°C in a humidified 
atmosphere containing 5% CO2, and the culture medium was changed in every 2 to 3 days 
as necessary. 
The initial passage numbers for melanoma cells used were: WM-115 (p9), WM-266-4 
(p6), IGR39 (p4), IGR37 (p7), WM793 (p16), and 1205Lu (p70). All the relevant 
experiments were conducted within 20 passages from revival of the initial frozen seeds. 
LookOut Mycoplasma PCR Detection Kit (MP0035, Sigma-Aldrich, MO) for detection of 
19 mycoplasma species was used following the manufacturer’s instructions. PCRs were 
performed using HotStart Taq Polymerase. Results were visualized on a 1.2% agarose gel, 
where mycoplasma-positive samples would show a band at 261 bp, and internal control 
DNA showed a band at 500 bp. WM-115, WM-266-4, IGR39, IGR37, WM793, and 
1205Lu melanoma cell lines were tested by this method to be free of mycoplasma on May 
9, 2018. In addition, these six melanoma cell lines were authenticated by ATCC on May 
24, 2018 using Short Tandem Repeat (STR) analysis as described in 2012 in ANSI 
Standard (ASN-0002) Authentication of Human Cell Lines. 
For SILAC experiments, [13C6,
15N2]-L-lysine and [
13C6]-L-arginine (Cambridge 
Isotopes Inc., MA), or the corresponding unlabeled lysine and arginine, were added to 
SILAC DMEM media depleted of L-lysine and L-arginine (Thermo Scientific Pierce, MA) 
until their final concentrations reached 0.398 and 0.798 mM, respectively, to yield the 
“heavy” and “light” media. The SILAC RPMI-1640 media were prepared in a similar 
fashion except that the final concentrations of the added lysine and arginine were 0.274 
mM and 1.15 mM, respectively. The SILAC media were again supplemented with 10% 
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dialyzed FBS (Corning, NY). WM-115 and WM-266-4 cells were cultured in the heavy-
DMEM medium, and IGR39, IGR37, WM793 and 1205Lu cells were cultured in the 
heavy-RPMI medium for at least six cell doublings to ensure complete heavy-isotope 
incorporation. 
2.1.2 Gene Ontology (GO) Analysis and Data Source for Bioinformatic Analyses 
Gene Ontology analyses were conducted using the web-based Database for Annotation, 
Visualization and Integrated Discovery (DAVID, version 6.7; https://david.ncifcrf.gov/).10 
Patient RNAseq data were obtained from The Cancer Genome Atlas (TCGA) via 
cBioPortal 11. We used data from 458 melanoma patients in the TCGA-SKCM project for 
bioinformatic analyses. The Cancer Cell Line Encyclopedia (CCLE) 
(http://www.broadinstitute.org/ccle/home) were employed for the comprehensive 
evaluation of mRNA expression for candidate genes among more than 1,000 cell lines 
representing 37 cancer types 12. Multi-tumor RAB38 mRNA expression box plot and scatter 
plot for melanoma cell lines were retrieved from the CCLE database using cBioPortal. 
Publicly available transcriptomic profiles with accession numbers GSE7553, GSE7929, 
GSE8401, GSE22153, GSE44662, GSE46522 and GSE70621 were downloaded from the 
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
database and analyzed using R (version 3.4.3). 
2.1.3 Sample Preparation and LC-MS/MS for Shotgun Proteomic Analysis 
For acquiring shotgun proteomic data to establish an MRM library for small GTPases, 
the individually collected cell pellets from 9 human cell lines were lysed, and the resulting 
cell lysates were collected by centrifugation and separated by electrophoresis using a 16% 
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SDS-PAGE gel. The gel bands in the molecular weight range of 15−37 kDa were cut into 
7 pieces, reduced with dithiothreitol, alkylated with iodoacetamide, and in-gel digested 
with trypsin at an enzyme/protein ratio of 1:100. 
In shotgun proteomic experiments, peptide samples were subjected to LC-MS/MS 
analysis on either an LTQ Orbitrap Velos mass spectrometer or a Q Exactive Plus mass 
spectrometer that was equipped with a nanoelectrospray ionization source and coupled to 
an EASY-nLC II (Thermo, San Jose, CA), as described previously.63 A homemade 
trapping column (150 μm × 50 mm), packed with ReproSil-Pur C18-AQ resin (5 μm in 
particle size and 120 Å in pore size, Dr. Maisch GmbH HPLC), and an analytical column 
(75 μm × 120 mm), packed with ReproSil-Pur 120 C18-AQ resin (3 μm in particle size and 
120 Å in pore size, Dr. Maisch GmbH HPLC), were used for peptide separation. Peptide 
samples were initially loaded onto the trapping column with 0.1% formic acid in water at 
a flow rate of 3.0 μL/min. The peptides were then separated using a 157-min linear gradient 
of 2−35% acetonitrile in 0.1% formic acid at a flow rate of 230 nL/min. The mass 
spectrometer was operated in data-dependent acquisition (DDA) mode, where one full MS 
scan (resolution = 60,000) at an automatic gain control (AGC) target of 106 was followed 
with up to 20 MS/MS scans for the most abundant ions observed in MS. The selected ions 
were excluded from further analysis for 90 s. Ions with singly or unassigned charge states 
were not fragmented. The maximum ion accumulation time was 1000 ms for each full MS 
scan, and 50 ms for each MS/MS scan. The raw data were searched against the IPI human 
database (version 3.68, 87,061 entries). For database search, up to one trypsin missed 
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cleavage per peptide was allowed, and MS/MS spectral assignment was performed with 
less than 1% false discovery rate (FDR). 
2.1.4 Retention Time (RT) Prediction for Small GTPase Peptides 
To facilitate automated and multiplexed MRM analyses, we generated an interactive 
MRM spectral library file containing the tandem mass spectra of peptides derived from 
small GTPases, which were acquired from the above-described shotgun proteomic 
experiments, using Skyline (version 3.5). Precursor and fragment ions for targeted GTPase 
peptides were selected and further refined to avoid spectral interference. If applicable, three 
unique peptides were selected for subsequent targeted analysis in the MRM mode.13 In 
addition, we employed the aforementioned iRT algorithm to develop the scheduled MRM 
method.14 To calculate the iRT score for each targeted peptide from small GTPases in the 
MRM spectral library, we selected 10 peptides from the tryptic digestion mixture of bovine 
serum albumin (BSA) as reference peptides to set up an iRT scale. By manually setting the 
iRT values of the BSA peptides AEFVEVTK and DAFLGSFLYEYSR as 0 and 100, 
respectively, a linear regression equation was obtained by plotting the iRT scores against 
their empirically measured retention times (RTs) derived from the LC-MS/MS analyses. 
Subsequently, the iRT values for the other eight standard BSA peptides were determined 
using the above-mentioned linear equation along with their empirically measured RTs in 
the shotgun proteomic experiments. 
The BSA peptide mixture was then spiked into the small GTPase peptide mixtures for 
the LC-MS/MS analyses on an LTQ Orbitrap Velos mass spectrometer equipped with an 
Easy-nLC II system with a 150-min linear gradient of 2–35% buffer B (0.1% formic acid 
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in acetonitrile) in buffer A (0.1% formic acid), or a Q Exactive Plus mass spectrometer 
equipped with an Easy-nLC 1000 system with a 172-min linear gradient of 8–35% buffer 
B (80% acetonitrile in water with 0.1 % formic acid) in buffer A (0.1% formic acid). RTs 
were extracted for all BSA standard peptides as well as targeted peptides using the Skyline 
MS1 filtering workflow. The iRT values for all small GTPase peptides were calculated 
based on linear regression of iRT and experimentally measured RT of peptides with 
previously determined iRT scores. 
2.1.5 Sample Preparation and Scheduled LC-MRM Analysis 
To rigorously examine the differential expression of small GTPases in paired 
primary/metastatic melanoma cells, we conducted forward- and reverse-SILAC 
experiments, where the light and heavy lysates of paired primary melanoma cells (WM-
115, IGR39 or WM793) were mixed with the heavy and light lysates from metastatic 
melanoma cells (WM-266-4, IGR37 or 1205Lu), respectively, at a 1:1 ratio (by mass). The 
mixed cell lysates were then loaded onto a 10% SDS-PAGE gel and separated by 
electrophoresis. The gel bands corresponding to the molecular weight range of 15–37 kDa 
were cut, reduced with 20 mM dithiothreitol, alkylated with 55 mM iodoacetamide, and 
in-gel digested with trypsin at an enzyme/protein ratio of 1:100. 
All LC-MRM analyses were performed on a TSQ Vantage triple-quadrupole mass 
spectrometer equipped with an Easy-nLC II system. The peptide mixtures were separated 
with a 157-min linear gradient of 2–35% acetonitrile in buffer B (0.1% formic acid in 
acetonitrile) in buffer A (0.1% formic acid) and at a flow rate of 230 nL/min. The spray 
voltage was 1.8 kV, Q1 and Q3 resolutions were 0.7 Da, and the cycle time was 5 s. The 
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optimal collisional energy (CE) set for each targeted peptide was calculated using a linear 
equation specific to the TSQ Vantage instrument and the precursor mass-to-charge ratio 
(m/z) according to the default setting in Skyline. 
The tryptic peptide mixture of BSA was subjected to unscheduled LC-MRM analyses 
prior to the analyses of targeted peptides of small GTPases in order to calibrate for possible 
retention time shifts due to changes in chromatographic conditions. The prediction of 
empirical RT based on the individual iRT scores of the targeted small GTPase peptides 
was then determined by the linear regression of RTs of BSA standard peptides obtained 
under the same chromatography conditions. This iRT-based predictor was examined 
between every six MRM runs by injecting another BSA reference peptide mixture to ensure 
precise RT prediction. 
A total of 432 peptides representing 113 non-redundant or 131 isoform-specific small 
GTPases were monitored in each scheduled LC-MRM run. For SILAC labeling 
experiments, the LC-MRM method was further expanded into two runs for monitoring the 
precursor and fragment ions of peptides harboring the light and heavy forms of lysine 
and/or arginine. In this regard, three transitions were monitored for each light-/heavy-
isotope-coded peptide for LC-MRM quantification. All the targeted transitions can be 
monitored in two LC runs by using the scheduled MRM mode with a 6-min retention time 
duration. 
All raw files were processed using Skyline (version 3.5) for the generation of extracted-
ion chromatograms and peak integration. The targeted peptides were first manually 
checked to ensure the overlaid chromatographic profiles of multiple fragment ions derived 
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from the light and heavy forms of the same peptide. The data were then processed to ensure 
that the distribution of the relative intensities of multiple transitions associated with the 
same precursor ion correlates with the theoretical distribution derived from the library 
tandem mass spectra acquired in shotgun proteomic experiments. To ensure reliable peak 
assignment, dot plot or dot product (dotp) values were calculated by comparison of 
transition ion intensities based on a linear regression model. In this regard, the dotp value 
has to exceed 0.80.15 In addition, the iRT values act an intrinsic property (i.e., 
hydrophobicity) of a peptide; hence, a substantial deviation of measured RT from that 
projected from the linear plot of RT over iRT signals a false-positive detection.14 The sum 
of peak area from all transitions of light- or heavy-labeled peptides was used for the 
quantification. 
2.1.6 Construction and Transfection of FLAG-tagged Fusion Protein Expression Plasmid 
To generate expression plasmid for 3×FLAG-tagged RAB38, the full-length coding 
sequence of human RAB38 gene was amplified by PCR using Phusion High-Fidelity DNA 
Polymerase (NEB). The PCR product was digested with HindIII and EcoRI, and the 
resulting DNA fragment was inserted into p3×FLAG-CMV-10 (Sigma) to construct the 
plasmid. The sequence of the constructed plasmid was validated by Sanger sequencing. 
For plasmid transfection, WM-115 cells were cultured in six-well plates and transfected 
at 70% confluency with either the p3×FLAG-CMV-10 empty vector or the FLAG-RAB38 
plasmid using TransIT-2020 transfection reagent (Mirus Bio LLC) following the 
manufacturer’s recommended protocol. Transfected cells were incubated for an additional 
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24 h and analyzed for gene expression of the relative targeted protein using immunoblotting 
with specific antibodies. 
2.1.7 siRNA Transfection 
siGENOME non-targeting (NT) siRNA control (D-001210-02-05) and RAB38 
SMARTpool (L-010059-00-0005) siRNA were purchased from Dharmacon (Lafayette, 
CO). The non-targeting siRNA control was designed not to target any known genes in 
human, mouse or rat, as described by the manufacturer. Briefly, WM-266-4, IGR37 and 
M14 melanoma cells were cultured in six-well plates and transfected at 50% confluency 
with 100 nM non-targeting siRNA or RAB38-targeting siRNA using TransIT-X2 
transfection reagent (Mirus Bio LLC) following the manufacturer’s protocol. Transfected 
cells were incubated for an additional 48–72 h and analyzed for the expression level of the 
RAB38 protein using immunoblotting with specific antibodies. 
2.1.8 Real-time Quantitative PCR (RT-qPCR) 
At 24–72 h following transfection, total RNA was extracted from the cells using the 
Total RNA Kit I (Omega Bio-Tech), and 1 μg of total RNA was reverse-transcribed to 
generate cDNA by using M-MLV reverse transcriptase (Promega) and an oligo(dT)16 
primer. Gene expression levels were evaluated by RT-qPCR using iQ SYBR Green 
Supermix kit (Bio-Rad) with 100 ng cDNA input in a 20-μL total reaction volume. 
Expression level of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was 
used as an internal control for normalization. All primers were used at a final concentration 
of 500 nM. The relative gene expression was analyzed by the comparative cycle threshold 
(2−ΔΔCt) method. 
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2.1.9 Immunoblotting 
Total protein was extracted from cell pellet using ice-cold CelLytic M cell lysis reagent 
(Sigma-Aldrich, MO) containing 1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, 
MO). After cell lysis, the protein concentration was determined by the Quick Start™ 
Bradford Protein Assay (Bio-Rad, CA). Approximately 10–50 µg whole cell lysates, mixed 
with 4×Laemmli SDS loading buffer, were electrophoresed in 10% SDS-PAGE gels and 
transferred to nitrocellulose membranes. The membranes were incubated with primary 
antibodies against human RAB12 (Thermo Fisher; rabbit polyclonal, 1:2,000), RAB27A 
(Abcam; rabbit polyclonal, 1:5,000), RAB31 (4D12, Santa Cruz; rabbit polyclonal, 
1:2,000), RAB32 (Thermo Fisher; rabbit polyclonal, 1:2,000), RAB38 (A-8, Santa Cruz; 
mouse polyclonal, 1:2,000), MITF (D-9, Santa Cruz; mouse polyclonal, 1:5,000), or β-
actin (Thermo Fisher; rabbit polyclonal, 1:10,000), followed by incubation with 
peroxidase-labeled donkey anti-rabbit secondary antibody (Thermo Fisher; 1:10,000) or 
mouse m-IgGκ BP-HRP (Santa Cruz; 1:10,000). Amersham ECL Prime Western Blot 
Detecting Reagent (GE Healthcare, CA) was used to visualize the protein bands. 
2.1.10 Migration and Invasion Assays 
For transwell migration assay, cells (0.5−1×105) were placed in the upper chamber of 
transwell inserts (Corning, NY) with serum-free DMEM medium. DMEM medium 
containing 10% FBS was added to the lower chamber as chemoattractants and the cells 
were incubated at 37°C for 24 h. After removal of unmigrated cells, the cells attached to 
the reverse side of the membrane were stained with 0.5% crystal violet, and 5 randomly 
selected fields were counted under an inverted microscope in each experiment. The 
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invasion assay was conducted under the same conditions except that the transwell 
membranes were pre-coated with Matrigel (Corning, NY). 
2.1.11 Gelatin Zymography Assay 
At 24 h following plasmid transfection or 72 h following siRNA transfection, the 
culture medium was removed, and the cells were washed twice with, and reconstituted in, 
serum-free DMEM medium. After a 24-h incubation, conditioned medium (CM) was 
collected by centrifugation to remove cell debris. The collected CM was further 
concentrated using Microcon centrifugal filter units with a molecular weight cutoff of 30 
kDa (EMD Millipore, CA) and the Quick Start™ Bradford Protein Assay was used to 
determine the total protein concentration. Subsequently, 5–10 μg total CM proteins were 
separated using 7.5% SDS-PAGE gels containing 0.1% gelatin. After electrophoresis, the 
gels were incubated with zymography washing buffer (2.5% Triton X-100, 50 mM Tris-
HCl, pH 7.5) at room temperature for 1 h to remove excess SDS and renature the matrix 
metalloproteinases (MMPs). The gels were then incubated at 37°C for 24 h in zymography 
developing buffer (1.0% Triton X-100, 50 mM Tris-HCl, pH 7.5) to induce gelatin 
digestion by the renatured enzymes. The gels were subsequently stained with 0.5% 
Coomassie blue G-250 and destained until clear bands were visible against the dark 
background, indicative of proteolytic activities of MMPs. 
2.1.12 Chromatin Immunoprecipitation (ChIP) and RT-qPCR 
For ChIP, approximately 1107 WM-115 and WM-266-4 cells were harvested and 
fixed in PBS with 1% formaldehyde at room temperature for 10 min. After cross-linking, 
the cell pellets were resuspended in 1 mL of lysis buffer (50 mM Tris-HCl, pH 8.0, 150 
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mM NaCl, 5 mM EDTA, 1% Triton X-100, and 0.1% sodium deoxycholate) and sonicated 
to obtain DNA fragments of 300–500 bp in length. Anti-MITF antibody (ab12039, Abcam) 
or normal IgG (2729S, Cell Signaling Technology) was used to precipitate the chromatin. 
The precipitated DNA was purified using the QIAquick PCR purification Kit (Qiagen, 
MD) and used for RT-qPCR analysis. The primers used in RT-qPCR coupled to ChIP were: 
RAB38 forward, GCCACAAACTTGTGAGGTGT; RAB38 reverse, 
CTTCAGACCTGTGGTCAACG; TBC1D16 forward, 
GGCCACATACAAAGGGATCG; TBC1D16 reverse, CTCGCGGAGGCAATCTGA. 
2.1.13 Bisulfite Sequencing 
Approximately 5103 cells collected from six melanoma cell lines: WM-115, WM-
266-4, IGR39, IGR37, WM793 and 1205Lu, respectively, were lysed and treated with 
bisulfite using the EZ DNA Methylation-Direct Kit (Zymo Research, CA). The resulting 
DNA was subsequently amplified using ZymoTaq DNA Polymerase (Zymo Research, 
CA). RAB38 primers were designed using the MethPrimer 2.0 online tool 
(http://www.urogene.org/methprimer2/) to amplify the 179 bp fragment of the promoter 
region of the bisulfite converted-RAB38 gene (Chr11: 87,908,686–87,908,864, UCSC 
Genome Browser Human Feb. 2009 Assembly, GRCh37/hg19). The outer PCR was set up 
using the following primers: RAB38 forward primer, 5-
GGTTAGGGTTATAGGTGAAAATAGT-3, RAB38 reverse primer, 5- 
AACTCCTCCCCTAAAAATTAATCC-3. The reaction mixture was heated to 95°C for 
10 min followed by 40 cycles, denaturing at 95°C for 30 sec, annealing at 55°C for 45 sec 
and elongating at 72°C for 1 min, followed by a final elongation step at 72°C for 7 min. 
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The successful amplification and the right size of the amplicon were validated using 2% 
agarose gel. Amplicons were purified using the E.Z.N.A. Gel Extraction Kit (Omega Bio-
tek, GA). The purified PCR products were cloned into the pGEM®-T vector (Promega 
Corporation, WI) and the ligation products were selected by blue/white colony screening. 
Ten white colonies selected for each cell line were grown in liquid Lysogeny broth (LB) 
media overnight and the plasmids were extracted using GeneJET Plasmid Miniprep kit 
(Thermo Fishier Scientific, MA). The plasmids were then subjected to Sanger sequencing 
and the methylation status of each individual CpG dinucleotides in the amplicon was 
subsequently determined. Sequencing results were analyzed by the BiQ Analyzer software 
(http://biq-analyzer.bioinf.mpi-inf.mpg.de/) to generate the lollipop-representation. 
2.1.14 5-Aza-2-deoxycytidine (5-Aza) Treatment. 
WM-115 and IGR39 cells were seeded at a density of 2×104 cells/mL and treated at 24 
h later with 5 μM 5-Aza (Sigma-Aldrich, MO). Dimethyl sulfoxide (DMSO) was used as 
the vehicle control. The cells were replenished with freshly prepared DMSO/5-Aza in 
complete growth medium in every 24 h for up to 96 h of treatment (four pulses). Total 
RNAs were isolated for cDNA conversion and RT-qPCR analyses. 
2.3 Results 
2.3.1 Development of a High-throughput LC-MRM Assay for Targeted Quantitative 
Profiling of Small GTPases in Cultured Human Cancer Cells 
We set out to develop a high-throughput, multiplexed MRM-based targeted proteomics 
method for interrogating small GTPases in the entire human proteome. In this context, 
Halvey et al. 16 developed an LC-MRM method for quantifying wild-type and mutant K-
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RAS proteins in cultured cancer cells and pancreatic cyst fluids after enrichment of low-
molecular weight (20–25 kDa) proteins using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). In addition, Zhang et al. 17 described the use of MRM in 
combination with SDS-PAGE-based enrichment of proteins in the molecular weight range 
of 15–25 kDa to measure simultaneously the activities of 12 small GTPases after affinity 
enrichment using the GTPase-binding domains of four effector proteins. Building upon 
these previous studies, we developed an SDS-PAGE fractionation coupled with LC-MRM 
workflow for targeted quantification of small GTPases at the entire proteome scale. 
A high-throughput LC-MRM workflow for the proteome-wide interrogation of small 
GTPases requires the collection of tandem mass spectra and chromatographic retention 
time of unique (or signature) peptides derived from the targeted small GTPases. Because 
the expression of small GTPases differs among different cell lines, we established an MRM 
spectral library based on the data collected from shotgun proteomic analyses of tryptic 
digestion mixtures of low-molecular weight proteins (15–37 kDa) from the lysates of 9 
human cell lines of different tissue origins. These included GM00637 (skin), HCT-116 
(colon), HEK293T (kidney), HL-60 (peripheral blood), Jurkat T (peripheral blood), K562 
(bone marrow), MCF-7 (breast), WM-115 (skin), and WM-266-4 (skin). To this end, we 
fractionated the whole-cell protein lysate using SDS-PAGE, excised the gel bands in the 
molecular weight region of 15–37 kDa, reduced the cysteine residues in proteins with 
dithiothreitol and alkylated them with iodoacetamide. The proteins were then digested in 
gel with trypsin and the resulting peptide mixtures subjected to LC-MS/MS analysis in the 
DDA mode. The identified proteins (>5000) were then filtered using the DAVID 
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bioinformatic tool with the Gene Ontology (GO) term of “small GTPase”.10 The tandem 
mass spectra of all peptides from small GTPases along with their retention time information 
were subsequently imported into Skyline (version 3.6)18 to establish the MRM spectral 
library. 
To achieve reliable MRM-based quantification, we selected an average of three 
peptides that are unique for each small GTPase, and when necessary, to its specific 
isoform(s). To maximize selectivity and sensitivity for the MRM measurements, we chose 
the transitions corresponding to the formation of the three most abundant y-ions based on 
the MS/MS acquired from shotgun proteomic analyses (Figure 2.1).19 The complete list of 
small GTPases of the Ras superfamily was organized according to the individual 
subfamilies (Ras, Rho, Rab, Sar1/Arf, Ran, and others). The current version of the MRM 
spectral library encompassed 432 distinct peptides representing 113 non-redundant small 
GTPases encoded by unique genes. To our knowledge, this is the first targeted proteomic 
method developed for profiling comprehensively the Ras superfamily of small GTPases. 
To increase the throughput of the assay, we employed scheduled LC-MRM with the 
use of normalized retention time (iRT) 14. The iRT is a dimensionless score for a peptide 
derived from its empirical retention time observed in shotgun proteomic analysis and the 
retention times for a set of standard peptides analyzed under the same LC conditions. In 
scheduled LC-MRM analysis, the mass spectrometer could be scheduled to collect subsets 
of transitions in predefined retention time windows according to the chromatographic 
setup, where the retention times for the targeted peptides were predicted from their iRT 
values in the library and from the actual retention times observed for the standard peptides. 
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In doing so, we established a robust and high-throughput MRM-based targeted proteomic 
workflow for the Ras superfamily of small GTPases, where the 432 unique peptides from 
small GTPases could be monitored in a single LC-MRM run. 
2.3.2 Scheduled LC-MRM Analysis Revealed Differential Expression of Small GTPases 
in Paired Primary/Metastatic Melanoma Cells 
Paired cell lines derived from the same cancer patients are powerful resources for 
investigating the mechanisms of cancer progression. Here we employed three pairs of 
primary/metastatic melanoma cell lines for the targeted analyses of small GTPases: The 
“WM” pair consists of WM-115 and WM-266-4, which were derived from the primary 
tumor site and the right thigh skin metastatic site of the same melanoma patient, 
respectively;20 the “IGR” pair is comprised of IGR39 and IGR37, which were respectively 
derived from the primary tumor site and the groin metastatic site of another individual;21 
in the “WMLu” pair, WM793 was initiated from a superficial spreading melanoma, and 
1205Lu was derived from a lung metastasis of WM793 cells after subcutaneous injection 
into the tail vein of an immune-deficient mouse.22 
We employed stable isotope-labeling by amino acid in cell culture (SILAC),23 in 
conjunction with the above-described SDS-PAGE fractionation and LC-MRM analysis, 
for assessing the differential expression of small GTPases in the three pairs of matched 
primary/metastatic melanoma cells (Figure 2.1). To this end, we first modified the Skyline 
MRM library by incorporating the corresponding transitions for the “heavy” forms of 
precursor and fragment ions. By using this approach, we were able to quantify 
approximately 100 small GTPases in each of the three paired melanoma cell lines. Among 
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the 101 small GTPases quantified for the WM pair (Figure 2.2), 14 and 10 were 
substantially up- and down-regulated (by at least 1.5-fold), respectively, in the metastatic 
(WM-266-4) relative to the primary (WM-115) melanoma cells (Figure 2.3). In addition, 
among the 93 small GTPases quantified for the IGR pair, 20 and 12 were considerably up- 
and down-regulated, respectively, in the metastatic (IGR37) relative to the primary 
(IGR39) melanoma cells (Figure 2.3). Of the 93 small GTPases quantified for the third 
pair, 9 and 24 were up- and down-regulated by at least 1.5-fold in the metastatic (1205Lu) 
compared to the primary (WM793) melanoma cells, respectively (Figure 2.3). 
We also explored the similarities and differences in the expression profiles of small 
GTPases by hierarchical clustering analysis of the quantitative proteomics data. It turned 
out that the features in differential expression of small GTPases, induced by metastatic 
transformation, were more similar for the WM and IGR pairs than between either of the 
two pairs and the WMLu pair (Figure 2.3). This might be attributed in part to the 
differences in transcriptional and/or epigenetic regulations in the three pairs of melanoma 
cell lines (vide infra) and the fact that the metastatic lines in the first two pairs were derived 
from melanoma patients, whereas that of the last pair was obtained from experimental 
metastasis in mouse, as noted above. 
It is worth noting that, by utilizing the iRT algorithms, we were able to accurately 
predict the actual retention times for the targeted peptides with the use of a 6-min retention 
time window. As depicted in Figure 2.4, the R2 values were 0.992 and 0.996 for LC-MRM 
measurements of peptide samples obtained from the WM-115/WM266-4 and 
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IGR39/IGR37 paired cell lines, respectively. Moreover, this method also displayed 
excellent reproducibility between different replicates. 
For comparison, we also analyzed the peptide samples from the WM-115/WM-266-4 
cells using shotgun proteomic approach on an LTQ Orbitrap Velos mass spectrometer. The 
results showed that the LC-MRM method outperformed the shotgun proteomic method in 
reproducibility and sensitivity, the latter of which is reflected by the pronouncedly larger 
numbers of small GTPases quantified by the former method (Figure 2.4). The excellent 
reproducibility of the MRM-based quantification is manifested by the observation that 101 
small GTPase proteins could be reproducibly quantified in all three sets of SILAC labeling 
experiments. In contrast, among the 59 small GTPases detected by the shotgun proteomic 
method, 9 and 4 were exclusively detected in the forward- and reverse-SILAC experiments, 
respectively (Figure 2.4). Taken together, the established targeted proteomic workflow 
provided excellent sensitivity and reproducibility, and it allowed for robust and high-
throughput quantifications of small GTPases in melanoma cells. 
2.3.3 Targeted Proteomics Revealed the Up-regulation of RAB27A and RAB38 in WM-
266-4 and IGR37 Metastatic Melanoma Cells 
One goal of the present study was to uncover small GTPases that drive and/or suppress 
melanoma metastasis. Hence, we expected to confirm the differential expression of some 
previously reported drivers and/or suppressors for melanoma metastasis. In this vein, 
RAB27A was shown to promote melanoma metastasis through the regulation of the MET 
network.24 Indeed, our LC-MRM data revealed significant up-regulations of RAB27A in 
the WM-266-4 and IGR37 metastatic melanoma cell lines relative to the corresponding 
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primary melanoma cells, though similar observation was not made for the WMLu pair 
(Figure 2.5). 
Our LC-MRM quantification data showed that 14, 20 and 12 small GTPases were 
differentially expressed by at least two-fold in the metastatic (i.e. WM-266-4, IGR-37, and 
1205Lu) compared to the corresponding paired primary (i.e. WM-115, IGR-39, and 
WM793) melanoma cells. Among other differentially expressed small GTPases, RAB38 
was expressed at much lower levels in two out of the three primary melanoma cell lines 
(WM-115 and IGR39) than the corresponding metastatic lines (WM-266-4 and IGR37), as 
determined from LC-MRM analyses and confirmed by Western blot analyses (Figure 2.6). 
RAB38 was, however, not detectable in the WM793 or 1205Lu cells by LC-MRM or 
Western blot analyses (Figure 2.6). We also validated, by using Western blot analyses, the 
LC-MRM quantification results for several other small GTPases, including RAB12, 
RAB31, and RAB32 (data not shown). The highly consistent results obtained from LC-
MRM and Western blot analyses underscored the robustness of the LC-MRM method in 
assessing quantitatively the differential expression of small GTPase proteins. 
2.3.4 Potential Roles of RAB38 in Melanoma Progression 
We next asked whether RAB38 expression level modulates prognosis in melanoma 
patients. We performed Kaplan-Meier survival analysis in melanoma patient cohort in the 
Cancer Genome Atlas (TCGA) database, and the results showed that poorer patient 
survival was significantly correlated with higher levels of mRNA expression of RAB38 
gene (hazard ratio, HR = 1.323; 95% confidence interval, 95% CI = 1.009−1.736; Logrank 
p = 0.0402) (Figure 2.7). Furthermore, pan-cancer analysis of TCGA data using cBio 
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Cancer Genomics Portal (cBioPortal: http://www.cbioportal.org/)25 revealed that the 
mRNA expression levels of RAB38 gene were highly up-regulated in two types of 
melanoma (skin cutaneous melanoma, SKCM; uveal melanoma, UVM) compared to other 
types of cancers (Figure 2.7). 
We also queried public databases for the expression levels of RAB38 gene in other 
melanoma cell lines. First, analysis of the NCI-60 Human Tumor Cell Lines Database 
(https://dtp.cancer.gov/discovery_development/nci-60/) revealed the marked up-
regulation of RAB38 gene in various metastatic melanoma cell lines (Figure 2.7). Likewise, 
the mRNA expression levels of RAB38 gene were up-regulated in the majority of 61 
metastatic melanoma cell lines in the Cancer Cell Line Encyclopedia (CCLE) Database 
(http://www.broadinstitute.org/ccle/home) (Figure 2.7). Moreover, we utilized publicly 
accessible transcriptomic profiles in the Gene Expression Omnibus (GEO) database to 
analyze the mRNA expression of small GTPases in melanoma cells. In particular, we 
assessed previously published data about the differential gene expression between the 
highly metastatic human melanoma cell lines derived from an animal metastasis model and 
the poorly metastatic parental lines (accession number: GSE7929).26 We found that RAB38 
mRNA levels were again significantly up-regulated in the highly metastatic melanoma 
cells relative to the poorly metastatic counterparts (Figure 2.7). Taken together, the above 
results suggested RAB38 as a potential driver for melanoma metastasis. 
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2.3.5 RAB38 Promotes Invasion of Melanoma Cells through Up-regulation of Matrix 
Metalloproteinases (MMPs) 
We next investigated, by employing transwell migration and invasion assay, whether 
the invasive phenotypes of melanoma cells could be modulated by the expression levels of 
RAB38 gene. Our results showed that ectopic overexpression of RAB38 protein in the WM-
115 primary melanoma cells to a similar level as that in the metastatic WM-266-4 cells 
resulted in a significant increase in the number of invaded cells (Figure 2.8). Reciprocal 
experiment with the metastatic WM-266-4 cells showed that the siRNA-mediated 
knockdown of RAB38 led to a significant decline in cell invasion, which is accompanied 
with a slight diminution of cell migration (Figure 2.8). In this vein, the knockdown 
efficiency of RAB38 gene by siRNA was confirmed by both real-time quantitative PCR 
(RT-qPCR) and immunoblot analysis. Collectively, we demonstrated that RAB38 
promotes melanoma invasion in vitro. 
We also examined the roles of matrix metalloproteinases (MMPs) in RAB38-mediated 
alterations in invasiveness of melanoma cells. Degradation of extracellular matrix (ECM) 
proteins by MMPs, a family of zinc- and calcium-dependent proteolytic enzymes, 
constitutes a crucial initiating step in tumor invasion. Among the 23 members of the human 
MMP family, MMP2 (gelatinase A) and MMP9 (gelatinase B) are responsible for 
remodeling the ECM environment and facilitating cancer metastasis.27 Hence, we explored 
how the expression levels of RAB38 alter the mRNA expression and enzymatic activities 
of MMP2 and MMP9. 
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Consistent with the RT-qPCR results showing the diminished mRNA expression of 
MMP2 and MMP9 genes, gelatin zymography assay showed that the RNAi knockdown of 
RAB38 led to markedly diminished activities of both the pro-enzyme and active forms of 
MMP2 and MMP9 in the metastatic WM-266-4 cells (Figure 2.9). This result supports the 
role of RAB38 in modulating the mRNA expression and activities of MMP2 and MMP9, 
thereby altering the invasive potential of melanoma cells. In a reciprocal experiment, 
overexpression of RAB38 induced slight, yet significant increases in the enzymatic 
activities of MMP2 and MMP9 in WM-115 primary melanoma cells, which were in 
accordance with the heightened mRNA expression of these two genes as revealed by RT-
qPCR analysis (Figure 2.9). Together, these results demonstrated that RAB38 regulates the 
expression levels and activities of MMP2 and MMP9 in melanoma cells. 
Having revealed the regulatory roles of RAB38 in the secretion of MMPs in WM-115 
and WM-266-4 melanoma cell lines, we extended our studies to IGR37 and M14 metastatic 
melanoma cells. In this context, M14 cells were also chosen for the study because these 
cells displayed pronounced expression of RAB38 (Figure 2.10). Consistent with our 
hypothesis, RT-qPCR experiments revealed down-regulations of MMP2 and MMP9 after 
RNAi knockdown of RAB38 in M14 cells (Figure 2.10). In addition, in IGR37 cells, we 
only observed diminished mRNA levels of MMP9, but not MMP2, after RNAi knockdown 
of RAB38 (Figure 2.10). Similar as what we observed for WM-266-4 cells, gelatin 
zymography assay results showed that RAB38 knockdown led to significantly decreased 
activities of MMP2 and MMP9 in M14 and IGR37 cells (Figure 2.10), lending further 
evidence to support that RAB38 regulates MMP2 and MMP9 activities in a range of 
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metastatic melanoma cell lines. The observation of a decreased level of secreted MMP2 
protein from IGR37 cells, but not the mRNA expression of the MMP2 gene in these cells, 
upon genetic depletion of RAB38 suggests that RAB38 modulates the level of secreted 
MMP2 through a post-transcriptional mechanism. 
2.3.6 Epigenetic Reactivation of RAB38 in Metastatic Melanoma Cells 
We next examined the mechanisms through which RAB38 gene was overexpressed in 
metastatic over primary melanoma cells. We first asked whether elevated RAB38 
expression is accompanied with previously reported genetic alterations in melanoma, 
including mutations in BRAF, NRAS and TP53 genes. It turned out that, in the TCGA 
SKCM patient cohort, the expression levels of RAB38 gene did not exhibit any significant 
correlations with frequently observed mutations in BRAF, NRAS, or TP53 gene. 
Numerous studies have underscored the significant roles of epigenetic and 
transcriptional regulations of oncogenes during cancer progression;28 hence, we next 
assessed whether these mechanisms contribute to elevated expression of RAB38 gene in 
metastatic melanoma cells. Microphthalmia-associated transcription factor (MITF) is the 
master regulator of melanocyte development, function, and survival through modulating 
many genes involved in differentiation and cell cycle progression.29 In this vein, earlier 
ChIP-Seq experiments conducted in 501Mel human melanoma cells identified MITF loci 
immediately upstream of the promoters of several Rab GTPase genes, including, among 
others, RAB27A and RAB38.30 Therefore, we next asked whether elevated expression of 
RAB38 in the metastatic WM-266-4 and IGR37 cells are due to heightened transcriptional 
regulation mediated by MITF. We indeed observed the up-regulation of MITF at both the 
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mRNA and protein levels in the two metastatic lines of melanoma cells (i.e. WM-266-4 
and IGR37) relative to the corresponding primary melanoma cells (i.e. WM-115 and 
IGR39), though the mRNA expression of MITF was not detectable in 1205Lu cells. 
To explore further the possible functional linkage between RAB38 expression and 
MITF regulation, we analyzed publicly available data for different cell line and patient 
cohorts. In cohort GSE7929, both MITF and RAB38 were highly up-regulated at the mRNA 
levels in the highly metastatic derivatives of A375 human melanoma cells in comparison 
with the poorly metastatic parental lines. In addition, interrogation of the gene expression 
data of 120 melanoma cell lines (120Mel) and the Cancer Cell Line Encyclopedia (CCLE) 
Database (http://www.broadinstitute.org/ccle/home) revealed that the mRNA expression 
levels of RAB38 and MITF were positively correlated. 
We also extended the bioinformatic analyses by examining RAB38/MITF expressions 
in different patient cohorts including the TCGA-SCKM cohort and two other patient 
cohorts (GSE7553 and GSE8401) retrieved from the GEO database. We again observed a 
clear positive correlation between MITF and RAB38 in both primary and metastatic 
melanoma tissues (Figure 2.11). Notably, RAB38 expression was significantly up-regulated 
in the metastatic melanoma tissues relative to primary melanoma tissues from patients 
displaying MITF-high signature, namely for the patient population stratified with higher 
levels of MITF expression (Figure 2.11); however, an opposite trend was observed for 
patients exhibiting MITF-low signature, suggesting that the upregulation of RAB38 in 
metastatic melanoma is likely driven by MITF. Moreover, pathway analysis of the RAB38 
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gene co-expression signature in the TCGA-SKCM data showed that MITF is highly 
enriched and functionally involved with RAB38 (Figure 2.11). 
We also extended the analyses of the TCGA data to two known driver genes for 
melanoma metastasis, i.e. RAB27A and TBC1D16, both of which are enriched in the RAB38 
gene co-expression signature and regulated by MITF (Figure 2.12). Similar to RAB38, in 
two additional patient cohorts (GSE7553 and GSE8401), we observed significantly higher 
levels of expression of RAB27A and TBC1D16 in the metastatic melanoma tissue samples 
carrying MITF-high signature (i.e. with high levels of MITF expression), but not in those 
with MITF-low signature (Figure 2.12). 
To further substantiate the direct regulation of RAB38 by MITF, we performed 
chromatin immunoprecipitation (ChIP) followed by quantitative PCR (ChIP-qPCR) 
analysis to assess the occupancy of MITF protein in the promoter regions of RAB38 and 
TBC1D16 genes. In this respect, the 47-kDa isoform of TBC1D16 was observed to be 
regulated by MITF through binding to its remote promoter region.31-32 Indeed, our ChIP-
qPCR results revealed higher levels of enrichment of MITF to the promoter elements of 
both RAB38 and TBC1D16 genes in WM-266-4 cells relative to WM-115 cells, suggesting 
that RAB38 is directly regulated by MITF in the metastatic WM-266-4 melanoma cells 
(Figure 2.12). 
Having assessed the MITF-mediated transcriptional regulation of RAB38, we next 
asked whether the expression of RAB38 in these melanoma cells are epigenetically 
modulated. Analyses of the previously published methylation microarray data for 
IGR39/IGR37 (accession number: GSE46522) and WM-115/WM-266-4 (accession 
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number: GSE70621) cells showed diminished levels of cytosine methylation at several 
CpG sites in the promoter region of RAB38 gene in the metastatic over primary melanoma 
cells (Figure 2.13). These results suggest that promoter hypomethylation and the ensuing 
epigenetic reactivation may elicit increased levels of RAB38 expression in the two 
metastatic lines (i.e. IGR37 and WM-266-4). To further substantiate this finding, we 
assessed the methylation status at 10 CpG sites in the promoter region of RAB38 gene in 
the three pairs of primary/metastatic melanoma cell lines by employing bisulfite 
sequencing. Strikingly, our results revealed that these 10 CpG sites were entirely 
unmethylated (0.0% methylation) in WM-266-4 and IGR37 cells, whereas the overall 
methylation levels at these sites were 98.0% and 41.0% in WM-115 and IGR39 cells, 
respectively (Figure 2.13). In contrast, these CpG sites are hypermethylated in both the 
WM793 (99.0%) and its matched metastatic melanoma line (i.e. 1205Lu, 93.0%) (Figure 
2.13). These results support that epigenetic reactivation contributes to elevated expression 
of RAB38 in the metastatic lines of the WM and IGR pairs of melanoma cells, whereas 
epigenetic silencing led to lack of detectable levels of RAB38 protein in the primary or 
metastatic melanoma lines of the WMLu pair. To further validate that RAB38 expression 
is regulated by CpG methylation, we treated WM-115 and IGR39 cells with a DNA 
demethylating reagent, 5-aza-2-deoxycytidine (5-Aza), for 96 h, and assessed the mRNA 
levels of RAB38 by RT-qPCR. Indeed, our results showed that expression level of RAB38 
was significantly increased upon 5-Aza treatment (Figure 2.13). 
We also assessed whether RAB38 hypomethylation occurs in metastatic melanoma 
patients of a previously reported melanoma cohort (accession number: GSE44662). It 
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turned out that the promoter methylation of RAB38 gene was significantly lower in 
metastatic than primary melanoma tissues (Figure 2.14). In addition, analysis of the TCGA-
SKCM cohort revealed that the mRNA expressions of MITF and RAB38 genes were 
inversely correlated with their promoter methylation levels, and promoter hypomethylation 
of the RAB38 gene was correlated with poor patient survival (Figure 2.14). 
Together, our above results furnished evidence to support a model where loss of 
cytosine methylation in the promoter region of RAB38 gene leads to its epigenetic 
reactivation, which involves augmented binding of MITF transcription factor to the 
promoter region. 
2.4 Discussion 
Small GTPases of the Ras superfamily are master regulators of cellular trafficking. 
Here, we developed a novel targeted quantitative proteomic method for human small 
GTPase proteome with an unprecedented level of coverage. Our MRM-based targeted 
proteomic method enabled a powerful and high-throughput discovery of small GTPases 
that become aberrantly expressed during metastatic transformation of melanoma. 
Our quantitative proteomic data, along with the results obtained from cell-based assays 
and from bioinformatic analyses of publicly available data, support the role of RAB38 in 
promoting melanoma metastasis. Thus, RAB38 joins other members of the small GTPase 
family that regulate melanoma metastasis, including RAB27A,5 RND3,33 and ARF6.34 
RAB38 displays a unique tissue-specific expression pattern, with the highest levels 
being observed in the lung and skin.35 Together with RAB27A and RAB32, RAB38 has a 
well-established function in regulating the melanosome biogenesis and maturation.36 It was 
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also found to be important for pigmentation in chocolate mice by regulating the trafficking 
of tyrosinase-related protein 1 (TYRP1).37 Furthermore, previous studies unveiled the role 
of RAB38 in mesenchymal subtypes and malignant progression of glioma, where elevated 
expression of RAB38 confers poor prognosis in glioma patients.38 However, no reports 
have yet elucidated the mechanistic relationship between RAB38 and the invasive 
properties of any type of tumor. Here, we unveiled a previously unrecognized role of 
RAB38 in regulating melanoma metastasis. Furthermore, our results support that RAB38 
promotes melanoma progression by regulating the secretion and activities of MMP2 and 
MMP9, which are essential for metastatic transformation of tumor cells. 
To the best our knowledge, this is the first report to link RAB38 with matrix 
metalloproteinase pathways. Several small GTPases were previously reported to be 
involved in the regulation of the MMP pathways through their roles in trafficking. For 
instance, RAB37 was previously identified as a metastasis suppressor in lung 
adenocarcinoma by influencing the metallopeptidase inhibitor 1 (TIMP1)-MMP9 
pathway.39 In particular, RAB37 was found to suppress metastasis through regulating the 
exocytotic trafficking of TIMP1, thereby inactivating MMP9 signaling and suppressing 
invasion. Moreover, RAB2A and RAB27B were shown to promote breast cancer invasion 
by stimulating endocytic trafficking of membrane type 1 (MT1)-MMP and MMP2, 
respectively.40-41 Thus, we reason that RAB38 may play a novel role in the endocytic or 
exocytotic trafficking of MMP enzymes and/or their regulators, and future studies are 
warranted for illustrating the exact mechanisms through which RAB38 regulates MMPs. 
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We also explored the potential upstream mechanisms of RAB38 regulation. In this 
connection, our results revealed a strong correlation between the mRNA expressions of 
RAB38 and MITF. Furthermore, we observed a complete loss of cytosine methylation, 
which is accompanied with elevated enrichment of MITF transcription factor, in the 
promoter of RAB38 gene in WM-266-4 cells relative to WM-115 cells, supporting that 
epigenetic reactivation contributes to the elevated expression of RAB38 gene in metastatic 
melanoma cells. The complete loss of promoter methylation was also observed for the 
metastatic IGR37 cells, but not for the metastatic 1205Lu cells or the paired WM793 
primary melanoma cells. These findings are consistent with the relative levels of RAB38 
proteins in the three paired melanoma cell lines. In this context, it is worth noting that 
Mueller et al.42 observed, from Western blot analysis, higher levels of RAB38 in 2 human 
melanocyte samples than 3 primary and 3 metastatic melanoma tissues, though these cells 
and tissues were not derived from the same patients. These observations are in line with 
the notion that melanoma is a highly heterogeneous type of cancer.43 Further studies are 
therefore needed to reveal the mechanisms underlying the metastatic transformation for the 
WM793/1205Lu paired cell lines. Nevertheless, the interrogation of TCGA and other 
patient cohort data uncovered a significant correlation between the elevated mRNA 
expression level of RAB38 gene, or its promoter hypomethylation, and poor prognosis in 
melanoma patients. Moreover, a strong correlation between the expression levels of MITF 
and RAB38 genes was observed in a large number of melanoma cell lines and tumor tissues. 
Thus, this epigenetic and transcriptional mechanism might be at play for a substantial 
subset of melanoma patients. 
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Apart from RAB38, our targeted proteomic approach led to the discovery of other small 
GTPases that may function in melanoma metastasis. For instance, the consistent down-
regulation of RAB12 in the WM-266-4 and 1205Lu metastatic melanoma cells relative to 
their primary melanoma counterparts suggests that this protein may serve as a suppressor 
for melanoma metastasis. RAB12 was found to regulate the constitutive degradation of 
transferrin receptor,44 and elevated levels of transferrin receptors were previously observed 
in melanoma cells metastasized to brain.45 Thus, RAB12 may suppress melanoma 
metastasis through elevated accumulation of transferrin receptors. Furthermore, we found 
that RAB31 was consistently down-regulated in all three metastatic melanoma lines 
relative to the corresponding primary lines. Grismayer et al.46 demonstrated that the 
increased levels of RAB31 led to a switch of invasive to proliferative phenotype in breast 
cancer cells. It will be important to explore, in the future, the role of RAB31 in the 
metastatic transformation of other types of cancer, including melanoma. 
Small GTPases, like other types of GTP-binding proteins, can shuffle between the 
GTP-bound active states and the GDP-bound inactive states, which are regulated by GEFs, 
GAPs and GDIs.2 The conformational alterations of small GTPases between these two 
states can modulate their binding towards different downstream effector proteins.2 In this 
vein, a limitation of our targeted proteomic approach is its inability in profiling the 
activities of small GTPases. This limitation can be overcome by further multiplexing the 
assay with affinity-based techniques. As discussed above, by combining affinity 
enrichment with gel-based fractionation, Zhang et al.17 developed an MRM-based assay to 
profile the activities of 12 small GTPases; however, the throughput of this assay was 
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relatively low. In addition, proteome-wide enrichment of active small GTPases using 
binding domains of their effector proteins is very challenging due to the tremendous 
structural diversity of effectors and the lack of knowledge about the effectors for some 
small GTPases. On the other hand, enrichment of small GTPases and other GTP-binding 
proteins with the use of acyl nucleotide affinity probes,47 together with LC-MRM analysis, 
may constitute an alternative approach for high-throughput profiling of activities of small 
GTPases. Such an approach is currently being explored in our laboratory. 
In conclusion, we developed successfully a novel MRM-based targeted quantitative 
proteomic method for the comprehensive profiling of small GTPases. By using this 
method, we assessed the differential expression of small GTPases in paired 
primary/metastatic melanoma cell lines. The method, when combined with bioinformatic 
analysis of publicly available data and cell-based assays, constitutes an integrated and 
effective approach to discover small GTPase that serve as drivers or suppressors for 
melanoma metastasis. We found that RAB38 promotes melanoma metastasis in vitro 
through the regulation of matrix metalloproteinases, and the increased expression of 
RAB38 in metastatic melanoma cells arises from diminished promoter methylation and 
heightened binding of the MITF transcription factor. It can be envisaged that the targeted 
proteomic method can also be employed for studying small GTPase signaling (e.g. for 
discovering small GTPase substrates for GEFs and GAPs) and for investigating the 
implications of small GTPases in other aspects of cancer biology or cancer therapy (e.g. in 
therapeutic resistance). 
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Our finding that epigenetic reactivation of RAB38 gene stimulates melanoma 
metastasis suggests that the expression level of RAB38, in conjunction with the expression 
level of MITF, may serve as a biomarker for the prognosis of melanoma patients. In 
addition, targeting epigenetic modulation of RAB38 and/or its interactions with other 
proteins may serve as the basis for the therapeutic interventions of metastatic melanoma. 
In the latter respect, small-molecule inhibitors were previously reported for suppressing 
the interactions between small GTPases and their effector or GEF proteins.48-49 
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Figure 2.1 Schematic diagram showing a targeted proteomic strategy for high-
throughput quantitative profiling of small GTPases in paired primary/metastatic 
melanoma cells. 
(A) A representative MS/MS obtained from data-dependent acquisition supporting the 
reliable identification of the peptide LLALGDSGVGK from RAB27B; (B) LC-MRM 
spectra for the same peptide from targeted analysis with light- and heavy-labeled lysine on 
the C terminus, respectively. The distribution of the peak intensities was consistent with 
the theoretical distribution found in the MS/MS from the MRM spectral library; (C) 
Schematic diagram showing the targeted proteomic workflow, relying on metabolic 
labeling with SILAC, SDS-PAGE fractionation, and LC-MRM analysis, for quantifying 
the differential expressions of small GTPases in WM-115 (primary) and WM-266-4 
(metastatic) melanoma cells. 
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Figure 2.2 Heatmap showing the differential expression of small GTPases in paired 
WM-115 and WM-266-4 melanoma cells. 
Shown are the Log2R(WM-266-4/WM-115) values obtained from scheduled LC-MRM 
analyses of samples from two forward- and one reverse-SILAC labeling experiments. The 
red and blue bars designate those small GTPases that are up-and down-regulated, 
respectively, in the WM-266-4 metastatic melanoma cells as compared with in the WM-
115 primary melanoma cells, as indicated by the scale bar. 
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Figure 2.3 LC-MRM-based targeted quantitative proteomic assay revealed 
differential expression of small GTPases during melanoma metastasis.  
(A−C) Bar graphs showing substantially up-regulated (>1.5-fold) and down-regulated 
(>1.5-fold) small GTPases quantified from LC-MRM experiments for: (A) WM-115/WM-
266-4 paired melanoma cell lines; (B) IGR39/IGR37 paired melanoma cell lines; and (C) 
WM793/1205Lu paired melanoma cell lines; Error bars in (A)–(C) represent means ± 
standard deviation of results from three independent SILAC labeling experiments (two 
forward- and one reverse-SILAC). 
(D) Hierarchical clustering of commonly quantified small GTPases among the WM, IGR 
and WMLu paired melanoma cell lines using the Z-score values for R(metastatic/primary) 
for individual proteins. 
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Figure 2.4 The scheduled LC-MRM platform provides accurate retention time (RT) 
prediction of targeted peptides, high sensitivity and excellent reproducibility. 
(A) The correlation between iRT and measured RT values in LC-MRM experiments on a 
TSQ Vantage triple-quadruple mass spectrometer (157-min linear gradient) with a very 
high correlation coefficient (R2 = 0.992); (G) Venn diagram showing the overlap of 
quantified small GTPases from WM-115 and WM-266-4 SILAC cell lysates obtained from 
LC-MRM analysis and shotgun proteomics experiments; (H) Venn diagram depicting the 
overlap of quantified small GTPases from WM-115 and WM-266-4 SILAC cell lysates the 
forward (F) and reverse (R) labeling experiments obtained from shotgun proteomics 
experiments. 
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Figure 2.5 LC-MRM and Western blots revealed consistently higher levels of 
expression of RAB27A proteins in metastatic melanoma cell lines (WM-266-4 and 
IGR37) than the paired primary melanoma cell lines (WM-115 and ICR39). 
(A) Extracted MRM traces for three transitions (y8, y7, and y6) monitored for a unique 
tryptic peptide from RAB27A, i.e. TSVLYQYTDGK, with light (blue) and heavy (red) 
labels in forward- and reverse-SILAC experiments for both WM-115/WM-266-4 and 
IGR39/IGR37 paired melanoma cells; (B) Western blot analysis confirmed the elevated 
expression of RAB27A in WM-266-4 and IGR37 cells; (C) Quantification results for 
RAB27A from LC-MRM and Western blot analyses. The values represent the mean and 
standard deviation of results obtained from three independent experiments. 
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Figure 2.6 LC-MRM and Western blots revealed consistently higher levels of 
expression of RAB38 proteins in metastatic melanoma cell lines (WM-266-4 and 
IGR37) than the paired primary melanoma cell lines (WM-115 and ICR39). 
(A) Extracted MRM traces for three transitions (y9, y8, and y7) monitored for a unique 
tryptic peptide from RAB38, i.e. LLVIGDLGVGK, with light (blue) and heavy (red) labels 
in forward and reverse SILAC experiments for both WM-115/WM-266-4 and 
IGR39/IGR37 paired melanoma cells; (B) Western blot analysis confirmed the elevated 
expression of RAB38 in WM-266-4 and IGR37 cells; (C) Quantification results for RAB38 
from LC-MRM and Western blot analyses. The values represent the mean and standard 
deviation of results obtained from three independent experiments. 
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Figure 2.7 Bioinformatic analyses revealed RAB38 as a potential driver for melanoma 
progression. 
(A) Kaplan-Meier plot of overall patient survival stratified by median RAB38 mRNA 
expression in the TCGA-SKCM cohort. Log-rank test p-value is displayed; (B) Box plot 
showing enriched RAB38 mRNA expressions in the TCGA-SKCM and the TCGA-UVM 
cohorts; (C) Scatter plot showing up-regulated RAB38 mRNA expression in various 
metastatic melanoma cell lines (highlighted as black dots) in the NCI-60 Human Tumor 
Cell Lines Database; (D) Scatter plot showing up-regulated RAB38 mRNA expressions in 
melanoma cell lines in the Cancer Cell Line Encyclopedia (CCLE) Database; (E) Scattered 
plot showing up-regulated RAB38 mRNA expressions in various metastatic melanoma cell 
lines (highlighted as dark grey dots) in the CCLE Database; (F) RAB38 mRNA levels were 
significantly up-regulated in the highly metastatic derivatives of A375 cells cell lines 
compared to the poorly metastatic A375 parental cells (GEO data series: GSE7929). The 
p values were calculated by using an unpaired two-tailed Student’s t test. 
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Figure 2.8 RAB38 enhanced melanoma metastasis in vitro. 
(A) In vitro migration and invasion assays showed similar migration rates but significantly 
increased invasion rates in FLAG-RAB38-expressing WM-115 cells as compared to empty 
vector control. Migration and invasion capabilities were measured by using transwell 
migration and Matrigel-based invasion assays, respectively; (B) Quantification results for 
in vitro migration and invasion assay shown in panel (A). (C) In vitro migration and 
invasion assays showed similar migration rates but significantly decreased invasion rates 
for WM-266-4 cells with siRAB38 knockdown as compared to non-targeting siRNA 
control; (D) Quantification results for in vitro migration and invasion assay shown in panel 
(C). Error bars represent mean ± standard deviation (n = 3). The p values were calculated 
by using an unpaired, two-tailed Student’s t test. 
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Figure 2.9 RAB38 regulates melanoma metastasis by mediating the expression levels 
and activities of MMP2 and MMP9. 
(A) RT-qPCR assays showed decreased expression levels of MMP2 and MMP9 in WM-
266-4 cells with siRAB38 knockdown as compared to non-targeting siRNA control. Error 
bars represent mean ± standard error of the mean (SEM) (n = 3); (B) Gelatin zymography 
assays revealed diminished enzymatic activities of MMP2 and MMP9 in WM-266-4 cells 
with siRAB38 knockdown as compared to non-targeting siRNA control; (C) 
Quantification results for gelatin zymography assays shown in (B). Error bars represent 
mean ± standard deviation (n = 3). (D) Real-time quantitative PCR (RT-qPCR) assays 
showed increased expression levels of MMP2 and MMP9 in FLAG-RAB38-expressing 
WM-115 cells as compared to empty vector control. Error bars represent mean ± SEM (n 
= 3); (E) Gelatin zymography assays revealed elevated enzymatic activities of MMP2 and 
MMP9 in FLAG-RAB38-expressing WM-115 cells as compared to empty vector control; 
(F) Quantification results for gelatin zymography assays shown in (E). Error bars represent 
mean ± standard deviation (n = 3). The p values for all figures are as follows: “∗”, 0.01 < 
p < 0.05; “∗∗”, 0.001 < p < 0.01; “∗∗∗”, p < 0.001. The p values were calculated by using 
a paired, two-tailed Student’s t test. 
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Figure 2.10 RAB38 mediates both the expression levels and activities of MMP2 and 
MMP9 in metastatic M14 and IGR37 cells. 
(A) RT-qPCR analysis showed pronouncedly higher expression levels of RAB38 in M14 
cells as compared to WM793 and 1205Lu cells. Error bars represent mean ± SEM (n = 3); 
(B) RT-qPCR analysis showed decreased expression levels of MMP2 and MMP9 in M14 
cells with siRAB38 knockdown as compared to non-targeting siRNA control. Error bars 
represent mean ± SEM (n = 3); (C) RT-qPCR analysis showed decreased expression level 
of MMP9, but not MMP2, in IGR37 cells with siRAB38 knockdown as compared to non-
targeting siRNA control. Error bars represent mean ± SEM (n = 3); The p values in (A) 
and (B) were calculated by using unpaired two-tailed Student’s t test: “∗”, 0.01 < p < 0.05; 
“∗∗”, 0.001 < p < 0.01; “∗∗∗”, p < 0.001; (D) Gelatin zymography assays revealed 
diminished enzymatic activities of MMP2 and MMP9 in M14 cells with siRAB38 
knockdown as compared to non-targeting siRNA control; (E) Gelatin zymography assays 
revealed diminished enzymatic activities of MMP2 and MMP9 in IGR37 cells with 
siRAB38 knockdown as compared to non-targeting siRNA control. 
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Figure 2.11 RAB38 expressions in large melanoma cell line or patient cohorts were highly correlated with the melanoma 
lineage-specific transcription factor MITF. 
(A−D) Heatmaps showing the correlations between RAB38 and MITF mRNA expressions in the: (A) Primary melanoma tissues 
in the GSE7553 cohort; (B) Metastatic melanoma tissues in the GSE7553 cohort; (C) Primary melanoma tissues in the GSE8401 
cohort; (D) Metastatic melanoma tissues in the GSE8401 cohort; 
(E−H) Box plots showing the RAB38 mRNA expressions in the: (E) Metastatic patient tissues carrying MITF-high signature in 
the GSE7553 cohort; (F) Metastatic patient tissues carrying MITF-low signature in the GSE7553 cohort; (G) Metastatic patient 
tissues carrying MITF-high signature in the GSE8401 cohort; (H) Metastatic patient tissues carrying MITF-high signature in the 
GSE8401 cohort. 
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Figure 2.12 Higher levels of expression of RAB38 in metastatic melanoma compared 
to primary melanoma were observed in melanoma patient with MITF high signature. 
(A) Pathway analysis showed enrichment of MITF, TBC1D16 and RAB27A in the RAB38 
co-expression signature; (B) Box plot showed RAB27A mRNA expressions in the 
metastatic patient tissues carrying MITF-high or MITF-low signature in the GSE7553 
cohort; (C) Box plot showed TBC1D16 mRNA expressions in the metastatic patient tissues 
carrying MITF-high or MITF-low signature in the GSE7553 cohort; (D) Box plot showed 
RAB27A mRNA expressions in the metastatic patient tissues carrying MITF-high or MITF-
low signature in the GSE8401 cohort; (E) Box plot showed TBC1D16 mRNA expressions 
in the metastatic patient tissues carrying MITF-high or MITF-low signature in the 
GSE8401 cohort; (F) ChIP-PCR assays showed enrichment of the association of MITF 
with the promoters of TBC1D16 and RAB38 genes in WM-266-4 cells relative to WM-115 
cells. Data were normalized to control IgG ChIP. Error bars represent means ± standard 
deviations (n = 3). 
88 
 
 
89 
 
Figure 2.13 Investigation of RAB38 methylation status in melanoma cell lines. 
(A) Bisulfite sequencing demonstrated the methylation status of CpG sites in the promoter 
region of RAB38 gene in the three paired primary/metastatic cell lines, where high levels 
of methylation were observed for the WM-115, IGR39, WM793 and 1205Lu, but not for 
the WM-266-4 and IGR37 melanoma cell lines. CpG sites in the promoter region of RAB38 
gene are indicated by short vertical bars, and exons are designated with black rectangles 
on the top. The arrow indicates the transcription start site (TSS). Each horizontal line 
represents one separate clone that was sequenced, and open and filled circles represent 
unmethylated and methylated CpG sites, respectively; (B) Increased mRNA expression 
levels of MITF, TBC1D16-47kDa and RAB38 after 5-aza-2′-deoxycytidine (5-Aza) 
treatment (96 h) in WM-115 cells; (C) Increased mRNA expression levels of MITF, 
TBC1D16-47kDa and RAB38 after 5-Aza treatment (96 h) in IGR39 cells; (D) Box plots 
representing DNA methylation in 4 primary melanoma and 33 metastatic melanoma 
samples (accession number: GSE44662). Metastatic melanomas contained lower RAB38 
promoter methylation. The error bars in panels (B) and (C) represent mean ± SEM. The p 
values were calculated by using an unpaired two-tailed Student’s t test: “ns”, not 
significant; “∗”, 0.01 < p < 0.05; “∗∗”, 0.001 < p < 0.01; “∗∗∗”, 0.0001 < p < 0.001; “∗∗∗∗”, 
p < 0.0001. 
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Figure 2.14 Occurrence and prognostic values of RAB38 promoter hypomethylation. 
(A) Methylation microarray data showed lower methylation levels at multiple CpG sites 
of the RAB38 promoter region in IGR37 cell line relative to IGR39 cell line in the 
GSE46522 cohort; (B) Methylation microarray data showed lower methylation levels at 
multiple CpG sites of the RAB38 promoter region in WM-266-4 cell line relative to WM-
115 cell line in the GSE70621 cohort; (C) Kaplan-Meier curves showing that the 
presence of RAB38 hypomethylation at multiple CpG sites in melanoma patients (n = 
464) is significantly associated with shorter overall survival in the TCGA-SKCM cohort; 
(D) Scatter plot showing the correlations of RAB38 mRNA expressions with RAB38 
promoter CpG methylation in the TCGA-SKCM cohort; (E) Scatter plot showing the 
correlations of MITF mRNA expressions with MITF promoter CpG methylation in the 
TCGA-SKCM cohort.  
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Chapter 3 Roles of Small GTPases in Acquired Tamoxifen Resistance in 
MCF‑7 Cells Revealed by Targeted, Quantitative Proteomic Analysis 
3.1 Introduction 
Breast cancer is the most prevalent cancer among women worldwide. According to the 
American Cancer Society, 268,000 new breast cancer cases and 41,400 deaths were 
estimated in 2018 in the United States.1 As a highly heterogeneous disease, breast cancer 
can be categorized into three major subtypes: estrogen receptor α-positive (ER-positive), 
human epidermal growth factor receptor 2 (HER2)-amplified (HER2-positive) and triple-
negative breast cancer (TNBC). Among them, the ER-positive subtype remains the most 
prevalent and diverse, accounting for approximately 80% of diagnosed cases of breast 
cancer.2 In this respect, antiestrogen drugs including tamoxifen and fulvestrant are 
frequently used, and tamoxifen remains the standard front-line endocrine therapy 
complementary to surgery. However, approximately half of patients who receive tamoxifen 
as the first-line therapy for recurrent diseases do not respond to the treatment because of 
intrinsic resistance. For those patients who initially respond to the drug, development of 
resistance is a major cause of treatment failure.3 
Small GTPases of the Ras family are crucial regulators of intracellular trafficking and 
can mediate a wide range of biological events.4 Several small GTPases play important roles 
in breast cancer progression, including RAB2A (tumorigenesis),5 RAB27B (migration and 
invasion)6, RAB31 (proliferation and metastasis),7 and RND1 (tumorigenesis and 
invasion).8 Defective endocytic pathways arising from down-regulation of small GTPases 
RAB5, RAC1, and RHOA were found in squamous-cell carcinomas (SCCs) carrying 
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resistance to chemotherapeutic drugs such as cisplatin.9 Cellular pathways that involve 
small GTPase signaling, including the Ras–Raf-1–MAPK pathway, Rac1–PAK1 pathway, 
and Cdc42-mediated redox pathway, have also been shown to mediate responses to 
tamoxifen in breast cancer cells.10-12 Therefore, we reason that a systematic interrogation 
of small GTPases involved in modulating tamoxifen resistance may offer a better 
understanding of the mechanisms of resistance in tamoxifen therapy. 
Mass spectrometry-based proteomic methods have been widely employed for studying 
drug resistance and for discovering novel biomarkers and therapeutic targets in breast 
cancer.13-15 Building upon the previously reported method of gel fractionation followed by 
liquid chromatography–tandem mass spectrometry (LC-MS/MS),16, 17 we recently 
developed a targeted quantitative proteomic approach, relying on stable isotope labeling 
by amino acids in cell culture (SILAC), gel fractionation, and LC-MS/MS in scheduled 
multiple-reaction monitoring (MRM) mode, for high-throughput profiling of small 
GTPases.18 In the present study, we employed this method to comprehensively investigate 
alterations in the expression of small GTPases during the development of tamoxifen 
resistance in a pair of matched wild-type (WT)/tamoxifen-resistant (TamR) breast cancer 
cell lines, i.e. MCF-7/WT and MCF-7/TamR. The quantitative proteomic data and cell-
based assays with the use of two ER-positive cell lines (i.e. MCF-7 and T47D), together 
with bioinformatic analysis of publicly available data, led to the discovery of a novel role 
for RAB31 in modulating acquired tamoxifen resistance. 
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3.2 Experimental Section 
3.2.1 Cell Culture 
MCF-7 cells were purchased from ATCC (#HTB-22). The tamoxifen-resistant variant 
of MCF-7 cells (MCF-7/TamR) was generously provided by Dr. Guandi Wang (Xavier 
University). The T47D cells were kindly provided by Dr. Ameae Walker (University of 
California, Riverside). The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS; Invitrogen-Gibco) and 
penicillin/streptomycin (100 IU/mL) at 37°C in an atmosphere with 5% CO2. The MCF-
7/TamR cells were continuously cultured in the above-described medium containing 0.10 
M (Z)-4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) for at least six months to allow 
them to develop resistance to the drug with an IC50 of ~5 M 4-OHT.13 
For other experiments, 4-OHT was dissolved in ethanol at a concentration of 10 mM 
and stored at -20°C. For SILAC experiments, [13C6,15N2]-L-lysine and [13C6]-L-arginine 
(Cambridge Isotopes Inc.), or their unlabeled counterparts, were added to SILAC DMEM 
medium depleted of L-lysine and L-arginine (Thermo Scientific Pierce) until their final 
concentrations reached 0.398 and 0.798 mM, respectively, to yield “heavy” and “light” 
media. Cells were cultured in the “heavy” SILAC DMEM medium for at least 6 cell 
doublings to ensure complete incorporation of heavy isotope-labeled amino acids. 
3.2.2 Sample Preparation and Scheduled LC-MRM Analysis 
To assess the differential expression of small GTPases in wild-type (WT) and 
tamoxifen-resistant (TamR) MCF-7 cells, we conducted SILAC-based quantitative 
proteomic experiments with forward and reverse labeling strategies. Briefly, we combined 
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lysates of light-labeled WT cells and heavy-labeled TamR cells at a 1:1 ratio in the forward 
labeling experiments. The reverse labeling experiment was conducted in the opposite way. 
The mixed cell lysates (100 μg in total) were loaded onto a 10% SDS-PAGE gel and 
separated by electrophoresis. The gel bands corresponding to the molecular weight range 
of 15–37 kDa were cut, reduced with 20 mM dithiothreitol, alkylated with 55 mM 
iodoacetamide, and digested in-gel with trypsin at an enzyme/protein ratio of 1:100. After 
tryptic digestion, the peptide mixtures were desalted and subjected to LC-MRM analyses. 
All LC-MRM experiments were performed on a TSQ vantage triple-quadruple mass 
spectrometer (Thermo Scientific) coupled with an EASY-nLC II system (Thermo 
Scientific). The samples were automatically loaded onto a 4-cm trapping column (150 μm 
i.d.) packed with ReproSil-Pur 120 C18-AQ resin (5 μm in particle size and 120 Å in pore 
size, Dr. Maisch GmbH HPLC) at 3 μL/min. The trapping column was coupled to a 20-cm 
fused silica analytical column (75 μm i.d.) packed with ReproSil-Pur 120 C18-AQ resin (3 
μm in particle size and 120 Å in pore size, Dr. Maisch GmbH HPLC). The peptide mixtures 
were then separated using a 157-min linear gradient of 2−35% acetonitrile in 0.1% formic 
acid at a flow rate of 230 nL/min. The spray voltage was set as 1.8 kV. Ions were isolated 
in both Q1 and Q3 using 0.7 fwhm resolution, for which the cycle time was set as 5 s. The 
optimal collisional energy (CE) for each targeted peptide was calculated using a linear 
equation specific to the TSQ Vantage instrument and the precursor mass-to-charge ratio 
(m/z) according to the default setting in Skyline.19 
To enable high-throughput quantitative analysis, we applied a previously developed 
scheduled LC-MRM method18, in which the mass spectrometer was programmed to 
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acquire the MS/MS of the precursor ions for a limited number of peptides in each 6-min 
retention time (RT) window. The MRM data for all targeted peptides were manually 
inspected to ensure correct peak picking. In this regard, the dot-product (dotp) value has to 
exceed 0.80.20 In addition, the iRT value represents an intrinsic property (i.e., 
hydrophobicity) of a peptide; hence, a substantial deviation of measured RT from that 
projected from the linear plot of RT over iRT signals a false-positive detection. 
3.2.3 Data Sources for Bioinformatic Analyses 
Patient RNAseq data were obtained from The Cancer Genome Atlas (TCGA) via 
cBioPortal (http://www.cbioportal.org/).21 The complete clinical data files were 
downloaded from the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). The Cancer 
Cell Line Encyclopedia (CCLE) (http://www.broadinstitute.org/ccle/home) were 
interrogated for the comprehensive evaluation of mRNA expression for candidate genes 
among more than 100 breast cancer cell lines.22 Publicly available transcriptomic profiles 
with accession numbers GSE3494, GSE4922, GSE6434, GSE24460, GSE26495 and 
GSE42568 were downloaded from the GEO database and analyzed using R (version 3.4.3). 
3.2.4 Patient Survival Analysis 
Kaplan–Meier survival curves were generated using an online database Kaplan-Meier 
plotter (kmplotter.com) for breast cancer.23 Data were analyzed using the JetSet best probe 
set to analyze gene expression and relapse-free survival (RFS). Briefly, gene names were 
entered into the database to obtain Kaplan–Meier survival plot where the hazard ratio (HR), 
95% confidence intervals (95% CI) and logrank p values were calculated and displayed. 
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3.2.5 Plasmid Construction 
pLKO.1-shRAB31 and pLKO.1-scramble plasmids were constructed by inserting a 
short hairpin double-stranded oligonucleotide targeting RAB31 or a scrambled sequence 
into the pLKO.1 lentiviral vector. Human RAB31 cDNA was amplified from an in-house 
cDNA library and subcloned into the p3×Flag-CMV10 vector. 
3.2.6 Generation of Stable Knockdown Cell Lines 
The lentiviral vectors pLKO.1-shRAB31 and pLKO.1-scramble were generated as 
described above. Recombinant lentiviruses were produced by co-transfection of HEK293T 
cells with the pLKO.1-scramble or pLKO.1-shRAB31 shRNA plasmids, envelope plasmid 
pLTR-G (Addgene #17532) and packaging plasmid pCMV-dR8.2 dvpr (Addgene #8455). 
Lentivirus-containing supernatant was harvested and filtered through 0.45-μm pore size 
filters at 48 h post-transfection. Infection of MCF-7 or T47D cells with recombinant 
lentivirus was conducted in the presence of 5 µg/ml polybrene. After removal of virus, the 
cells were selected in 1 µg/mL puromycin-containing medium for 3 days to eliminate 
uninfected cells. After selection, the cells were maintained in medium containing 1 µg/mL 
puromycin and used for subsequent experiments.  
3.2.7 Cell Proliferation Assay 
The proliferation of cells under 4-OHT treatment was evaluated using a cell counting 
kit-8 (CCK-8; Dojindo Laboratories). Briefly, MCF-7/WT, T47D and MCF-7/TamR cells 
were seeded in a 96-well flat-bottomed microplate (3000 cells/well) in complete growth 
medium (100 μL/well) for 24 h. The cells were then incubated with or without various 
concentrations of 4-OHT for 5 days in the dose-dependent experiments, or with 1 μM 4-
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OHT in the time-dependent experiments, and ethanol was used as the vehicle control. At 
the end of treatments, 10 µL of the CCK-8 dye was added to each well and the cells were 
incubated at 37℃ for 4 h prior to using the Synergy™ H1 Hybrid Multi-Mode Microplate 
Reader (BioTek Instruments) for measuring the absorbance at 450 nm. 
3.2.8 Colony Formation Assay 
MCF-7/WT or MCF-7/TamR cells were cultured in complete growth media. The cells 
were seeded at a density of 2000 cells/well in 2 mL of medium in six-well plates and 
allowed to adhere overnight. The next day, the cells were treated with 1 μM 4-OHT, and 
an equal volume of ethanol was used as a vehicle control. The cells were then allowed to 
grow until colonies reached > 50 cells per colony for the control group (approximately 10 
to 14 days). Colonies were then fixed with glutaraldehyde for 30 min, stained with crystal 
violet (0.1% in 20% methanol) for 30 min, and washed. Colony numbers were determined 
manually. The experiments were conducted in triplicate, and the data represent means ± 
standard errors of the means. 
3.3 Results and Discussion 
3.3.1 Application of a High-throughput LC-MRM Assay for Studying Acquired Tamoxifen 
Resistance 
We set out to explore the alterations of small GTPases during the development of 
tamoxifen resistance in ER-positive breast cancer. To this end, we employed our recently 
developed scheduled MRM-based targeted proteomic method18 to assess, in high-
throughput, the reprogramming of the small GTPase proteome during development of 
tamoxifen resistance.  The method involved metabolic labeling of MCF-7 cells and 
100 
 
isogenic cells that are resistant to tamoxifen using SILAC, SDS-PAGE for the enrichment 
of proteins in the molecular weight range of 15-37 kDa (the molecular weights for ~95% 
of small GTPases fall in this range), in-gel tryptic digestion, and LC-MS/MS analysis of 
the resulting tryptic peptides in the scheduled MRM mode (Figure 3.1). 
To obtain reliable quantification results, we conducted SILAC experiments in 
triplicate, with two sets of forward labeling and one set of reverse labeling. The method 
facilitated the quantification of a total of 96 small GTPases, among which 13 and 10 
proteins were significantly down- and up-regulated (with >1.5-fold change), respectively, 
in the drug-resistant MCF-7 cells relative to in the parental line (Figure 3.1). In this vein, 
we chose a cutoff of 1.5-fold change on the basis of the average relative standard deviation 
(RSD = 14%) for all the quantified small GTPases. The method facilitated the coverage of 
approximately 65% of the human small GTPase proteome in two LC-MRM runs.  
We found that several RAB small GTPases were down-regulated (e.g., RAB27B, 
RAB30, RAB31, and RAB32), whereas several others were up-regulated (e.g., RAB7A, 
RAB18, and RAB6B), in tamoxifen-resistant cells (Figure 3.1). The extracted-ion 
chromatograms (XICs) for several differentially expressed small GTPases were displayed 
in Figure 3.2, including ARL3 (ARF subfamily), RHOF (RHO subfamily), RAB30 (RAB 
subfamily), and RRAS2 (RAS subfamily). Notably, we observed a ~2-fold up-regulation 
of RRAS2 protein in the tamoxifen-resistant MCF-7 cells. In this vein, RRAS2 is known 
to promote primary tumorigenesis and late steps of metastasis in breast cancer cells, and it 
can also contribute to increased resistance to tamoxifen.24-26 Hence, our method validated 
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the differential expression of a small GTPase that was previously shown to be involved 
with tamoxifen resistance. 
There have been no literature precedents about the functions of ARL3, RHOF, and 
RRAS in drug resistance in breast cancer. Nevertheless, ARL3 was suggested to be 
transcriptionally regulated by ER-related mechanisms.27 In addition, RRAS inhibits the 
proliferation, migration and cell cycle progression of cultured breast cancer cells.28 RHOF 
plays an important role in controlling the formation of filopodia, which may contribute to 
proliferation, invasion and formation of micrometastases of cancer cells. RHOF, however, 
enhances the resistance of pancreatic cancer to gemcitabine through regulation of the 
epithelial-to-mesenchymal transition.29  The potential roles of ARL3, RRAS, and RHOF 
in modulating tamoxifen resistance warrant future investigation. 
To assess the performance of our MRM-based method, we also analyzed the same 
samples by employing LC-MS/MS in the data-dependent acquisition (DDA) mode. As 
shown in Figure 3.3, DDA analyses only led to the identification of 51 and 45 small 
GTPases in the two forward-SILAC samples (F1 and F2, respectively), and 44 small 
GTPases in the reverse-SILAC sample (R). In stark contrast, the LC-MRM approach led 
to substantially higher coverage of the small GTPase proteome (Figure 3.3). As noted, the 
quantification was based on three independent LC-MRM experiments, which included two 
forward- and one reverse-SILAC labeling experiments, and the small GTPases reported 
were reproducibly quantified in all three replicates, with the mean RSD being 14%. 
Therefore, these results demonstrated that the scheduled LC-MRM method outperformed 
the shotgun proteomic approach in terms of reproducibility and sensitivity. Additionally, 
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we observed an excellent linear fit (R2 = 0.9238) for the log2-transformed SILAC ratios of 
all the quantified small GTPases obtained from one forward- and one reverse-SILAC 
labeling experiment (Figure 3.3), which again underscored the excellent reproducibility of 
the method. With respect to retention time (RT) scheduling, all of the 10 standard peptides 
derived from BSA exhibited an excellent linear fit (R2 = 0.9996) between the observed RTs 
and the iRT values in the library (Figure 3.3). Highly reliable and reproducible RT 
prediction was also reflected by the superb linearity for the RTs observed for the small 
GTPase peptides in different replicates (Figure 3.3). 
To achieve confident identification of targeted peptides, we manually processed the 
LC-MRM data to ensure the coelution of the MRM transitions with the dot-product (dotp) 
value being >0.8, as calculated by Skyline.20 The dotp of a peptide was based on the 
correlation for the ratio of the MRM peak intensities observed versus those in the library 
MS/MS acquired from shotgun proteomic experiments. Shown in Figure 3.4 are the 
representative XICs displaying nearly identical retention times for different MRM 
transitions monitored for each of the three distinct peptides of RAB31 with high dotp 
values (>0.95). Relative quantification was achieved by integrating the areas of the peaks 
found in the XICs acquired from the LC-MRM analyses (Figure 3.4 shows the MRM traces 
acquired from the forward- and reverse-SILAC labeling experiments). The down-
regulation of RAB31 protein in the tamoxifen-resistant line was further confirmed by 
Western-blot analysis (Figure 3.4). In addition to RAB31, we also validated the differential 
expression of RAB27A and RAB27B proteins by Western-blot analysis (Figure 3.5), 
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supporting that the LC-MRM method is capable of accurately profiling the differential 
expression of small GTPases. 
3.3.2 Prognostic Values of RAB31 in Breast Cancer Revealed by Bioinformatic Analyses 
As discussed above, our LC-MRM results confirmed a known protein target that 
promotes acquired tamoxifen resistance: RRAS2. We next sought to further examine the 
roles of other differentially expressed small GTPases in breast cancer by performing 
Kaplan–Meier survival analysis for significantly up- and down-regulated proteins shown 
in Figure 3.1. Particularly, for down-regulated proteins, lower mRNA expression levels of 
ARL3, RHOF and RAB30 were significantly associated with poor relapse-free survival 
(RFS) (Figure 3.6). In contrast, higher RRAS2 mRNA levels are significantly correlated 
with poor RFS (Figure 3.6). For patients who received endocrine therapy (tamoxifen only), 
increased RAB31 expression predicted better outcomes, whereas for those without 
endocrine therapy, RAB31 did not serve as an effective indicator for RFS (Figure 3.7). 
Notably, among those genes that exhibited significantly altered protein abundance in 
tamoxifen resistance, only the mRNA expression of RAB31 is significantly correlated with 
tamoxifen efficacy in ER-positive breast cancer patients, but not that of ARL3, RAB30, 
RRAS2 or RHOF (Figures 3.6 and 3.7). We also assessed the prognostic values of RAB31 
stratified by ER status and found only a significant correlation between RAB31 expression 
and survival in ER-positive, but not ER-negative breast cancer patients (Figure 3.7). 
We also interrogated several Gene Expression Omnibus (GEO) data sets for Kaplan–
Meier survival analysis and differential mRNA expression analysis: GSE3494 (Karolinska 
Institute, n = 236),30 GSE4922 (Genome Institute of Singapore, n = 347),31 GSE6434 
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(Baylor College of Medicine, n = 24),32 GSE42568 (Dublin City University, n = 115),33 
GSE24460 (National Cancer Institute, n = 52),34 and GSE26495 (Emory University).35 The 
GSE6434, GSE26495 and GSE24460 data sets revealed significantly decreased mRNA 
levels of RAB31 in docetaxel-, tamoxifen- and doxorubicin-resistant MCF-7 cell lines, 
respectively (Figure 3.8). In this respect, docetaxel and doxorubicin are other small-
molecule drugs commonly used in chemotherapy against breast cancer. Therefore, these 
results suggest that RAB31 down-regulation could be a common event in drug-resistant 
MCF-7 cells. For survival analysis, lower RAB31 expression was significantly associated 
with poorer RFS and overall survival (OS) in the GSE42568 cohort (Figure 3.8). 
Meanwhile, the same trend holds for the disease-specific survival (DSS) in the GSE3494 
data set (Figure 3.8). Notably, in the GSE4922 cohort, RAB31 is significantly down-
regulated in the most metastatic grade III tumors as compared with in grade I tumors 
(Figure 3.8), supporting a potential role for RAB31 in breast cancer progression.36 Taken 
together, these results suggest that RAB31 may serve as a potential biomarker for 
predicting acquired tamoxifen resistance in breast cancer patients. 
3.3.3 Correlation of RAB31 Expression with ER Status and Breast Cancer Subtypes 
To elucidate the association between RAB31 expression and breast cancer subtypes, we 
next interrogated a large and comprehensive breast cancer patient cohort: The Cancer 
Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA). Our results showed that RAB31 
mRNA expression levels were significantly correlated with the mRNA expression levels 
of the ESR1 gene, which encodes ER, in the TCGA-BRCA cohort (Figure 3.9). In 
addition, the same correlations could be observed for the GSE4922 and GSE23988 data 
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sets (Figure 3.9). Aside from ER status, we extended the expression analysis to elucidate 
the association between RAB31 mRNA levels and different molecular subtypes of breast 
cancer: luminal A, luminal B, HER2-enriched, basal-like, and normal-like.37 As shown in 
Figure 3.9, the mRNA expression levels of RAB31 were significantly lower in the basal 
subtype and the HER2-enriched subtype than in the luminal-A subtype. Clinical data 
demonstrate reduced responses to endocrine therapy in tumors with HER2 amplification. 
Suppressed expression of RAB31 might therefore be correlated with reduced ER 
expression and the HER2-overexpressing resistant phenotypes. 
3.3.4 RAB31 Knockdown Rendering Elevated Tamoxifen Resistance in MCF-7/WT and 
T47D Cells 
The above results showed that diminished RAB31 expression confers poor prognosis 
for ER-positive breast cancer patients, especially for those who received tamoxifen as a 
first-line therapy. Hence, we reason that RAB31 may be associated with tamoxifen efficacy 
and therefore may play a role in tamoxifen resistance. To further examine the role of 
RAB31 in tamoxifen resistance, we used lentiviral transduced shRNA to enable stable 
knockdown of RAB31 gene expression in MCF-7 cells. Western-blot analysis showed that 
two separate shRNA sequences gave rise to 60–70% depletions of RAB31 protein 
compared with that from the control shRNA sequence (shScramble) in MCF-7 cells (Figure 
3.10). We next performed cell proliferation assay to assess the effects of RAB31 
knockdown on tamoxifen response in MCF-7 cells. We found that, upon treatment with 1 
μM (Z)-4-hydroxytamoxifen (4-OHT), an active metabolite of tamoxifen, genetic 
depletion of RAB31 led to significantly higher cell viability at 72 and 96 h, but not at 24 or 
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48 h (Figure 3.10). Moreover, RAB31 knockdown led to higher resistance to 4-OHT 
treatment in a broad range of doses (Figure 3.10). Collectively, the results support that loss 
of RAB31 could modulate tamoxifen response in MCF-7 cells. 
To further substantiate the above findings, we assessed how shRNA-mediated 
depletion of RAB31 in T47D cells alters the sensitivity of these cells toward tamoxifen. 
Consistent with our hypothesis, diminished expression of RAB31 in both MCF-7 and T47D 
cells led to increased proliferation rates and elevated resistance toward tamoxifen (Figure 
3.11). In addition, RAB31 knockdown gave rise to augmented resistance to tamoxifen in 
T47D cells (Figure 3.11). Taken together, the above results support the role of RAB31 in 
tamoxifen efficacy in two ER-positive breast cancer cell lines, i.e. MCF-7 and T47D. 
3.3.5 Sensitization of MCF-7/TamR Cells to 4-OHT Treatment by RAB31 Overexpression 
We next examined how a gain of function of RAB31 modulates tamoxifen sensitivity 
by ectopically overexpressing the RAB31 gene in tamoxifen-resistant MCF-7/TamR cells. 
The cell proliferation assay results indicated that RAB31-overexpressing MCF-7/TamR 
cells exhibited elevated sensitivity towards 4-OHT treatment as compared to the empty 
vector group in both dose-dependent and time-dependent manner (Figure 3.12). In 
agreement with the cell proliferation assay results, colony formation assays showed that 
ectopic expression of RAB31 conferred significantly increased tamoxifen sensitivity for 
the MCF-7/TamR cells (Figure 3.12). In summary, our results substantiated the role of 
RAB31 in suppressing acquired tamoxifen resistance in MCF-7/TamR cells. 
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3.4 Conclusions 
In the present study, we applied a targeted quantitative proteomic method to assess the 
differential expression of small GTPases in paired wild-type and tamoxifen-resistant MCF-
7 cells. The method provided high-throughput, accurate and reproducible quantifications 
of the relative expression levels of >90 small GTPases in the paired cell lines. Among them, 
10 and 13 small GTPases were up- and down-regulated by at least 1.5-fold in the drug-
resistant cells compared with in the parental MCF-7 cells. In this context, it is worth noting 
that our current targeted proteomic approach relies on SILAC labeling, which is not 
applicable to clinical specimens (e.g. biological fluids and tumor tissue samples) from 
breast cancer patients that manifest de novo or acquired tamoxifen resistance. Nevertheless, 
the targeted proteomic method can be adapted for handling clinical specimens with the use 
of heavy isotope-labeled synthetic peptides, and such an approach is currently being 
explored in our laboratory. 
Combined with bioinformatic analyses, we identified RAB31 as a novel predictive 
marker for acquired tamoxifen resistance. Through the use of two ER-positive cell lines 
(i.e. MCF-7 and T47D), we uncovered, for the first time, a role of RAB31 in modulating 
tamoxifen sensitivity. The functions of RAB31 were also explored in other cancer types.38 
RAB31 can localize to endocytic compartments and functions in the post-Golgi, endocytic 
or exocytic trafficking of the epidermal growth factor receptor (EGFR) in A431 and HeLa 
cells.39 Silencing of RAB31 inhibited the endocytic trafficking of the ligand-bound EGFR 
to late endosomes and its subsequent degradation. It is also worth noting that increased 
levels of receptor tyrosine kinases including EGFR and HER2 can directly alter the cellular 
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response to tamoxifen.40 Therefore, we reason that down-regulation of RAB31 in MCF-
7/TamR cells may perturb EGFR trafficking, thereby influencing drug resistance. 
In addition to receptor tyrosine kinase signaling, ER-associated proteins are essential 
players in tamoxifen resistance. Some suggest elevated ESR1 mRNA levels in tamoxifen-
resistant ER-positive breast cancer cells.25 However, several lines of evidence 
demonstrated suppressed yet functional ER-regulated signaling pathway in MCF-7/TamR 
cells, as reflected by down-regulated ESR1 expression.13, 41-43 Notably, RAB31 is among 
the 11 genes that are robustly overexpressed in ER-positive breast carcinoma samples,44 
which is in line with the observation that the promoter region of the RAB31 gene harbors 
an ER-responsive element.45 On the basis of these findings, we reason that down-regulated 
RAB31 in tamoxifen-resistant MCF-7 cells may arise from ER-modulated molecular 
adaptations. 
Taken together, we showed, for the first time, that targeted quantitative proteomics, in 
combination with bioinformatics, provided novel insights into the roles of small GTPases 
in acquired tamoxifen resistance in breast cancer. It can be envisaged that the method can 
also be employed for understanding the therapeutic resistance of other types of cancer. 
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Figure 3.1 Targeted quantitative analysis of small GTPases in tamoxifen resistance. 
(A) Schematic diagram showing the targeted quantitative proteomic analysis, relying on 
metabolic labeling with SILAC, SDS-PAGE fractionation, and scheduled LC-MRM 
analysis; (B) Heatmap showing the differential expression of small GTPases in MCF-7/WT 
and MCF-7/TamR cells. The log2 ratios of relative levels of proteins in TamR over WT 
cells obtained from two forward and one reverse-SILAC labeling experiments (F1 and F2: 
forward experiments, R1: reverse experiment) are shown. As indicated by the scale bar, 
the red and blue bars designate the small GTPases that are up-and down-regulated, 
respectively, by at least 1.5-fold in the drug-resistant over parental MCF-7 cells; (C) Bar 
chart showing substantially up-regulated (>1.5-fold) and down-regulated (>1.5-fold) small 
GTPases quantified from three LC-MRM experiments. 
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Figure 3.2 LC-MRM for the quantification of the relative levels of expressions of 
ARL3, RHOF, RAB30, and RRAS2 proteins in the paired MCF-7/WT and MCF-
7/TamR cells. 
(A) Representative extracted-ion chromatograms (XICs) for the quantification of the 
ARL3, RHOF, RAB30, and RRAS2 proteins in one forward- and one reverse-SILAC 
labeling experiments; (B) Quantification results of the LC-MRM analyses (n = 3). The p 
values were calculated by using a paired two-tailed Student’s t test (* p < 0.05, ** p < 0.01, 
*** p < 0.001). Error bars represent standard deviations. 
 
116 
 
Figure 3.3 Performances of the scheduled LC-MRM method for targeted quantitative 
analysis of differential expression of small GTPases in tamoxifen resistance. 
(A) Venn diagrams displaying the overlap between quantified small GTPases in the 
forward- and reverse-SILAC labeling experiments, as obtained from MRM analyses and 
DDA analyses, respectively, and the comparison about the performances of the two 
methods; (B) Correlation between the log2-transformed SILAC ratios (Log2R) obtained 
from one forward- and one reverse-SILAC labeling experiments with a relatively high 
correlation coefficient (R2 = 0.9238); (C) Correlation between BSA standard iRT and 
measured RT values with a very high correlation coefficient (R2 = 0.9996); (D) Measured 
RTs obtained in two forward labeling reactions (F1 vs. F2) with a very high correlation 
coefficient (R2 = 0.9988); (E) Measured RTs obtained in one forward- and one reverse-
SILAC labeling reactions (F1 vs. R) with a very high correlation coefficient (R2 = 0.9987). 
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Figure 3.4 RAB31 is down-regulated in tamoxifen-resistant MCF-7 cells. 
(A) Representative MRM traces for three transitions monitored for each of the three unique 
tryptic peptides derived from RAB31: FHSLAPMYYR (y8, y6, and y5), QDSFYTLK (y6, 
y4, and y3), and GSAAAVIVYDITK (y7, y6, and y5); (B) Extracted-ion chromatograms 
(XICs) for the quantification of the three peptides in panel (A) in one forward- and one 
reverse-SILAC labeling experiments; (C) Validation of the differential expression of 
RAB31 in MCF-7/WT and MCF-7/TamR cells by Western-blot analysis; (D) Comparison 
of quantification results obtained from LC-MRM and Western-blot analyses (n = 3). The 
p values were calculated by using a paired two-tailed Student’s t test (** p < 0.01). Error 
bars represent standard deviations. 
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Figure 3.5 LC-MRM and Western-blot analyses for the quantification of the relative 
levels of expressions of RAB27A and RAB27B proteins in the paired MCF-7/WT and 
MCF-7/TamR cells. 
(A) Representative XICs for the quantification of the tryptic peptide FLALGDSGVGK 
derived from RAB27A in one forward- and one reverse-SILAC labeling experiments; (B) 
Validation of the differential expression of RAB27A in MCF-7/WT and MCF-7/TamR 
cells by Western-blot analysis; (C) Comparison of quantification results obtained from LC-
MRM and Western-blot analyses (n = 3) in panels (A) and (B); (D) Representative XICs 
for the quantification of the tryptic peptide LLALGDSGVGK derived from RAB27B in 
one forward- and one reverse-SILAC labeling experiments; (E) Validation of the 
differential expression of RAB27B in MCF-7/WT and MCF-7/TamR cells by Western-
blot analysis; (F) Comparison of quantification results obtained from LC-MRM and 
Western-blot analyses (n = 3) in panels (D) and (E). The p values were calculated by using 
a paired two-tailed Student’s t test (** p < 0.01). Error bars represent standard deviations. 
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Figure 3.6 Representative Kaplan–Meier survival curves for the implications of 
ARL3, RHOF, RAB30, and RRAS2 mRNA expressions in survival of breast cancer 
patients. 
Kaplan–Meier survival analyses for relapse-free survival (RFS) in all breast cancer patients 
(left panel) and in ER-positive breast cancer patients receiving only treatment with 
tamoxifen but not chemotherapy (right panel). The patient population was stratified by 
median mRNA expression levels of the (A) ARL3, (B) RAB30, (C) RHOF, and (D) RRAS2 
genes, respectively. Analysis was performed using KM-plotter (kmplot.com/analysis). The 
p values were calculated by using a log-rank test. Number of patients, hazard ratios (HR) 
and 95% confidence intervals (95% CI) are indicated. 
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Figure 3.7 RAB31 expression predicts breast cancer patient outcome. 
Kaplan–Meier survival analyses of the implications of mRNA expression of the RAB31 
gene for relapse-free survival (RFS) in breast cancer patients: (A) all breast cancer patients 
(n = 3951); (B) ER-positive breast cancer patients receiving tamoxifen but without 
chemotherapy (n = 809); (C) ER-positive breast cancer patients (n = 2061); (D) ER-
negative breast cancer patients (n = 801). The patient population was stratified by median 
RAB31 mRNA expression levels. The p value was calculated by using a log-rank test. 
Number of patients, hazard ratios (HR) and 95% confidence intervals (95% CI) are 
indicated. 
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Figure 3.8 Bioinformatic analysis revealing RAB31 as a potential predictive marker 
for tamoxifen resistance. 
Differential expression analysis for RAB31 in: (A) docetaxel-, (B) tamoxifen- and (C) 
doxorubicin-resistant MCF-7 cell lines in three cohorts GSE6434, GSE26495 and 
GSE24460, respectively (Dox: docetaxel; Tam: tamoxifen; Adr: Adriamycin or 
doxorubicin). Kaplan–Meier survival analyses for: (D) relapse-free survival (RFS) in the 
GSE42568 data set; (E) overall survival (OS) in the GSE42568 data set; (F) disease-
specific survival (DSS) in the GSE3494 data set; (G) differential RAB31 expression in 
different grades of breast cancer progression in the GSE4922 data set. The patient 
population was stratified by median RAB31 mRNA expression levels. The p values for the 
Kaplan–Meier curves were calculated by using the log-rank test. The p values for the box-
whisker plots were calculated by using an unpaired two-tailed Student’s t test (# p > 0.05, 
* p < 0.05, ** p < 0.01). 
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Figure 3.9 RAB31 expression is correlated with ER status and breast cancer subtypes. 
Box-whisker plot showing correlated expressions of RAB31 and ESR1, the latter of which 
encodes estrogen receptor alpha (ERα), in the: (A) TCGA-BRCA cohort; (B) GSE4922 
data set; (C) GSE23988 data set. Whisker shows 10th and 90th percentile; box boundaries 
show 25th and 75th percentile and the lines represent median values. (D) A scatter plot 
showing RAB31 expression across the five molecular subtypes of breast cancer (n = 831) 
in the TCGA-BRCA cohort, and the lines represent median value. The p values for the 
box-whisker plots were calculated by using an unpaired two-tailed Student’s t test. 
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Figure 3.10 RAB31 knockdown confers increased tamoxifen resistance. 
(A) Validation of stable knockdown of RAB31 in MCF-7 cells by Western-blot analysis; 
(B) Quantification results for Western-blot validation of stable shRAB31 knockdown 
MCF-7 cell lines; (C) Colony formation assay for stable shRAB31/shScramble MCF-7 
cells; (D) Quantification results for colony formation assay; (E) Cell proliferation assay for 
stable shRAB31/shScramble MCF-7 cells upon treatment with different doses of 4-OHT. 
The p values were calculated by using a paired two-tailed Student’s t test (** p < 0.01). 
Error bars represent standard deviations. 
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Figure 3.11 RAB31 knockdown renders elevated tamoxifen resistance and 
proliferation rates. 
(A) Cell proliferation assay for stable shRAB31-2 and shScramble MCF-7 cells; (B) 
Validation of stable knockdown of RAB31 in T47D cell lines by Western-blot analysis; 
(C) Cell proliferation assay for stable shRAB31-2 and shScramble T47D cells; (D) Cell 
proliferation assay for stable shRAB31-2 and shScramble T47D cells under dose-
dependent 4-OHT treatment; (E) Cell proliferation assay for stable shRAB31-2 and 
shScramble T47D cells under time-dependent 1 μM 4-OHT treatment. The data represent 
the means ± standard deviations of results from three parallel experiments. Some error bars 
appear to be smaller than the symbols. 
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Figure 3.12 Ectopic expression of RAB31 led to elevated tamoxifen sensitivity. 
(A) Cell proliferation assay for MCF-7/TamR cells after treatment with different doses of 
4-OHT; (B) Cell proliferation assay for MCF-7/TamR cells after treatment with 4-OHT 
(1 μM) for different periods of time; (C) Colony formation assay for MCF-7/TamR cells 
expressing empty vector or FLAG-RAB31; (D) Quantification results for colony 
formation assay. The p values were calculated by using a paired two-tailed Student’s t 
test (# p > 0.05, * p < 0.05, ** p < 0.01). Error bars represent standard errors of the 
means. 
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Chapter 4 Targeted Quantitative Proteomic Approach for Probing Altered 
Protein Expression of Small GTPases Associated with Colorectal Cancer 
4.1 Introduction 
Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide, and 
it ranks third in terms of incidence but second in terms of mortality.1-2 According to the 
stage definition by the American Joint Committee on Cancer (AJCC), five-year survival 
rates ranged from 93.2% for stage I to 8.1% for stage IV CRC patients.3 Approximately 
40–50% of all patients with CRC will ultimately develop into metastatic disease either at 
the time of diagnosis or develop distant relapses after therapy, of which the median overall 
survival is less than two years.4 Therefore, a better understanding about the metastatic 
transformation of CRC cells could lead to more precise therapeutic strategies that improve 
patient outcomes. 
The Ras superfamily of small (20–35 kDa) GTPases function as molecular switches 
that play important roles in carcinogenesis and tumor progression by regulating 
intracellular trafficking, cell signaling and malignant secretion.5-6 Among them, KRAS is 
one of the most frequently mutated oncogenes that drives colorectal tumorigenesis, 
accounting for 40% of sporadic CRCs. In addition to mutations, aberrant regulation of 
small GTPase expression has been shown to have a role in CRC progression. For instance, 
overexpression of RAB3C promoted colorectal tumor progression in vitro and vivo.7 
Moreover, miR-27b and miR-204-5p suppressed proliferation and invasion of CRC cells 
by inhibiting RAB3D and RAB22A, respectively8-9, and down-regulation of RAB25 was 
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found to be associated with reduced metastatic potential of CRC cells in vivo.10 Therefore, 
we reason that a systematic investigation about small GTPases associated with metastatic 
transformation of CRC cells may lead to novel molecular targets for the improvement of 
therapeutic efficacy. In this study, we applied a recently established high-throughput, 
targeted proteomic approach to robustly quantify the differential expression of small 
GTPases in the SW480/SW620 matched primary/metastatic cells derived from the same 
patient.11 We also examined, by using bioinformatic analyses, whether the aberrant 
expression of these small GTPases were dysregulated in clinical samples and showed 
prognostic values. Finally, we identified SAR1B as a potential metastasis suppressor and 
a prognostic biomarker that could modulate in vitro migration and invasion of CRC cells 
by regulating epithelial–mesenchymal transition (EMT). 
4.2 Materials and Methods 
4.2.1 Cell Culture 
The CRC cell lines used in this study were SW480 (ATCC# CCL-228) and SW620 
(ATCC# CCL-227), which were established from a primary human colon adenocarcinoma 
and a lymph node metastasis of the same patient, respectively. All cell lines were 
maintained in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen-Gibco) 
supplemented with 10% fetal bovine serum (FBS; Invitrogen-Gibco) and 
penicillin/streptomycin (PS, 100 IU/mL) in a humidified atmosphere with 5% CO2 at 37 
°C, and the culture medium was changed in every 2 to 3 days as necessary. 
For stable isotope labeling by amino acids in cell culture (SILAC) experiments, 
“heavy” and “light” SILAC DMEM media depleted of L-lysine and L-arginine (Thermo 
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Scientific™ Pierce) were freshly prepared by adding 0.146 g/L 13C6 15N2 L-lysine (Lys-8) 
and 0.84 g/L 13C6 L-arginine (Arg-6) (Cambridge Isotopes Inc.) or the corresponding un-
labeled lysine (Lys-0) and arginine (Arg-0) to DMEM, which as supplemented with 10% 
dialyzed FBS (Corning) and PS (100 IU/mL). SW480 and SW620 cells were cultured in 
the heavy-DMEM medium for at least 10 days or six cell doublings to assure complete 
heavy-isotope incorporation. 
4.2.2 Sample Preparation and LC-MRM Analysis 
To assess the differential expression of small GTPases in SW480 and SW620 cells, we 
conducted SILAC-based quantitative proteomic experiments with forward and reverse 
labeling strategies. Briefly, we combined lysates of light-labeled SW480 cells and heavy-
labeled SW620 cells at a 1:1 ratio in the forward labeling experiments. The reverse labeling 
experiment was conducted in the opposite way. The mixed cell lysates (100 μg in total) 
were loaded onto a 10% SDS-PAGE gel and separated by electrophoresis. The gel bands 
corresponding to the molecular weight range of 15–37 kDa were cut, reduced with 20 mM 
dithiothreitol, alkylated with 55 mM iodoacetamide, and digested in-gel with trypsin at an 
enzyme/protein ratio of 1:100. After tryptic digestion, the peptide mixtures were desalted 
and subjected to LC-MRM analyses on a TSQ Vantage triple-quadruple mass spectrometer, 
which was equipped with a nanoelectrospray ionization source and coupled with an EASY-
nLC II HPLC system (Thermo Fisher Scientific, San Jose, CA). The samples were 
automatically loaded onto a 4-cm trapping column (150 μm i.d.) packed with ReproSil-Pur 
120 C18-AQ resin (5 μm in particle size and 120 Å in pore size, Dr. Maisch GmbH HPLC) 
at 3 μL/min. The trapping column was connected to a 20-cm fused silica analytical column 
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(75 μm i.d.) packed with ReproSil-Pur 120 C18-AQ resin (3 μm in particle size and 120 Å 
in pore size, Dr. Maisch GmbH HPLC). A 157-min linear gradient of 2−35% acetonitrile 
in 0.1% formic acid was employed for peptide separation, and the flow rate was 230 nL/min. 
The spray voltage was set at 1.8 kV. Ions were isolated in both Q1 and Q3 using 0.7 fwhm 
resolution, where the cycle time was set as 5 s. The optimal collisional energy for each 
targeted peptide was calculated using a linear equation specific to the TSQ Vantage 
instrument and the precursor mass-to-charge ratio (m/z), according to the default setting in 
Skyline.12 
To enable high-throughput quantitative analysis, we applied a previously developed 
scheduled LC-MRM method, where the mass spectrometer was programmed to acquire the 
MS/MS of the precursor ions for a limited number of peptides in each 6-min retention time 
(RT) window.11 The MRM data for all targeted peptides were manually inspected to ensure 
correct peak picking. In this regard, the dot-plot or dot-product (dotp) value has to exceed 
0.80.13 In addition, the iRT value represents an intrinsic property (i.e., hydrophobicity) of 
a peptide; hence, a substantial deviation of measured RT from that projected from the linear 
plot of RT over iRT signals a false-positive detection.14 
4.2.3 Immunoblotting 
Total protein lysate was prepared from cell pellet using ice-cold CelLytic M cell lysis 
reagent (Sigma-Aldrich, MO) containing protease inhibitor cocktail (1:100). After cell 
lysis, the protein concentration was determined using Quick Start™ Bradford Protein 
Assay (Bio-Rad). Approximately 10–20 µg whole-cell protein lysates, mixed with 4× 
Laemmli SDS loading buffer, were loaded onto 10% polyacrylamide gels and, after 
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electrophoresis, the proteins were transferred onto nitrocellulose membranes. After 
blocking with 5% non-fat milk in PBS with 0.1% Tween-20 (PBST) at 25 °C for 1 h, the 
membranes were incubated with primary antibodies against human ARF4 (Proteintech; 
rabbit polyclonal, 1:5,000), RAB6A (38-TB, Santa Cruz; mouse polyclonal, 1:1,000), pan-
RAB6 (3G3, Santa Cruz; mouse polyclonal, 1:1,000), RAB27A (Abcam; rabbit polyclonal, 
1:5,000), RAB31 (4D12, Santa Cruz; rabbit polyclonal, 1:2,000), SAR1A (K-44, Santa 
Cruz; mouse polyclonal, 1:1,000), SAR1B (AT1C7, Santa Cruz; mouse polyclonal, 
1:1,000), Slug (PA5-11922, Thermo Fisher; rabbit polyclonal, 1:1,000), or β-actin (Thermo 
Fisher; rabbit polyclonal, 1:10,000). After overnight incubation with primary antibodies at 
4°C with 5% bovine serum albumin (BSA) in PBST, the membranes were then incubated 
with peroxidase-labeled donkey anti-rabbit secondary antibody (Thermo Fisher; 1:10,000) 
or mouse m-IgGκ BP-HRP (Santa Cruz; 1:10,000) for 1 h at 25 °C. Amersham ECL Prime 
Western Blot Detecting Reagent (GE Healthcare) was used for visualization of protein 
bands. 
4.2.4 Data Sources for Bioinformatic Analyses 
Patient RNA-Seq data were obtained from The Cancer Genome Atlas (TCGA) via 
cBioPortal (http://www.cbioportal.org/). The data of four different human expression 
microarrays with accession numbers of GSE14333, GSE17536, GSE21510, GSE39582, 
and the corresponding clinical information were downloaded from the National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/). The data were analyzed using R/Bioconductor 
(version 3.4.3). 
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4.2.5 Generation of Stable Knockdown Cell Lines and siRNA Transfection 
The lentiviral vectors pLKO.1-shSAR1B and pLKO.1-scramble plasmids were 
constructed by inserting a short hairpin double-stranded oligonucleotide targeting human 
SAR1B or a scrambled sequence into the AgeI/EcoR1 sites of the shRNA vector pLKO.1 
(Addgene #10878; Cambridge, MA). Expression of the shRNA was driven by the human 
U6 promoter. Recombinant lentiviruses were produced by co-transfection of HEK293T 
cells with the shRNA plasmids pLKO.1-shScramble or pLKO.1-shSAR1B, envelope 
plasmid pLTR-G (Addgene #17532) and packaging plasmid pCMV-dR8.2 dvpr (Addgene 
#8455). Lentivirus-containing supernatant was harvested and filtered through 0.45-μm 
pore size filters at 48 h post-transfection. Infection of SW480 cells with recombinant 
lentivirus was conducted in the presence of 5 µg/ml polybrene. After removal of virus, the 
cells were selected in 5 µg/mL puromycin-containing medium for 3 days to eliminate 
uninfected cells. After selection, the cells were maintained in a medium containing 2.5 
µg/mL puromycin and were used for subsequent experiments. For siRNA transfection, 
siGENOME non-targeting (NT) siRNA control (D-001210-02-05) and an siRNA sequence 
(5′-UGAUGUUGUGGUCAAAGUGAU-3′) targeting RAB31 were purchased from 
Dharmacon (Lafayette, CO). siRNAs were transfected into SW480 cells using RNAiMAX 
(Invitrogen) following the manufacturer’s protocol. Cells were either harvested or used for 
subsequent experiments at 72 h after transfection. 
4.2.6 Cell Proliferation Assay 
The cell proliferation was evaluated using a cell counting kit-8 (CCK-8; Dojindo 
Laboratories). Briefly, SW480 cells were seeded in a 96-well flat-bottomed microplate 
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(3000 cells/well) in complete growth medium (100 μL/well) for 24 h. At the desired time 
points, 10 µL of the CCK-8 dye was added to each well and, after incubation at 37℃ for 4 
h, the absorbance at 450 nm for the cells was recorded using the Synergy™ H1 Hybrid 
Multi-Mode Microplate Reader (BioTek Instruments). 
4.2.7 Migration and Invasion Assays 
Transwell chambers (Corning) were rehydrated at 37 °C and 1×105 cells were then 
added to the top chamber in serum-free medium and the bottom chamber was filled with 
medium containing 10% fetal bovine serum. The invasion assay was conducted under the 
same conditions except that the transwell membranes were pre-coated with Matrigel 
(Corning). The cells were cultured for 48 h at 37 °C in a 5% CO2 humidified incubator. To 
quantify migrated or invaded cells, the cells from the top-side of the membrane were gently 
removed using a cotton-tipped swab and invading cells attached to bottom of the membrane 
were fixed with 70% ethanol and stained with 0.5% crystal violet. Cell numbers from 5 
representative fields were counted for each insert. 
4.2.8 Quantitative Reverse Transcription PCR (RT-qPCR) 
Total RNA was extracted from cells using The E.Z.N.A.® Total RNA Kit I (Omega Bio-
Tech), and cDNA was synthesized via oligo(dT)18 primed reverse transcription by 
employing M-MLV reverse transcriptase (Promega). After a 60-min reaction at 42°C, the 
reverse transcriptase was deactivated by heating at 75°C for 5 min. RT-qPCR experiments 
was performed using iQ SYBR Green Supermix kit (Bio-Rad) on a Bio-Rad iCycler system 
(Bio-Rad), and the PCR conditions were as follows: 95°C for 3 min; 45 cycles at 95°C for 
15 s, 55°C for 30 s, and 72°C for 45 s. The comparative cycle threshold (Ct) method (ΔΔCt) 
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was used for the relative quantification of gene expression.15 Relative gene expression was 
normalized to that of the internal control (GAPDH). 
4.3 Results 
4.3.1 Targeted Quantitative Profiling of Differential Expression of Small GTPases during 
Metastatic Transformation of CRC Cells 
The SW480/SW620 pair of isogenic, primary/metastatic CRC cell lines constitute a 
valuable in vitro cellular model for studying CRC metastasis. The SW620 cell line was 
isolated from the lymph node metastatic site of the same patient as its non-metastatic 
counterpart (i.e. SW480).16 This pair of cell lines have been widely explored with various 
comparative shotgun and targeted proteomics approaches at the whole proteome and 
secretome levels to discover potential biomarkers and therapeutic targets for CRC.17-22 
To systematically investigate the differential protein expression of small GTPases in 
the paired SW480/SW620 cells, we employed a previously established targeted proteomic 
workflow, which involves SILAC, SDS-PAGE fractionation, and scheduled multiple-
reaction monitoring (MRM) analysis.11 To obtain reliable quantification results, we carried 
out SILAC experiments in triplicate, with two sets of forward labeling (Figure 4.1) and one 
set of reverse labeling. In this vein, the throughput for the method is high, where the entire 
library of small GTPase tryptic peptides could be monitored in two LC-MRM runs with 
retention time scheduling by using the iRT algorithm.14 We also examined the run-to-run 
reproducibility of the MRM-based quantification. As illustrated in Figure 4.1, the log2-
transformed SILAC ratios for all the quantified small GTPases obtained from forward and 
reverse SILAC labeling experiments exhibited an excellent linear fit (R2 = 0.928). MRM 
138 
 
analyses facilitated reproducible quantification of 83 small GTPases in each of the three 
SILAC labeling experiments (Figure 4.2). By contrast, analysis of the same samples by 
LC-MS/MS in the data-dependent acquisition (DDA) mode only led to the identification 
of 37 and 35 small GTPases in the two forward SILAC samples (F1 and F2, respectively), 
and 31 small GTPases in the reverse SILAC sample (R) (Figure 4.1). Moreover, MRM 
exhibited better sensitivity than the shotgun proteomic approach, as reflected by the 
substantially increased coverage of the small GTPase proteome in two LC-MRM runs 
without further sample pre-fractionation (Figure 4.1). 
We also analyzed the previously published shotgun or targeted proteomic data acquired 
from the SW480/SW620 paired cell lines. Figure 4.3 showed the Venn diagrams 
representing small GTPases quantified in this study as compared to those reported by three 
independent proteomic studies.18, 20-21 The results clearly revealed that SDS-PAGE 
fractionation followed by scheduled MRM analysis allowed for a more in-depth coverage 
of the small GTPase proteome. It is of note that the method reported by Cai et al.21 , which 
utilizes the acyl-phosphate GTP affinity probe, enabled proteome-wide enrichment of 
GTP-binding proteins, not solely restricted to small GTPases. 
The above results demonstrated that the scheduled LC-MRM approach facilitates 
highly sensitive and reproducible quantitative profiling of small GTPases in CRC cell lines 
with an elevated throughput and depth of coverage. 
4.3.2 Validation of Differential Protein Expression by Western-blot Analyses 
Among all the quantified small GTPases, 18 and 7 proteins were significantly down- 
and up-regulated (with >1.5-fold change), respectively, in the metastatic SW620 cells 
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relative to primary SW480 cells (Figure 4.1). In this vein, we employed 1.5-fold change as 
a cutoff based on the mean relative standard deviation (RSD = 6.7%) for all the quantified 
small GTPases.  Notably, several Rho small GTPases exhibited significantly altered 
expression, including RHOB, RHOF, and RHOG. Figure 4.4 displayed the selected-ion 
chromatograms (SICs) for these small GTPases. Down-regulation of RHOB and up-
regulation of RHOG in SW620 relative to SW480 cells were previously reported in two 
independent studies.21, 23 Importantly, RHOB is a well-recognized tumor suppressor for 
CRC and clear-cell renal cell carcinoma (ccRCC).23-25 Since the protein abundance of 
RHOB was down-regulated by ~2-fold in SW620 over SW480 cells, our results validated 
a known suppressor for CRC metastasis. 
Among the small GTPases with altered protein expression, RAB6B displayed a 
pronouncedly decreased expression (by ~10-fold) in SW620 relative to SW480 cells 
(Figure 4.1). Owing to the high degree of sequence homology among the three RAB6 
isoforms (RAB6A/B/C), common antibody-based approach including Western blot may 
be susceptible to cross-reactivity and hence could be challenging in distinguishing different 
isoforms. By selecting proteotypic peptides which have distinct sequences for different 
protein isoforms, our MRM-based approach successfully revealed the substantial down-
regulation of RAB6B, but not RAB6A/C, in SW620 relative to SW480 cells (Figure 4.4). 
Meanwhile, Western-blot analyses validated the MRM data for RAB6A and pan-RAB6 
proteins (RAB6A/B/C) but failed to distinguish RAB6A/C from RAB6B (Figure 4.4). In 
addition, we verified the robustness and accuracy of the MRM-based quantitation for other 
GTPases. As shown in Figure 4.5 and Figure 4.6, we confirmed the up-regulation of 
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SAR1A and RAB27A, and down-regulation of SAR1B, RAB31 and ARF4 in the 
metastatic SW620 cells relative to the primary SW480 cells. Taken together, the MRM 
method constitutes a highly accurate quantitative tool with excellent throughput and 
specificity. 
4.3.3 Potential Roles of SAR1A and SAR1B in CRC Progression 
We sought to examine, among the differentially expressed small GTPase proteins, 
which can potentially promote or suppress CRC progression. Therefore, we assessed the 
gene expression data from patients in The Cancer Genome Atlas Colon Adenocarcinoma 
(TCGA-COAD) data set, and we found that there were significantly lower mRNA 
expressions of ARF4, RAB6B, RHOF, and SAR1B genes in CRC tissues than in normal 
tissues (n = 50; p < 0.05, paired Student’s t-test) (Figure 4.7). 
We also interrogated other public CRC data sets accessible from the National Center 
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database, 
including GSE14333 (n = 290, Ludwig Institute for Cancer Research), GSE17538 (n = 
232, Vanderbilt University), GSE21510 (n = 274, Juntendo University), and GSE39582 (n 
= 585, Ligue Nationale contre le Cancer).26-29 We again observed significantly lower 
mRNA expressions of ARF4, RAB6B, RHOF, and SAR1B in CRC tissues than in normal 
tissues (Figure 4.8). However, higher mRNA expression of ARF4, RAB6B and RHOF was 
significantly associated with poorer CRC patient survival, which is contradictory to their 
plausible roles in suppressing metastasis (Figure 4.8). The discrepancy between the 
proteomic data and the bioinformatic data may arise from high degree of patient-to-patient 
variability. Meanwhile, SAR1A expression is consistently up-regulated in human CRC 
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tissues compared to the adjacent normal tissues in both TCGA-COAD and GSE21510 
cohorts (Figure 4.9). Kaplan–Meier survival analyses showed that CRC patients with 
higher SAR1A expression presented a higher risk of death [hazard ratio (HR) = 2.353, 95% 
confidence interval (CI) = 1.349 to 4.106, p = 0.0026], and those with higher SAR1B 
expression displayed a more favorable outcome (HR = 0.5915, 95% CI = 0.3723 to 0.9398, 
p = 0.0262) (Figures 4.7 and 4.8). These observations are in keeping with the quantitative 
proteomic data showing the down-regulated SAR1A and up-regulated SAR1B in SW620 
over SW480 cells. Furthermore, lower SAR1B expression is significantly correlated with 
more advanced pathological stages of CRC (Figure 4.8). Collectively, these findings 
substantiated SAR1B as a potential suppressor and a prognostic biomarker for CRC 
progression, and SAR1A and SAR1B may assume distinct roles in disease development. 
4.3.4 SAR1B Knockdown Led to Elevated in vitro Migration and Invasion of SW480 Cells 
by Modulating Epithelial–Mesenchymal Transition (EMT) 
To explore the potential roles of SAR1B in CRC metastasis, we next sought to examine 
how the migratory and invasive abilities of CRC cells are modulated by genetic depletion 
of SAR1B. We found that shRNA-mediated knockdown of SAR1B in SW480 cells elicited 
marked elevations in both the migratory and invasive abilities, as manifested by results 
from both transwell migration/invasion assay and wound-healing assay (Figure 4.10). 
These observations were in accordance with the acquisition of a mesenchymal phenotype.  
We next performed real-time quantitative PCR (RT-qPCR) experiments to assess the 
expression of EMT markers in SW480 cells upon shRNA-mediated stable knockdown of 
SAR1B. The results indeed demonstrated that knockdown of SAR1B led to a significant 
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reduction in the levels of epithelial marker E-cadherin (CDH1) and increased mRNA 
expression of the mesenchymal marker Vimentin (VIM), indicating a shift to a more 
mesenchymal phenotype (Figure 4.10). We, however, did not observe any significant 
changes in mRNA expression for other mesenchymal markers including SNAI1/2 and 
ZEB1/2. In addition, the mRNA level of CDH2 gene was not detectable in SW480 or 
SW620 cells. Likewise, loss of SAR1B did not alter the proliferation rate of SW480 cells 
(Figure 4.10). Together, SAR1B may contribute to suppression of CRC motility and 
metastasis partly through modulating EMT, but not by regulating proliferation. 
4.3.5 RAB31 Promotes Proliferation, Migration and Invasion of SW480 Cells in vitro 
RAB31 was previously shown to play a role in breast cancer proliferation and acquired 
tamoxifen resistance.30-31 Our targeted proteomic data revealed a more than 4-fold down-
regulation of RAB31 in the metastatic SW620 cells, which is in keeping with the 
quantitation results from Western-blot analysis (Figure 4.11). However, there were no 
significant differences observed for the RAB31 expression between CRC and normal 
tissues in the TCGA-COAD data set (Figure 4.11). Moreover, Kaplan–Meier survival 
analyses revealed that higher RAB31 mRNA levels are correlated with worse disease-free 
survival (DFS), which argues against the hypothesis that RAB31 may serve as a suppressor 
for CRC metastasis (Figure 4.11). 
We further investigated whether knock-down of RAB31 affects the behavior of SW480 
cells by assessing cell proliferation and transwell migration/invasion. The siRNA-mediated 
knockdown of RAB31 in SW480 cells was confirmed by Western-blot analysis (Figure 
4.12). We observed significantly diminished cell proliferation, in vitro migration and 
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invasion of SW480 cells after genetic depletion of RAB31 expression, which is 
accompanied by diminished level of mesenchymal marker Slug (Figure 4.12). Although 
RAB31 is substantially down-regulated in SW620 cells, it appeared to be a metastasis 
driver instead of a suppressor based on the cellular experiments. Therefore, these results 
underscored that some of the dysregulated small GTPases may be simply accompanied 
with CRC metastasis and they may not modulate metastatic transformation of CRC. This 
observation emphasizes the importance of validating the findings made from proteomic 
experiments with bioinformatic analysis and cell-based assay. 
4.4 Conclusions 
In this study, we employed our recently developed MRM-based targeted proteomic 
method for high-throughput, reproducible and in-depth quantification of small GTPases in 
the matched primary/metastatic SW480/SW620 CRC cells. Among the 83 quantified small 
GTPases, we found that SAR1A and SAR1B proteins were significantly elevated and 
reduced, respectively, in SW620 over SW480 cells. Furthermore, low level of SAR1B 
expression was significantly associated with poor survival in CRC patients and with 
elevated disease stages, suggesting its potential role in suppressing CRC progression. Our 
results also indicated that loss of SAR1B conferred elevated in vitro migratory and invasive 
abilities of SW480 cells, accompanied by reduced E-cadherin and elevated Vimentin 
expression. Metastasis consists of multiple steps of cellular transformation, during which 
the acquisition of enhanced cell motility, migratory capability and invasiveness is essential 
to the early stage of metastatic dissemination.32 Hence, we reason that diminished SAR1B 
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promotes motility and in vitro metastasis of SW480 cells partly through modulating EMT 
maker gene expression. 
The two SAR1 proteins, SAR1A and SAR1B, are ubiquitously expressed in many types 
of cancer. Aberrant expression or mutations in the SAR1A and SAR1B genes were shown 
to play an important role in regulating cholesterol biosynthesis.33-34 SAR1B promotes 
secretion of both apoB48- and apoB100-lipoproteins, whereas overexpression of SAR1A 
displays the opposite effect, preferentially blocking the secretion of the lipid-laden 
particles.34 Furthermore, reduction in total serum cholesterol could be a signal of occult 
CRC.35 We therefore speculate that the crucial role of SAR1B in lipid biosynthesis and 
secretion may contribute to CRC progression. Interestingly, a previous study showed that 
the expressions of SAR1B and SAR1A were significantly decreased and increased, 
respectively, in the intestinal biopsies of patients with Anderson's disease as compared to 
healthy individuals.36 Hence, they may display functionally redundant, yet distinct roles in 
regulating vesicular trafficking and cargo transport. Although we demonstrated that 
SAR1A is up-regulated in the metastatic SW620 cells and displayed prognostic values in 
large patient cohorts, the detailed molecular mechanisms underlying the role of SAR1A in 
CRC progression warrant further investigation. 
In addition to SAR1 proteins, ARF4 was found to be down-regulated in the metastatic 
SW620 cells relative to the primary SW480 cells, as shown by both MRM and Western-
blot analyses. In a large-scale secretome study reported by Barderas et al.37 using paired 
CRC cell lines KM12C/KM12SM, ARF4 was found to be down-regulated in the secretome 
of the highly metastatic KM12SM cells relative to that of the primary KM12C cells. ARF4 
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induces breast cancer cell migration and functions as an anti-apoptotic protein in human 
glioblastoma cells.38-39 Therefore, ARF4 may participate in the secretory pathways to 
suppress the malignant transformation of CRC cells. 
In conclusion, we applied an MRM-based targeted proteomic method for high-
throughput quantitative measurement of small GTPases associated with CRC metastasis 
by employing paired SW480/SW620 cell lines. Among the 25 small GTPases that 
exhibited differential expression with at least a 1.5-fold change in metastatic SW620 
relative to primary SW480 cells, we found that SAR1B was significantly down-regulated 
during metastatic transformation and the SAR1B mRNA expression was significantly 
correlated with disease stages and prognosis in CRC patient cohorts. We also reported that 
SAR1B depletion in SW480 cells promoted cell motility and transwell invasion, partly 
through modulation of EMT. Collectively, these results suggested that SAR1B may serve 
as a prognostic biomarker and a potential suppressor for CRC metastasis. 
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Figure 4.1 MRM-based targeted quantitative profiling of small GTPases associated 
with CRC metastasis. 
(A) Schematic diagram depicting the targeted quantitative proteomic workflow, relying on 
forward SILAC labeling, in-gel fractionation, and scheduled LC-MRM analysis; (B) 
Correlation between the log2-transformed SILAC ratios (log2R) obtained from one 
forward- and one reverse-SILAC labeling experiments with a relatively high correlation 
coefficient (R2 = 0.9280); (C) Venn diagrams displaying the overlap between quantified 
small GTPases in the triplicate SILAC experiments obtained from MRM and DDA 
analyses, respectively, and the comparison between the performances of the two methods; 
(D) Bar charts showing significantly up- and down-regulated (>1.5-fold) small GTPases 
quantified from three LC-MRM experiments. 
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Figure 4.2 Scheduled MRM analysis of differential expression of small GTPases in 
paired SW480/SW620 cells. 
Heatmap showing the differential expression of small GTPases in paired SW480/SW620 
cells. Shown are the Log2R(SW620/SW480) values obtained from two forward and one 
reverse SILAC labeling experiments (F1 and F2: forward experiments, R1: reverse 
experiment). As indicated by the scale bar, the red and blue bars designate those small 
GTPases that are up-and down-regulated, respectively, by at least 1.5-fold in the SW620 
over SW480 cells. 
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Figure 4.3 In-depth coverage of the small GTPase proteome facilitated by the Ge-LC-
MRM-based quantification. 
Venn diagrams showing the overlapped small GTPases quantified in this study and three 
independent proteomic studies. 
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Figure 4.4 LC-MRM quantification of RHOB, RHOF, RHOG, and RAB6 in paired 
SW480/SW620 cells. 
(A) Selected-ion chromatograms (SICs) for the quantification of tryptic peptides 
IQAYDYLECSAK (RHOB), AALYLECSAK (RHOF) and YLECSALQQDGVK 
(RHOG) in one forward and one reverse SILAC labeling experiments; (B) Western-blot 
validation of the protein abundance of pan-RAB6 (RABA/B/C) and RAB6A, and the SICs 
for the quantification of tryptic peptides ELNVMFIETSAK (RAB6A), QITIEEGEQR 
(RAB6B) and TDLADKR (RABA/C). 
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Figure 4.5 Validation of differential expression of SAR1A and SAR1B in 
SW480/SW620 cells. 
Selected-ion chromatograms (SICs) for the quantification of tryptic peptides: (A) 
TDAISEEK from SAR1A and (B) EMFGLYGQTTGK from SAR1B, in one forward- and 
one reverse-SILAC labeling experiments; Western-blot validation of the differentially 
expressed SAR1A (A) and SAR1B (B) proteins in SW480/SW620 cells, and quantitative 
comparison of protein ratios obtained from LC-MRM and Western-blot analyses (n = 3). 
The p values were calculated by using a paired two-tailed Student’s t test (*p < 0.05, **p 
< 0.01). The data represent the mean and standard deviation of results obtained from three 
parallel experiments. 
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Figure 4.6 Validation of differential expression of RAB27A and ARF4 in 
SW480/SW620 cells. 
SICs for the quantification of tryptic peptides (A) SWIPEGVVR from RAB27A and (B) 
LGLQSLR from ARF4, in one forward- and one reverse-SILAC labeling experiments; 
Western-blot validation of the differentially expressed (A) RAB27A and (B) ARF4 in 
SW480/SW620 cells, and quantitative comparison of protein ratios obtained from LC-
MRM and Western-blot analyses (n = 3). The p values were calculated by using a paired 
two-tailed Student’s t test (*0.01 ≤ p < 0.05, **0.001 ≤ p < 0.01, ***p < 0.001). The data 
represent the mean and standard deviation of results obtained from three parallel 
experiments. 
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Figure 4.7 Down-regulated SAR1B in CRC confers better patient prognosis and 
associates with lower disease stages. 
Comparison of SAR1B expression levels in paired CRC tissues (CRC) with adjacent non-
tumor tissues (normal) in (A) TCGA-COAD (n = 50) and (B) GSE21510 (n = 44) cohorts; 
The p values were calculated by using a paired two-tailed Student’s t test (****, p < 
0.0001). Kaplan–Meier survival analysis of CRC patients stratified by the median SAR1B 
mRNA expression in (C) GSE17538 (n = 232) and (D) GSE39582 (n = 585) cohorts; The 
log-rank (Mantel–Cox) test was used to calculate the p values. (E) Correlation of SAR1B 
mRNA expression with different CRC stages in the GSE39582 (n = 585) cohort. The p 
values were calculated by using an unpaired two-tailed Student’s t test (*p < 0.05). 
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Figure 4.8 Prognostic values of ARF4, RHOF and RAB6B in CRC patient cohorts.  
Differential mRNA expression of ARF4, RHOF and RAB6B in the (A, D, G) GSE21510 
(n = 44) (B, E, H) TCGA-COAD (n = 50) cohorts. The p values were calculated by using 
an unpaired two-tailed Student’s t test (ns, p > 0.05; *, 0.01 ≤ p < 0.05; **, 0.001 ≤ p < 
0.01; ****, p < 0.0001). Kaplan–Meier survival analysis of CRC patients stratified by the 
median mRNA expression levels of (C) ARF4 and (F) RHOF in the GSE14333 cohort (n 
= 290) and (I) RAB6B in the GSE17536 cohort (n = 232). The log-rank (Mantel–Cox) test 
was performed to calculate the p values. 
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Figure 4.9 Higher expression of SAR1A in CRC confers unfavorable patient 
prognosis. 
Comparison of SAR1A expression levels in paired CRC tissues (CRC) with adjacent non-
tumor tissues (Normal Tissue) in the (A) TCGA-COAD (n = 50) and (B) GSE21510 (n = 
44) cohorts; The p values were calculated by using a paired two-tailed Student’s t test (ns, 
p > 0.05, ** 0.001 ≤ p < 0.01). Kaplan–Meier survival analysis of CRC patients stratified 
by the median SAR1A mRNA expression in (C) GSE14333 (n = 290) and (D) GSE17538 
(n = 232) cohorts. The log-rank (Mantel–Cox) test was performed to calculate the p values. 
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Figure 4.10 Depletion of SAR1B modulates the migratory and invasive capacities of 
SW480 cells. 
(A) Representative images and (B) quantification results for migration/invasion assay 
showing the effects of stable SAR1B knockdown (shSAR1B) on the in vitro migratory and 
invasive abilities of SW480 cells compared to the control (shScramble). (C) Representative 
images and (D) quantification results for wound healing assay showing the effects of stable 
SAR1B knockdown (shSAR1B) on the wound healing abilities of SW480 cells compared 
to the control (shScramble). (E) RT-qPCR expression analyses of EMT marker genes in 
SW480 cells with stable shScramble or shSAR1B knockdown. Gene expression was 
normalized to the relative expression of GAPDH. “n.d.”, not detectable.  (F) Cell 
proliferation of shScramble/shSAR1B SW480 cells. The p values were calculated by using 
a paired two-tailed Student’s t test (*, 0.01  p < 0.05, **, 0.001  p < 0.01). The data 
represent the means and standard deviations of results obtained from three parallel 
experiments. 
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Figure 4.11 Higher expression of RAB31 is associated with worse CRC patient 
outcome and higher disease stages. 
(A) SICs for the quantification of a tryptic peptide GSAAAVIVYDITK from RAB31; (B) 
Western blot validation of the differentially expressed RAB31 in SW480/SW620 cells, and 
quantitative comparison of protein ratios obtained from LC-MRM and Western blot 
analyses (n = 3). The p values were calculated by using a paired two-tailed Student’s t test 
(*, 0.01 ≤ p < 0.05; **, 0.001 ≤ p < 0.01). The data represent the mean and standard 
deviation of results obtained from three parallel experiments. (C) Comparison of RAB31 
expression levels in paired CRC tissues (CRC) with adjacent non-tumor tissues (Normal 
Tissue) in the TCGA-COAD cohort (n = 50); (D) Correlation of RAB31 mRNA expression 
with different CRC stages in the GSE39582 cohort (n = 585). The p values were calculated 
by using an unpaired two-tailed Student’s t test (ns, p > 0.05; *, 0.01 ≤ p < 0.05). Kaplan–
Meier survival analysis of CRC patients stratified by the median RAB31 mRNA expression 
in (E) GSE14333 (n = 290) and (F) GSE17536 (n = 232) cohorts. The log-rank (Mantel–
Cox) test was performed to calculate the p values. 
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Figure 4.12 RAB31 knockdown modulates the migratory and invasive capacities and 
cell proliferation of SW480 cells. 
(A) Western blot results showing the siRNA-mediated knock-down of RAB31 in SW480 
cells and the resulting altered level of Slug protein; (B) Representative images depicting 
the migratory and invasive abilities of SW480 cells upon siRNA-mediated depletion of 
RAB31; (C) Cell proliferation of SW480 cells upon siRNA-mediated knockdown of 
RAB31. 
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Chapter 5 A Targeted Quantitative Proteomic Approach for High-
throughput Quantitative Profiling of Small GTPases in Brain Tissues of 
Alzheimer’s Disease Patients 
5.1 Introduction 
Alzheimer’s disease (AD) is among the most common neurodegenerative diseases 
worldwide and is a leading cause for dementia in the elderly.1 In the United States, AD 
affects approximately 10% people with ages over 65 and remains the 5th leading cause of 
death in this population.2 The hallmarks of AD pathology in the brains include synapse 
loss, the accumulation of extracellular beta-amyloid (Aβ) plaques and twisted strands of 
the hyper-phosphorylated tau protein (neurofibrillary tangles) inside neurons, which 
promote neuronal death and ultimately dementia.3 As region-specific neurodegenerative 
disorders, AD can lead to neuronal loss that is predominantly found in the cerebral cortex 
and hippocampus, where the cerebral cortex can be further divided into different lobes, the 
frontal, parietal, temporal, and occipital.4 
The advent of quantitative proteomics in recent years has allowed for high-throughput 
interrogation of proteomic alterations accompanied by the early development and 
progression of AD in various sample types or post-mortem brain regions including 
temporal neocortex,5 cerebral cortex,6 cerebrospinal fluids,7-8 hippocampus,9-10 frontal 
cortex11-13 and anterior cingulate gyrus.14 Very recently, McKetney et al.15 reported a 
proteomic resource comprising nine anatomically distinct sections from post-mortem AD 
patient brain tissues. Among the various proteomic techniques, targeted proteomics was 
widely applied in clinics for validation of disease biomarker for AD.8, 16 
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Small GTPases of the Ras superfamily are essential regulators of intracellular 
trafficking and signal transduction, and therefore, they represent a potential therapeutic 
strategy in disease treatment.17 A growing body of literature has emphasized the 
importance of Rab small GTPases as crucial signaling modules in the brain.18-20 Rab7A 
and Rab35 regulate secretion and endolysosomal degradation of the tau protein, 
respectively.21-22 Moreover, Rab6A is among the 16 hub genes associated with metastable 
AD subproteome,23 and Rab6 showed elevated expression levels in the temporal cortex, 
but not hippocampus of AD brains compared to non-demented controls.24 In addition, the 
mRNA expressions of Rab4, Rab5 and Rab7 were up-regulated in the hippocampus from 
individuals with AD.25 Augmented mRNA expressions of Rab4, Rab5, Rab7, and Rab27 
were also observed in the basal forebrain of AD patients.26 In addition to Rab GTPases, 
Arf and Rho GTPases also play important roles in regulation of membrane dynamics and 
trafficking in neuronal cells.27 Given the importance of synaptic trafficking in 
neurodegenerative diseases, we reason that a comprehensive investigation of the 
association of small GTPases with AD could further our understanding of disease etiology 
and explore their potential as possible molecular targets for therapeutic intervention. Here 
we utilized a novel multiplexed and high-throughput targeted quantitative proteomic 
approach that involves multiple-reaction monitoring (MRM) and the use of stable isotope-
labeled standard (SIS) peptides. We further applied this method to assess the altered 
expression of small GTPases in the frontal cortex region of post-mortem patient brain 
tissues with various AD stages. 
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5.2 Materials and Methods 
5.2.1 MRM Library Construction 
We recently established a Skyline library incorporating more than 130 proteins from 
the small GTPase of Ras superfamily based on in-house shotgun proteomic data.28 Built 
upon the old library and an online targeted proteomic experiment design tool Picky 
(https://picky.mdc-berlin.de),29 the current MRM library incorporates 148 proteins that 
represent 138 unique gene IDs along with a total of 1670 MRM transitions. Cysteine 
carbamidomethylation (C +57.0215 Da) was set as a fixed modification, and heavy lysine 
(K +8.0 Da) and heavy arginine (R +10.0 Da) modifications were incorporated as heavy-
isotope labels. 
5.2.2 Brain Tissue Homogenization and Protein Extraction 
Snap-frozen human brain tissues from medial frontal cortex were obtained from 15 
individuals, and the AD cases were neuropathologically diagnosed as Braak stages 3−6. 
Among them, 5 individuals with high AD pathology (Braak stages 5−6, “high AD” group), 
5 individuals with medium AD pathology (Braak stages 3−4, “intermediate AD”), and 5 
age-matched individuals with no or low AD pathology (Braak stage 1 or none, “no AD”). 
Each tissue piece (approximately 100 mg in wet weight) was homogenized in a 300 μL of 
RIPA lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1% NP-40, pH 7.5), 
supplemented with protease inhibitor cocktail (1:100, v/v) using a Bullet Blender (Next 
Advance) and 100 mg of 0.5 mm zirconium oxide beads (Next Advance). After 
centrifugation at 15,000 RPM for 30 min at 4 °C, the supernatant was transferred to another 
170 
 
vial. Total protein concentration was determined using the Quick Start Bradford Protein 
Assay (Bio-Rad). 
5.2.3 MS Sample Preparation 
Approximately 10 μg of tissue lysate was separated on a 10% SDS-PAGE gel, followed 
by excision of gel bands in the molecular weight range of 15−37 kDa. The excised gel 
bands were cut into pieces (1-mm3 volume), reduced with dithiothreitol, alkylated with 
iodoacetamide, and digested in-gel with trypsin (enzyme/substrate 1:50) at 37 °C 
overnight. 
The peptide samples were desalted, reconstituted in 40 μL of buffer A (0.08% formic 
acid) and 36 μL of sample was spiked with 4 μL of crude SIL peptide stock solution (20 
fmol/μL)  prior to scheduled LC-MRM analysis, to yiled a final spike-in concentration of 
2 fmol/μL. Approximately 4 μL (20 ng equivalent) of sample was loaded onto a 4-cm long 
in-house prepared trapping column packed with 5 μm Reprosil-Pur C18-AQ resin (Dr 
Maisch) and separated on a 25-cm long 75 μm ID fused silica columns packed in-house 
with 3 μm Reprosil-Pur C18-AQ resin (Dr Maisch). The LC-MS platforms consisted of a 
Dionex UltiMate 3000 RSLCnano UPLC system coupled to a TSQ Altis triple-stage 
quadrupole mass spectrometer with a Flex nano-electrospray ion source (Thermo Fisher). 
Sample elution was performed over a gradient of 12−33% Buffer B (0.08% formic acid in 
80% acetonitrile) over 70 min, and from 33−100% B over 5 min at a flow rate of 300 
nL/min. The column was reconditioned with 100% B for 3 min and equilibrated with 1% 
B for 10 min at a flow rate of 300 nL/min. The mass spectrometer was operated with an 
ion spray voltage of 2200 V, a capillary offset voltage of 35 V, a skimmer offset voltage 
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of -5 V, and a capillary inlet temperature of 325 °C. Both Q1 and Q3 were set at a resolution 
of 0.7 fwhm, and Q2 gas pressure used for peptide fragmentation was set at 1.5 mTorr. 
Collision energies specific to peptide precursors were calculated in Skyline software 
(version 4.2.0). A modified iRT calculator was employed for retention time prediction and 
generation of the MRM method in Skyline, as described recently.28 
5.2.4 Data Analysis 
The raw data were directly imported into Skyline for visualization of chromatograms 
of target peptides to manually determine the detectability of target peptides. For each 
peptide, the transitions without matrix interference were used for precise quantification. 
Three criteria were used to determine the peak detection and integration: (1) scheduled 
retention time, (2) relative distribution of each transition (dotp value), and (3) co-elution 
of endogenous (light) peptides and heavy IS peptides. All the data were manually inspected 
to ensure that the intensity distribution of selected transitions match with theoretical 
distributions in the spectral library, with dotp being greater than 0.8.30 MRM peak area 
normalization was applied with the use of crude SIL peptides as IS or SS. 
5.2.5 Heavy Isotope-labeled Synthetic Peptides 
Crude synthetic peptides labeled with 13C/15N on C-terminal lysine and arginine (>70% 
in peptide purity and >99% in isotopic purity) were synthesized and purified by New 
England Peptides (Cambridge, MA). The lyophilized form of peptides was reconstituted 
with 15% acetonitrile in 0.1% formic acid, aliquoted and stored at -80 °C until use to avoid 
freeze/thaw cycles. The crude heavy peptide standards of small GTPases were added to 
each sample at a final concentration of 0.5, 2, and 5 fmol/μL. 
172 
 
5.2.6 Immunoblotting 
After tissue homogenization, the protein concentration in the total brain tissue lysates 
was determined using Quick Start Bradford Protein Assay (Bio-Rad). Approximately 10 
µg of lysates were mixed with 4× Laemmli SDS loading buffer, boiled at 95 °C for 5 min, 
and loaded onto 10% polyacrylamide gels. After electrophoresis, the proteins were 
transferred onto nitrocellulose membranes. After blocking with 5% non-fat milk in PBS 
with 0.1% Tween-20 (PBST) at 25 °C for 1 h, the membranes were incubated with primary 
antibodies against human Rab27B (Proteintech; rabbit polyclonal, 1:2,000), RAB31 
(4D12, Santa Cruz; rabbit polyclonal, 1:2,000), or β-actin (Thermo Fisher; rabbit 
polyclonal, 1:10,000). After overnight incubation with primary antibodies at 4°C with 5% 
bovine serum albumin (BSA) in PBST, the membranes were then incubated with 
peroxidase-labeled donkey anti-rabbit secondary antibody (Thermo Fisher; 1:10,000) or 
mouse m-IgGκ BP-HRP (Santa Cruz; 1:10,000) for 1 h at 25 °C. Amersham ECL Prime 
Western Blot Detecting Reagent (GE Healthcare) was used for visualization of protein 
bands. 
5.3 Results 
5.3.1 Targeted Assay Development 
In the past decade, LC-MS/MS in the multiple-reaction monitoring (MRM) mode has 
allowed for sensitive, reproducible and reliable protein quantitation in different biological 
matrices through multiplexed and targeted quantification of peptides.31 In MRM-based 
quantification, specific transitions of precursor ions selected in Q1 to fragment ions 
selected in Q3 are monitored using a triple-quadrupole instrument, generating signals for 
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quantification. Therefore, analytical robustness of the method is highly dependent upon the 
selection of optimal proteotypic peptides and transitions that represent the proteins of 
interest.32 Recently, we established a Skyline MRM spectral library in combination with 
the metabolic labeling by stable isotope labeling of amino acids in cell culture (SILAC) for 
high-throughput quantitative profiling of small GTPases in human cancer cell lines.28 This 
library was constructed primarily using shotgun proteomic data generated in-house, 
covering 134 proteins representing 113 unique gene IDs. With retention time scheduling, 
all targeted transitions for small GTPases can be monitored in two LC-MRM runs with the 
use of a 6-min retention time window. 
To further expand the MRM library, we referred to an online targeted proteomic 
experiment design tool Picky (https://picky.mdc-berlin.de) to map comprehensively the 
candidate peptides for small GTPases of human or mouse origins.29 The peptides were 
chosen based on their intensities as well as sequence uniqueness. With the use of this tool, 
we were able to expand the library to 148 proteins representing 138 unique gene IDs, 
covering 90% of the human small GTPase proteome. To the best of our knowledge, this is 
the most comprehensive MRM library for small GTPases thus far. Because a relatively 
large number of transitions (~1680) were monitored in a single LC run, we employed 
retention time scheduling using iRT.33 All targeted transitions for small GTPases can be 
monitored in a single LC-MRM run in scheduled MRM analysis, with a retention time 
window of 4 min to yield the maximum concurrent transitions of ~50 (Figure 5.1). 
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5.3.2 Analytical Performance of Crude SIL Peptides 
The absolute quantification (AQUA), which involves the spiking of samples with high-
purity (>98%) stable isotope-labeled peptides as internal standards (SIS), enables highly 
reliable and specific targeted quantification of protein or post-translational modifications.34 
Peptides labelled with a stable isotope (13C and 15N) are chemically identical to their native 
counterparts and thus have identical chromatographic behavior. The AQUA method 
usually requires the generation of calibration curves by stable isotope dilution using high-
purity SIS peptides and is therefore more expensive and labor-intensive. 
Other studies used MRM signals for a single or selected group of peptides derived from 
housekeeping proteins (e.g. GAPDH or actin) to normalize MRM signals from the targeted 
peptides.35-36 Additionally, the labeled reference peptide (LRP) approach emerged as a 
cost-effective normalization strategy for a larger number of target proteins, in which a 
single isotope-labeled peptide standard is used as the reference for all target peptides in an 
analysis.35 Compared to label-free quantification, the LRP method can compensate for 
technical variations during sample analysis and thus yield more reliable normalization.37 
Crude synthetic peptides, on the other hand, display quite limited uses in targeted 
quantitation due to their large variation in purities. Owing to simplified purification, a 
larger set of candidate peptides can be incorporated into MRM assays. Despite preliminary 
purification, lower-purity crude peptides may still contain a wide range of impurities such 
as residual salts, deblocking and scavenger reagents, and truncated and partially deblocked 
peptides.38 To this end, we synthesized 131 peptides carrying a uniformly [13C,15N]-labeled 
arginine or lysine at the C termini. In order to eliminate possible quantification bias 
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introduced by the impurities present in the crude standards, we first evaluated, by 
employing MRM analysis, the analytical performance of the small GTPase crude peptides 
synthesized by NEP in a 96-well plate format. We confirmed the absence of isotope 
interference for all peptides (Figure 5.2). In addition, we detected 114 out of 131 crude SIL 
peptides in a single LC-MRM run (Figure 5.3), which exhibited a broad dynamic range 
spanning 3 orders of magnitude (Figure 5.3). Failure in detection of the other peptides may 
be attributed to ion suppression resulting from matrix effects or low abundance of the 
peptides in the crude peptide pool. 
5.3.3 Evaluation of Relative Quantitation by Crude SIL Peptides 
Next, we sought to investigate the use of crude peptides in performing relative 
quantitation. Despite their lower purities, crude SIL peptides can be added at an equivalent 
concentration to all samples thus can be used for correction of sample losses during transfer 
and normalization across runs due to LC injection variations. Figure 5.1 displays the linear 
correlations obtained by the spike-in concentration and the peak area ratios (light/heavy), 
where most peptides exhibit high linear regression coefficients (R2 > 0.995). The results 
again supported the feasibility of spiking crude SIL peptides in samples for relative 
quantitation. We further optimized the concentration of crude peptides spiked in the 
samples as internal standards (IS). Among the three spike-in concentrations (0.5, 2, 5 
fmol/μL), we found that using 2 fmol/μL could result in more properly distributed 
light/heavy ratios and dynamic range (Figures 5.1−5.3). Collectively, we determined 2 
fmol/μL as the spike-in concentration used for the subsequent experiments. 
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For other library peptides without their heavy counterparts as IS, we adapted slightly 
from the LRP method and adopted the concept of RT-defined surrogate standards (SS). 
Unlike IS peptides, which share high chemical and chromatographic similarities with target 
peptides, heavy SS peptides were chosen based upon their high intensity, lower variability 
and similar chromatographic behaviors. Therefore, we selected twelve SS peptides that 
elute at varied retention time windows across the entire gradient (Figure 5.4). As depicted 
in Figure 5.5, we found that the SS peptides eluting at similar retention times exhibited 
more similar distribution of MRM signal intensity or peak area, compared to those eluting 
at different retention times. Relative to existing normalization methods used in MRM-
based quantitation, such as label-free and LRP method using a single peptide derived from 
house-keeping proteins, we reasoned that the use of crude SIL peptides offers a cost-
effective and reliable alternative in MRM-based quantification. 
5.3.4 Targeted Proteomic Analysis of Small GTPases in AD Brain Tissue Samples 
To explore the potential roles of small GTPases in AD progression, we applied the 
established MRM assay to assess the differential expressions of small GTPases in the 
frontal cortex region of post-mortem patient brain tissues with differed disease stages 
(Figure 5.6). In total, we were able to quantify reproducibly more than 80 small GTPases 
among the 15 brain tissue samples (Figure 5.7). As the availability of such clinical material 
for analysis is often limited, we also demonstrated that a relatively small amount of protein 
input (∼10 μg/sample) is sufficient to achieve a good coverage of target proteins by the 
established LC-MRM method. Figure 5.7 shows a heatmap for a more detailed comparison 
of the mean quantification results obtained from each small GTPase among the two disease 
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groups (intermediate AD, and high AD) normalized to the mean values of the normal group 
(no AD). 
5.3.5 Altered Expression of Small GTPases Involved with Synaptic Functions 
Synaptic vesical trafficking that involves continuous cycles of exocytosis and 
endocytosis is required for the maintenance of proper synaptic functions.39-40 By 
performing network analysis, Kokotos et al.41 revealed that Rab small GTPases constitute 
a key functional hub within the activity-dependent bulk endocytosis (ADBE) proteome in 
cerebellar granule neurons. Table S2 shows the network analysis of the synaptic Rab small 
GTPases reported in literature. 
A loss of synaptic contacts in both the neocortex and hippocampus represents one of 
the major neuropathological hallmarks associated with AD.42 A couple of Rab GTPases 
were previously determined by Pavlos et al.43 as the exocytotic (Rab3A, Rab3B, Rab3C, 
and Rab27B) and endocytic (Rab4B, Rab5A/B, Rab10, Rab11B, and Rab14) Rab 
machinery of synaptic vesicles (SVs). Interestingly, the LC-MRM data revealed aberrant 
expressions of several synaptic small GTPases, such as Rab3A/C, Rab4A/B and Rab27B 
in disease progression of AD. Among the several highly homologous Rab3 isoforms 
(Rab3A, Rab3B, Rab3C and Rab3D), Rab3A is the most abundant in the brain, where it is 
localized on SVs and participates in Ca2+-triggered neurotransmitter release.44 In general, 
these Rab3 isoforms usually play largely overlapping yet redundant secretory functions in 
neurons and are crucial to synaptic integrity.45 Rab3B was not quantified by the LC-MRM 
method, which is presumably due to its low protein abundance. Based on the LC-MRM 
results, we observed increased protein expression of Rab3A, Rab3C and Rab3D in later 
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stages of AD (Figure 5.7), which indicate important, yet previously unrecognized functions 
of small GTPase-regulated synaptic trafficking and signaling in promoting AD pathology. 
Furthermore, two synaptic small GTPases, Rab4A and Rab4B, were significantly up-
regulated in the “high AD” group of patients compared to the “intermediate AD” group 
(Figure 5.8). However, there were no significant changes when the comparison was 
imposed on “no AD” group and “high AD” group. It is also noteworthy that Rab4 was 
found to be up-regulated at mRNA levels in the basal forebrain and the hippocampus 
regions of AD brains in two independent studies.25-26 In contrast to the microarray-based 
studies, our MRM-based approach indicated that both isoforms of Rab4 (Rab4A and 
Rab4B) may be involved with synaptic functions that could potentially implicate with AD 
progression. For other synaptic GTPases such Rab10, there were no obvious alteration in 
expression among the three patient groups (Figure 5.8). Collectively, we showed that the 
MRM quantitation results obtained by two normalization methods (IS-based and SS-based) 
were highly similar, and that dysregulated synaptic trafficking could play potential roles in 
disease progression of AD. 
5.3.6 Validation of Proteomic Data by Western Blot Analysis 
In addition to Rab3, Rab27B also play a distinct yet overlapping role in SV trafficking 
and involves with Ca2+-dependent exocytosis.43 Quite interestingly, we also observed 
substantial, yet statistically insignificant, increases of Rab27B in higher stages of AD 
(Figure 5.9). The endogenous/heavy peptide LLALGDSGVGK showed a dotp value 
between 0.93 and 0.97, and the endogenous peptide FITTVGIDFR displayed a dotp value 
between 0.89 and 0.93 (Figure 5.10). Furthermore, the quantification results among the 15 
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brain samples normalized by both IS and SS peptides showed a reasonably high linear 
regression (R2 = 0.961) (Figure 5.10). Again, we demonstrated that the quantitation 
performances between these two normalization methods are adequately reliable. 
To validate the proteomic results, we also performed western blot analysis and found 
that there was a moderate correlation between the MRM-based and the immunoblot-based 
analyses, which displayed a modest linear regression coefficient of R2 = 0.5889 (Figure 
5.9). These results indicate the differences in dynamic range of the quantification results 
obtained from the two methods, which led to a higher degree of variation with increased 
protein abundance. 
5.4 Discussion 
Previous systems biology analyses and proteomic studies revealed substantial 
reprogramming of a plethora of cellular processes involved with AD pathology and disease 
progression, such as energy metabolism, glycolysis, oxidative stress, apoptosis, signal 
transduction, and synaptic functioning.5 Potential roles of small GTPases participating in 
synaptic trafficking and modulation of neurodegeneration have been increasingly 
discussed recently.20 In this study, we found a substantial up-regulation of Rab27B protein 
level in higher disease stage of AD, which is in accordance with the dysregulated Rab27B 
in AD reported in previous proteomic and transcriptomic studies. Furthermore, several 
other synaptic GTPases, such as Rab3A/C and Rab4A/B, were found to be up-regulated in 
brain tissues with higher AD levels. It is also expected that the proteomic profiles within 
different brain regions are likely to change qualitatively and/or quantitatively during aging 
and/or in different disease states. Thus, identification of proteins unique to each brain 
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region, those associated with neurodegenerative mechanisms could yield opportunities to 
overcome major obstacles in the development of new protective and restorative therapies 
for prominent neurodegenerative diseases. 
5.5 Conclusions 
In this study, we developed a targeted quantitative MRM-based proteomic assay for 
quantification with >1,600 transitions representing 550 peptide precursors in a 45-min LC 
gradient. With the use of crude SIL peptides, we further applied the established MRM assay 
to assess quantitatively the differential expression of small GTPases in the frontal cortex 
regions of post-mortem brain tissue samples acquired from patients with different AD 
stages. Furthermore, we describe the proof-of-principle for targeted measurement of small 
GTPases in human brain tissues by performing relative quantitation employing crude SIL 
peptides as both internal standards (IS) and surrogate standards (SS). Our results led to the 
discovery of the altered expressions of several synaptic GTPase proteins, including 
Rab3A/C, Rab4A/B and Rab27B in higher AD stages, suggesting a potential role of 
synaptic trafficking in AD progression. 
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Figure 5.1 Sensitivity, multiplexing capability, reproducibility, and accuracy of the 
MRM-based quantification at the peptide level. 
(A) Number of concurrent transitions scheduled in each cycle with a 2-min, 5-min and 10-
min retention time window, respectively; (B) Linear regression of the peak area ratios 
(heavy/light) for 6 representative peptides obtained from three LC-MRM experiments with 
different spike-in concentrations. Crude SIL standards were spiked at 0.5, 2 and 5 fmol/μL, 
respectively. (C) Scatter plots depicting distribution of the peak area ratios (heavy/light) 
for all quantified peptides obtained from three LC-MRM experiments with different spike-
in concentrations. 
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Figure 5.2 Confirmation of the qualities of the crude stable isotope-labeled (SIL) 
peptides by MRM analyses. 
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Figure 5.3 Coverage, dynamic range and spike-in concentration optimization for the 
crude SIL peptides in the MRM analyses. 
(A) A Venn diagram showing the coverage of the SIL peptides detected in a single LC-
MRM run; (B) A scatter plot depicting the dynamic range of the peak areas resulting from 
LC-MRM analysis of 2 fmol of crude SIL peptides; (C) A table describing the peak area 
ratios (light/heavy) obtained from three LC-MRM experiments. 
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Figure 5.4 Selection for the twelve surrogate standard (SS) peptides across the 
designated retention time windows. 
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Figure 5.5 Comparison of the peak areas extracted for the selected SS peptides in the 
MRM analyses across similar or different retention time windows. 
(A) A connected scatter plot illustrating the peak area variations across three SS peptides 
(#1, #2, #3) eluted at similar retention time windows; (B) A connected scatter plot 
illustrating the peak area variations across three SS peptides (#1, #7, #12) eluted at different 
retention time windows. 
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Figure 5.6 A schematic workflow illustrating sample preparation for LC-MRM 
analysis. 
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Figure 5.7 A heatmap showing the relative quantification of small GTPases in brain 
tissues obtained from Alzheimer’s disease (AD) patients. 
(A) A Venn diagram showing the overlap between quantified small GTPase, quantified 
SIL standards and total targeted small GTPases in the library; (B) A heatmap showing the 
relative quantification (in log2 scale) of small GTPases in brain tissues obtained from 
Alzheimer’s disease (AD) patients. 
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Figure 5.8 Representative MRM quantification results for three synaptic GTPases, 
Rab4A, Rab4B, and Rab10. 
(A) A bar graph illustrating the MRM-based quantification results obtained from three 
peptides derived from Rab4A; (B) A box plot summarizing the quantification results in 
panel (A); (C) A bar graph illustrating the MRM-based quantification results obtained from 
two peptides derived from Rab4B; (D) A box plot summarizing the quantification results 
in panel (C). (E) A bar graph illustrating the MRM-based quantification results obtained 
from three peptides derived from Rab10; (F) A box plot summarizing the quantification 
results in panel (E). Tukey's multiple comparison test was performed to calculate the p 
values (#, p > 0.05; *, 0.01 ≤ p < 0.05). 
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Figure 5.9 Rab27B is up-regulated in higher stages of AD. 
(A) A box plot summarizing the quantification of Rab27B levels among the three patient 
groups; (B) Western blot analysis of Rab27B in the 15 brain tissue samples; (C) A bar 
graph showing the quantification results obtained by western blot analysis and MRM 
analysis; (D) Linear regression between the quantification results obtained by western blot 
analysis and MRM analysis. 
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Figure 5.10 Quantification details for Rab27B by two normalization methods. 
(A) The relative contribution of each transition to targeted MRM analysis of the 
endogenous LLALGDSGVGK peptide derived from Rab27B; (B) The relative 
contribution of each transition to targeted MRM analysis of the isotope-labeled 
LLALGDSGVGK peptide;  (C) The relative contribution of each transition to targeted 
MRM analysis of the endogenous FITTVGIDFR peptide; (D) Bar charts of the 
quantification results normalized from IS peptide (LLALGDSGVGK) and SS peptide 
(FITTVGIDFR); (E) Linear regression of the quantification results shown in panel (D). 
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Chapter 6 Concluding Remarks 
In this dissertation, we developed and utilized mass spectrometry-based approaches for 
targeted quantitative proteomic analysis of small GTPases of the Ras superfamily in cancer 
cells and tissue samples. By employing multiple-reaction monitoring (MRM) and two 
different labeling strategies, i.e. stable isotope labeling by amino acids in cell culture 
(SILAC) and crude synthetic stable isotope-labeled (SIL) peptides, we have successfully 
achieved high-throughput targeted quantitative profiling of small GTPases by assessing the 
altered protein expressions of these proteins related to cancer metastasis and drug 
resistance in cultured cancer cells and development of neurodegenerative diseases in 
patient-derived tissue samples. 
Specifically, the work detailed in Chapter 2 describes the development of a novel 
targeted proteomic assay for profiling small GTPases in cultured human cells, which 
involved metabolic labeling by SILAC, fractionation by SDS-PAGE and scheduled MRM 
analysis. By using this scheduled Ge-LC-MRM method, we assessed the differential 
expression of small GTPases in paired primary/metastatic melanoma cell lines, which lead 
to reproducible quantitation of more than 90 small GTPases in two 157-min LC runs. 
Moreover, we validated quantification results by proteomic analysis by performing 
Western-blot analysis. Combined with bioinformatic analyses of publicly available patient 
data and cell-based assays, we uncovered a previously unrecognized role of small GTPase 
RAB38 in promoting melanoma metastasis in vitro and predicting poor melanoma patient 
prognosis. We further demonstrated that RAB38 promotes melanoma metastasis in vitro 
through the regulation of matrix metalloproteinases, and the increased expression of 
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RAB38 in metastatic melanoma cells arises from diminished promoter methylation and 
heightened binding of the MITF transcription factor. 
In Chapters 3 and 4, we discuss the application of the MRM-based targeted proteomic 
approach established in Chapter 2 as a tool to probe the altered expression of small 
GTPases associated with acquired tamoxifen resistance in breast cancer and colorectal 
cancer metastasis. In Chapter 3, in total 96 small GTPases were robustly quantified in wild-
type MCF-7 and the paired tamoxifen-resistant breast cancer cells, among which down-
regulation of RAB31 was analyzed further. By conducting bioinformatic analyses and cell-
based assays, we provided evidence that decreased expression of RAB31 predicted poor 
breast cancer patient survival and modulated development of acquired tamoxifen resistance 
in vitro. In Chapter 4, differential expression of small GTPases in paired primary/metastatic 
colorectal cancer cell (CRC) lines SW480 and SW620 was assessed, leading to robust 
quantitation of 83 small GTPases. Among them, we identified SAR1B as a potential 
suppressor and prognostic marker for CRC metastasis by combining the proteomic data 
with bioinformatic analyses of publicly available patient data. We also showed that 
diminished SAR1B expression could stimulate epithelial–mesenchymal transition (EMT), 
thereby promoting motility and in vitro metastasis of SW480 cells. 
Although SILAC-based quantitation provides high accuracy and precision, many 
biological materials such as body fluids and tissue samples are not readily amenable to 
metabolic labeling. Therefore, in Chapter 5, we explored the analytical performance of 
scheduled Ge-LC-MRM analysis in conjunction with a different labeling strategy, which 
relies on the use of crude synthetic stable isotope-labeled (SIL) peptides. Furthermore, we 
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benchmarked the quantitative performance of crude SIL peptides as both internal standards 
and surrogate standards, allowing quantification of more peptides by the MRM assay. To 
investigate the link between small GTPases and progression of Alzheimer’s disease (AD), 
we analyzed, by Ge-LC-MRM analysis, the total lysates of frontal cortex from post-
mortem patient AD brain tissues Alzheimer’s disease (AD) with varied AD pathology: “no 
AD” (n = 5), “intermediate AD” (n = 5), and “high AD” (n = 5). To this end, we quantified 
~80 small GTPases from the 15 samples with high sensitivity and reproducibility in one 
45-min LC run. Among the differentially expressed small GTPases, we observed 
substantial up-regulation of several synaptic GTPases in tissues with higher levels of AD, 
including Rab3A/C, Rab4A/B and Rab27B. Future experiments are warranted to provide 
mechanistic evidence of altered synaptic trafficking contributed by dysregulated small 
GTPases. 
Together, by taking advantage of the above-mentioned methods, high-throughput and 
targeted quantitative profiling of small GTPases in cultured cancer cells and tissue samples 
is enabled. The work in this dissertation presented a novel and systematic targeted 
proteomic approach to investigate the previously unrecognized roles of dysregulated small 
GTPase expressions in a wide array of biological events relevant to public health, such as 
cancer progression, AD pathology and cellular response upon exposure to environmental 
toxicants. 
MRM has been the standard for targeted proteomics during the past two decades with 
superior sensitivity, reproducibility and specificity; however, as with any other proteomic 
technique, it is highly dependent on sample preparation and instrument optimization and 
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more susceptible to background interference resulting from sample matrix. Future 
directions for targeted assay development by using parallel-reaction monitoring (PRM) are 
therefore highly encouraged. Extending the methods described in this dissertation to other 
members of GTP-binding proteins such as heterotrimeric G proteins is currently being 
explored. 
 
